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Modern Medical Science is the gentle Art 
of Rediscovery 
Dirk Durrer 
In October 1978 I assumed the position of cardiolo-
gist at the Catharina Hospital in Eindhoven at the time 
when the cardiothoracic surgery programm began in 
this hospital. At that time I did not know the number of 
patients that had to be treated daily. During our fellow-
ship training in cardiology, particularly in a university 
hospitaL there was time to discuss problems with 
teachers and to consider solutions. In a large non-
academic cardiology department like that of the Catha-
rina hospitaL the situation is different: quick decisions 
are necessary. 
From 1978 onwards. clinical cardiology changed at 
such pace that even some universities had difficulty to 
implement new therapeutic developments such as per-
cutaneous transluminal coronary angioplasty and 
thrombolysis. In those early years we had a relatively 
small staff which made it difficult to keep up with these 
rapid changes. I was in a privileged position. since my 
colleagues gave me the opportunity to visit leading 
centres and to learn about new developments and im-
plement them in our daily practice of cardiology. It was 
necessary to critically assess the clinical value of these 
developments by continuous monitoring and evalua-
tion of the results. 
The fact. that we could start a fellowship programm in 
cardiology in 1980 was of great significance. We con-
sidered this a recognition that we were successful in 
both implementing and critically assessing these new 
developments. In this thesis aspects of new treatment 
modalities in modern cardiology are addressed: throm-
bolysis and percutaneous transluminal coronary angi-
oplasty. 
THROMBOL VSIS 
The role of thrombosis in the etiology of acute 
myocardial infarction was first described by Herrick in 
1912. 1 In 1933 Tillett described that Lancefield Group 
A beta hemolytic streptococci isolated from patients 
produced a fibrinolytic substance2• called streptoki-
nase. Subsequently Sherry proved that the diffusion of 
streptokinase into the thrombus resulted in lysis ofthe 
clot. Streptokinase also activated plasminogen in the 
systemic circulation which produced fibrinogenolysis 
and impaired hemostasis.3•5 The first use of streptoki-
nase for treatment of acute myocardial infarction was 
reported by Fletcher in 19586• but the results were 
inconclusive. The finding that there were only a few 
complications and a low in-hospital mortality rate in 
patients treated with intravenous streptokinase led to 
large-scale studies. Stampfer and Yusuf7·s pooled all 
data from 18 studies. performed between 1963 and 
1979. which indicated that there was approximately a 
20% reduction in the mortality rate over the subsequent 
weeks following therapy with intravenous streptoki-
nase for acute myocardial infarction compared with 
conventional therapy. Nevertheless. thrombolysis was 
not accepted in medical practice until Rentrop in 1979 
demonstrated by angiography. that the intracoronary 
administration of streptokinase dissolved a coronary 
artery thrombus.9 Soon afterwards we began to treat 
acute myocardial infarction in our hospital with intra-
coronary streptokinase in selected patients with prom-
ising results. However. several practical limitations to 
this approach became evident. Twenty-four hour avail-
ability or stand-by of the catheterization laboratory 
staff is needed which is both laborious and expensive. 
After Schr0der10 again advocated the intravenous use 
of streptokinase in -1985 and others" had showed that 
the results were comparable with those of intracoro-
nary administration. the enthousiasm for intracoronary 
administration diminished rapidly. 
In 1983. the research department of Beecham labo-
ratories introduced a new thrombolytic agent for intra-
venous use: anisoylated plasminogen streptokinase ac-
tivator complex (APSAC). now called anistreplase. 12 
We concentrated on the use of this drug in our hospital 
and were the first to investigate anistreplase in patients. 
The results of the first 13 patients with acute myocar-
dial infarction treated with this thrombolytic agent in 
our department were reported in 1984. 13 The reper-
fusion rate tested by angiography was high (92%). This 
was sufficient reason to continue investigation with 
this new drug. 
We subsequently undertook a study. together with 
other hospitals in our region. in which we compared 
anistreplase to streptokinase. in patients with acute 
myocardial infarction. The first chapter of this thesis 
presents the results of this trial. In this open multicenter 
VII 
randomized trial we compared the reperfusion rates 
produced by intravenous anistreplase with those of 
intracoronary streptokinase at 90 minutes after dosing. 
and assessed in both groups the reocclusion rates at 24 
hours after dosing. Side-effects. coagulation and fibri-
nolytic parameters were also studied. In addition we 
compared both drugs with respect to their effect on 
major components of the coagulation- and fibrinolytic 
system and investigated the relations between the sys-
temic lytic state and clinical items as reperfusion. 
reocclusion and bleeding complications. The results 
are presented in chapter two. 
Since not all patients receiving anistreplase or strep-
tokinase in the trial had successful reperfusion. we 
investigated a possible explanation for unsuccessful 
thrombolytic therapy. In chapter three we report the 
effects of antibodies on reperfusion. reocclusion and 
haemostatic changes and the depletion of antibodies in 
response to the drug. 
In addition the effect of anistreplase on blood- and 
plasma viscosity. platelet function and any possible 
influence on the cardiac output during administration 
of this drug in patients with acute myocardial infarction 
were studied in more detail (chapter four). 
Chapter five deals with the use of nonionic contrast 
medium and its rheological effect. This contrast medi-
um is often used to investigate patients with myocar-
dial infarction. but its influence on hemorheology and 
platelet function had not been reported. When a noni-
onic contrast medium therefore is used during studies 
in patients with acute myocardial infarction. the influ-
ence on blood rheology or platelet function should be 
taken into account and corrections should be made. 
In chapter six the role of PTCA after intravenous 
streptokinase in acute myocardial infarction is dis-
cussed. A discussion on this subject is like the waves in 
the sea. advancing and receding. Several well designed 
randomized trials concerning PTCA in myocardial in-
farction patients have addressed this issue: Erbel et 
al. 14• Topol et ai. 15 and Simoons et al. 16• but controver-
sy remains. The benefits and risks of PTCA performed 
directly or electively after successful or unsuccessful 
thrombolysis in a selected group of patients are dis-
cussed in this chapter. 
PERCUTANEOUS TRAIIISLUMII\lAI. 
CORONARY AIIIGIOPLASTY 
The American radiologists Dotter and Judkins 
proved in 1964 that it is possible to reduce a severe 
stenosis in an artery by percutaneous angioplasty. 17 
They used progressively increasing sizes of catheters 
to decrease the stenosis and to increase the blood flow 
in patients with peripheral arteriosclerosis. In Europe 
Zeitler started to use this method and in 1974 Griintzig, 
trained by Zeitler. modified the multiple catheter sys-
tem of Dotter by developing a distensible double-
lumen balloon catheter made of polyvinylchloride. a 
material of low compliance. When the balloon was 
inflateS it created a circumferential pressure rather 
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than the axial force of the Dotter technique on the 
arteriosclerotic plaque. Grtintzig further miniaturized 
the balloon, tested the technique in human cadaver 
experiments and in September 1977 performed the first 
percutaneous transluminal coronary angioplasty 
(PTCA) in Ziirich. 18 This therapeutic tool represented 
a major breakthrough in the treatment of coronary 
artery stenosis. In the following years coronary angio-
plasty was also used to study the acute effects of 
myocardial ischemia. produced by inflation of the bal-
loon as reported by Serruys in 198619 
In the second part of this thesis several aspects 
related to the PTCA-procedure are described. 
Chapter seven reports the long-term follow-up (8.5 
years) of the first 100 patients with a left anterior 
descending coronary artery lesion treated with PTCA. 
The results were satisfactory. even though at that time 
PTCA catheters were rigid and non steerable. in con-
trast with the current flexible. steerable catheters. 
In chapter eight we describe the initial and long-term 
results of coronary angioplasty and coronary bypass 
surgery in patients 75 years or older. This is a fast 
growing group in our society with an increased morbid-
ity. Therefore it is important to make the correct deci-
sion as to who should be operated on and who should 
have PTCA, when medical treatment fails. Results 
indicated that the complications of PTCA were less 
than those of surgery. but still there were failures and 
complications such as acute occlusion and even cardio-
genic shock. 
Emergency coronary bypass operation is an accepted 
solution for such PTCA complications but requires 
close collaboration with cardiothoracic surgeons. 
Therefore we analyzed the possible risk factors in order 
to attempt to predict the likelihood of unfavorable 
outcome (chapter nine). 
Since PTCA provokes ischemia during balloon infla-
tion. which can be harmful for the left ventricle. we 
collaborated with the Cardiochemistry laboratory of 
the Thoraxcenter in Rotterdam in studies on the effects 
of intravenous diltiazem and metoprolol during angi-
oplasty of single-vessel coronary artery disease. The 
goal of both studies was to see if it would be possible 
to protect the left ventricle against ischemia with these 
drugs. The results are presented in chapters ten and 
eleven. 
Thus. the two sections of this thesis deal with two new 
therapeutic approaches in patients with coronary artery 
disease. which have been introduced in a large cardiol-
ogy practice of a non-academic centre over the last I 0 
years. Continuous critical assessment of such a new 
technology remains mandatory and requires good doc-
umentation of indications and results. This requires 
close collaboration with academic institutions and par-
ticipation in multicenter clinical trials. 
As Pasteur said: 
.. Keep your enthusiasm. but let strict verification be its 
constant companion ... 
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CHAPTER I 
Comparison of Intravenous Anisoylated 
Plasminogen Streptokinase Activator Complex 
and lntracoronary Streptokinase in Acute 
Myocardial Infarction 
Hans J.R.M. Bonnier, MD, Rombout F. Visser, MD, Huub C. Klomps, MD, 
Hans J.M.L. Hoffmann, Msc, and the Dutch Invasive Reperfusion Study Group* 
Coronary angiography was used to compare the ef~ 
ficacy of anisoylated plasminogen streptokinase ac-
tivator complex (APSAC) administered intrave-
nously and streptokinase given by intracoronary in-
fusion in inducing reperfusion in patients with a 
proven acute myocardial infarction. Forty-two pa-
tients received 30 U of APSAC intravenously over 
5 minutes and 43 patients received 250,000 iU of 
streptokinase given via intracoronary infusion over 
90 minutes, after occlusion of the infarct-related 
vessel was demonstrated by angiography. Reperfu· 
sion was achieved in 23 (64%) of 36 patients 
(mean time to reperfusion 46 minutes) treated with 
AP5AC and 25 (67%) of 37 patients (mean time to 
reperfusion 45 minutes) treated with int:racoronary 
streptokinase, who were angiographically evaluat-
ed 90 minutes after the start of treatment. Twenty-
four hours after treatment, reocclusion had oc-
curred in 1 (5%) of 22 patients in the APSAC 
group and in 3 (13%) of 23 patients in the strepto-
kinase group. No major bleeding was observed in 
either treatment group despite a similar systemic 
lytic state that lasted for up to 48 hours. Two pa-
tients treated with APSAC died after severe left 
ventricular failure unrelated to therapy. The results 
indicate that APSAC given intravenously is as ef-
fective as streptokinase given intracoronary in pro-
ducing thrombolysis in acute myocardial infarction. 
The major advantages of APSAC are its rapid and 
convenient administration by a single intravenous 
injection, the low rate of arterial reocclusion and 
good patient tolerance. 
(Am J Cardiel 1988;62:25-30) 
From the Departments of Cardiology and Clinical Laboratories. Cath· 
arina Hospital, the Department of Cardiology. St. Joseph Hospital, 
Eindhoven, and the Department of Cardiology, St. Jans HospitaL 
Weert, the Netherlands. Manuscript received December 28. 1987: re-
vised manuscript received and accepted March 15. 1988. 
Address-for reprints: Hans J.R.M. Bonnier. MD, Department of 
Cardiology, Catharina Hospital. Michelangelolaan 2. 5623 EJ Eindho--
ven. the Netherlands. 
* See Appendix. 
The role of coronary thrombosis as an initiator of acute myocardial infarction (AMI) has been well documented and is generally accepted. 1 The ben-
eficial effect of intravenous thrombolytic therapy with 
streptokinase was demonstrated in a large European 
multicenter trial, 2 which showed that for successful lysis 
of coronary artery thrombi patients should receive lytic 
therapy within 3 to 6 hours of the onset of symptoms of 
an AMI. The development of coronary catheterization 
and angiographic techniques, and the realization that 
standard intravenous infusion rates of streptokinase 
may have been insufficient to produce thrombolysis and 
hence salvage of myocardial tissue, led Rentrop et aJ3.4 
to treat early AMI with direct intracoronary infusions 
of streptokinase. These investigators were able to dem-
onstrate rapid arterial reperfusion in more than 70% of 
the patients and their results have been reviewed in de-
tail by Udall.5 Recently, Vermeer6 compared intrave-
nous and intracoronary streptokinase therapy in AMI 
and concluded that the intracoronary route gave better 
patency rates than the intravenous route. The principal 
disadvantage of streptokinase is that it has to be admin-
istered over 30 to 60 minutes 7 because of a significant 
incidence of hypotension and because systemic adminis-
tration of streptokinase is followed by rapid nonspecific 
degradation by inactivators, thus reducing the delivery 
of active material to the site of the thrombus. Also, 
while the intracoronary route is the more effective,6 the 
technique is more complicated and may delay further 
the start of treatment. Research has been directed to 
the development of better intravenous thrombolytic 
agents, with properties that would facilitate early treat-
ment of AMI. The properties of the anisoylated plas-
minogen streptokinase activator complex (APSAC), 
with its longer fibrinolytic activity and greater resis-
tance to early inactivation, make it particularly suitable 
for rapid intravenous injection in patients with AMI.' 
We performed this open, multicentered randomized 
trial to compare the reperfusion rates produced by in-
travenous APSAC with those of intracoronary strepto--
kinase at 90 minutes after dosing, and to assess, in both 
groups, the reocclusion rates at 24 hours after dosing, 
side effects and coagulation and fibrinolytic parame-
ters. 
METHODS 
Patients: Eighty-five patients (71 men and 14 wom-
en) ranging in age from 36 to 75 years (mean 55) par-
1 
TABLE I Clinical Variables on Admission 
Therapy 
APSAC SK Total 
(n = 42) (n = 43) (n = 85) 
Male/Female 35/7 36!7 71/14 
Mean age (yrs) (range) 55 (37-70) 55 (36-75) 55 (36-75) 
Anterior infarct 18 21 39 
Inferior infarct 24 22 46 
Angiography 
Initial perfusion grade 
0 36 32 68 
I 6 II 17 
T1me from onset of pain 
to therapy 
Mean (hrs) 2.5 2.3 2.4 
::S:2.5 hrs 19 26 45 
>2.5 hrs 23 17 40 
ASPAC an&lylated plasminogen streptokmasc activator complex; SK 
streptokinase. 
TABLE II Definitions of Periusion 
Grade 0 No antegrade flow beyond the 
(no perfusion) point of occlusion 
Grade 1 Contrast material passes beyond 
(penetration the area of obstruction but "hangs up" 
without pertusion) and fails to opacify the entire coronary 
bed distal to the obstruction 
Grade 2 Contrast material passes across the 
(partial perfusion) obstruction and opacities the coronary 
bed distal to the obstruction. However, 
the rate of entry of contrast material 
into the vessel or its rate of clearance 
from the distal bed, or both, are 
perceptibly slower than its entry into or 
clearance from comparable areas not 
pertused by the previously occluded 
vessel 
Grade 3 Antegrade flow into the bed distal to the 
(complete reperfusion) obstruction occurs as promptly as 
antegrade flow into the bed proximal to 
the obstruction. Clearance of 
contrast material from the involved bed 
is as rapid as clearance from an 
uninvolved bed in the same vessel or the 
opposite artery 
ticipated in the study. All patients had been referred to 
emergency departments within 4 hours of the onset of 
chest pain caused by AMI. Participating patients had 
chest pain of at least 30-minute duration and ST-seg-
ment elevation of at least 0.1 m V in 1 or more of the 
standard leads or at least 0.2 m V in 1 or more of the V 
leads in a 12-lead electrocardiogram. The symptoms 
were not relieved by sublingual glyceryl trinitrate. lf a 
patient had no contraindications to thrombolytic thera-
PY and informed consent was obtained, a coronary angi-
ography was performed. In case of an occluded infarct-
related vessel (TIM! grade 0 or 1 ), the patients were 
randomly assigned to treatment with either 30 U of in-
travenous APSAC or 250,000 !U of intracoronary 
streptokinase; 42 patients received APSAC and 43 re-
ceived streptokinase on an open basis. The 2 groups 
were similar in sex ratio, age, site of infarction and car-
diovascular characteristics (Table I). The mean time 
between onset of pain and start of lytic therapy was 
2 
slightly shorter in the streptokinase group (2.3 hours) 
compared with the APSAC group (2.5 hours). 
Treatment: APSAC is formulated in a mixture of 
clinical grade human albumin, D-mannitol and L-lysine 
(Eminase®, Beecham). It was supplied in vials contain-
ing 30 units of APSAC as a sterile off-white powder. 
Each 30 U dose of APSAC was dissolved in 5 ml of 
water for injection or physiologic saline and adminis-
tered intravenously over 5 minutes. Streptokinase was 
supplied as lyophilized powder in vials containing 
250,000 IU of purified streptokinase (Kabikinase®. Ka-
biVitrum). It was administered by intracoronary infu-
sion in physiologic saline at rates between 2.000 and 
5,000 IU /min. Ten patients were given intravenous bo-
lus injections of I 0,000 IU after each angiographic pro-
cedure. The total doses ranged from 64,000 IU in 45 
minutes (1 patient) to 500,000 !U in 90 minutes (1 pa-
tient). The mean streptokinase dosage was 275,000 IU 
and the mean time of administration 67 minutes. All 
patients received 5,000 IU of heparin before catheter-
ization. No additional heparin was given during the 
thrombolytic therapy. Anticoagulation therapy with 
heparin was started 4 hours after dosing. 
Angiographic evaluation: Angiography of the oc-
cluded infarct-related coronary artery was carried out 
by the Judkins technique before the patients were ran-
domized. After the start of lytic therapy, angiography 
was performed at IS-minute intervals for up to 90 min-
utes to assess coronary artery reperfusion. The catheter 
was removed after 90 minutes, but the sheath was left 
in the peripheral artery for 48 hours to minimize bleed-
ing from the puncture site. Approximately 24 hours af-
ter dosing, additional angiograms were performed to as-
sess the degree of reperfusion or to discover if reocclu-
sion had occurred. The degree of perfusion at each 
angiographic assessment was classified according to the 
criteria used in the TIM! trial9 (Table II). The angie-
grams were read blind by an independent cardiologist. 
ln the postdosing assessments, patients with grades 0 or 
I were considered to show no reperfusion of the infarct-
related vessels and those with grades 2 or 3 to show 
reperfusion. 
Coagulation parameters and fibrinolytic assays: 
Blood samples for analysis in the Central Caogulation 
Laboratory were taken before lytic therapy and at 90 
minutes, 12, 24 and 48 hours after therapy to assess 
fibrinogen concentration (clotting-rate method of 
Clauss), euglobulin clot lysis time, streptokinase resis-
tance titer and other parameters of fibrinolysis and co-
agulation. The blood for fibrinogen determinations was 
collected in tubes with a citrate anticoagulant, to which 
0.7 M E-aminocaproic acid had been added as an inhibi-
tor of in vitro fibrinogenolysis. All samples were pro-
cessed immediately after collection and plasma was fro-
zen at -70°C for future analysis. 
Adverse effects: Two deaths occurred, both in the 
APSAC group. One patient, a 58-year-old man, died of 
severe left ventricular failure during catheterization. 
This patient had had an AMI 5 years earlier. The sec-
ond, a 61-year-old woman, also died of left ventricular 
failure 2 days after treatment. This patient had shown 
T .ABLE m Results of Coronary Angiography 90 Minutes After Start of Treatment 
Therapy 
Intravenous lntracoronary 
APSAC (n = 42) SK (n "43) p Value 
Evaluated 36 37 
Not evaluated 6 6 
Site of Reperiusion No reperiusion Reperiusion No reperiusion 
Infarct (%) (%) (%) (%) 
AU evaluated patients Anterior 9 (60) 6 (40) 13 (72) 5 (28) NS (p <0.80) 
Inferior 14 (67) 7 (33) 12 (63) 7 (37) NS (p <0.98) 
Total 23 (64) 13 (36) 25 (68) 12 (32) NS (p <0.20) 
Initial perfusion 
Grade 0 Anterior 7 (54) 6 (46) 8 (62) 5 (38) 
Inferior 13 (65) 7 (35) 10 (67) 5 (33) 
Total 20 (61) 13 (39) 18 (64) 10 (36) 
Grade 1 Anterior 2 (100) - 5 (100) -
Inferior 1 (100) - 2 (50) 2 (50) 
Total 3 (100) - 7 (78) 2 (22) 
NS not significant. Other abbreviations as in Table I. 
TABLE IV Results of Coronary Angiography by Time of Treatment After Onset of Symptoms 
Therapy 
Intravenous lntracoronary 
APSAC (n "42) SK (n "43) p Value 
Evaluated 36 37 
Not evaluated 6 6 
Time to treatment Reperiusion No reperiusion Reperiusion No repertusion 
after onset of symptoms (%) (%) (%) (%) 
<2.5 hours 10 (77) 3 (23) 15 (65) 8 (35) NS 
?::::2.5 hours 13 (57) 10 (43) 10 (71) 4(29) NS 
Total 23 (64) 13 (36) 25 (6~) 12 (32) 
NS not significant. Other abbreviations as in Table I. 
TABLE V Results of Coronary Angiography 24 Hours After the Start of Treatment on Patients with Reperiusion 90 Minutes After 
the Start of Treatment 
Therapy 
Intravenous 
APSAC (n = 23) 
Evaluated 22 
Not evaluated 1 
Site of Reocclusion 
Infarct (%) 
AU evaluated patients Anterior 
-
Inferior 1 (7) 
Total 1 (5) 
reperfusion of an anterior infarct-related vessel after 90 
minutes and early reocclusion had not occurred. There 
was no evidence that there was a relation between these 
deaths and the patients' APSAC therapy. Otherwise, 
only minor adverse events occurred, with 2 patients de-
veloping hematoma at the puncture site after APSAC 
therapy and another showing hypotension of 5-minute 
duration that resolved after treatment. None of the pa-
tients required blood transfusions. 
lntracoronary 
SK (n "25) 
23 
2 
No reocclusion Reocc!usion No reocclusion 
(%) (%) (%) 
8 (100) 2 (17) 10 (83) 
13 (93) 1 (9) 10 (91) 
21 (95) 3 (13) 20 (87) 
One patient in the streptokinase group had angiogra-
phy stopped because of vomiting. Another developed 
hypotension during infusion (infusion was stopped after 
45 minutes and a total dose of 96,000 IU of streptoki-
nase). The hypotension disappeared after treatment. 
Slalis11ical analysis: A 2-tailed chi-square test was 
used in analyzing the reperfusion data, with a = 0.05 
and df = I. The Fisher exact test was used to test for 
possible differences between the group of patients treat-
3 
ed within 2.5 hours and those treated 2.5 to 4 hours. 
Values obtained from the Fisher exact test were 2-
tailed, tested at a = 0.05. One-factor analysis of vari-
ance was performed on coagulation parameters and the 
results of fibrinolytic assays. 
RESULTS 
Angiographic findings: The findings 90 minutes af-
ter the start of lytic therapy were taken as the point for 
determining whether or not a patient had gained satis-
factory reperfusion of the infarct-related vessel, with the 
angiographic examination 24 hours after therapy car-
ried out to determine if the infarct-related vessel was 
still patent or if rethrombosis had occurred (Tables Ill 
and V). 
Intravenous anisoylated plasminogen streptokinase 
activator complex: Thirty-six of the 42 patients who re-
ceived intraveous APSAC had coronary angiography 
performed 90 minutes after treatment. Twenty three 
(64%) of these patients showed reperfusion; 9 (60%) 
from the group with anterior infarcts and 14 (67%) 
from the group with inferior infarcts. The mean time to 
reperfusion was 46 minutes (Table Ill). All 13 patients 
who did not show reperfusion at 90 minutes had shown 
no perfusion (TIMI grade 0) at the pretreatment angi-
ography. Six (46%) of these patients had anterior in-
farcts and 7 (54%) inferior infarcts. Of the 13 evaluated 
patients who received APSAC within 2.5 hours of the 
onset of symptoms, reperfusion was achieved in I 0 
(77%) patients, compared with 13 (57%) of the 23 pa-
tients who were treated between 2.5 hours and 4 hours 
after the onset of symptoms (difference not significant) 
(Table IV). One of the 6 patients not assessed at 90 
minutes had died of severe left ventricular failure dur-
ing catheterization. The other 5 patients had shown re-
perfusion but coronary angiography was discontinued 
before 90 minutes. In 2 of these patients a percutaneous 
transluminal coronary angioplasty was performed at 60 
minutes and 75 minutes, respectively, after treatment; 
in the other 3 angiography was stopped for various rea-
sons at 45, 60 and 75 minutes after treatment, respec-
tively. 
lntracoronary streptokinase: Coronary angiography 
was performed 90 minutes after the start of infusion of 
streptokinase in 37 of the 43 patients. Twenty-five 
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FIGURE 1. Course of fibrinogen and euglobulin dot lysis time 
(mean± standard deviation) in patients treated with intrave~ 
nous anisoylated plasminogen streptokinase activator complex 
(thatched bars) and intracoronary streptokinase (clear bars). 
* p <0.02; * * p <0.005 by analysis of variance. 
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(68%) patients showed reperfusions of the infarct-relat-
ed vessels; 13 (72%) from the group with anterior in-
farcts and 12 (63%) from the group with inferior in-
farcts (Table HI). The mean time to reperfusion was 45 
minutes. Five (42%) of the 12 patients who did not 
show reperfusion had anterior infarcts and 7 (58%) had 
inferior infarcts. Ten of these 12 had shown no perfu-
sion (TIMl grade 0) at pretreatment coronary angiog-
raphy. Fifteen (65%) of the 23 evaluated patients who 
received streptokinase within 2.5 hours of the onset of 
symptoms showed reperfusion, compared with 10 (71%) 
of the 14 patients who were treated between 2.5 hours 
and 4 hours after the onset of symptoms (difference not 
significant) (Table IV). Six patients could not be evalu-
ated at 90 minutes. Three of them showed reperfusion 
at 60 minutes but angiography was not continued; I of 
these patients had angiography discontinued because of 
vomiting while in the other 2 angiography was discon-
tinued because of other reasons. Two of the patients 
who were not examined at 90 minutes did not show re-
perfusion at 60 minutes and 75 minutes, respectively, 
requiring mechanical clearance by guidewire perfora-
tion of the infarct-related vessel followed by percutane-
ous transluminal coronary angiop!asty. One patient was 
withdrawn from the trial as his age (75 years) was out-
side the range specified in the protocol (:$70 years). 
Of the 23 patients in the APSAC group, 22 patients 
with reperfusion at 90 minutes were reassessed by coro-
nary arteriography after 24 hours. One patient was not 
reassessed because the procedure failed. Only I (5%) 
patient with an inferior infarct showed reocclusion (Ta-
ble V). Coronary angiography was performed at 24 
hours in 23 of the 25 patients treated with streptokinase 
who had shown reperfusion at 90 minutes. One of the 2 
patients not assessed had undergone percutaneous trans-
luminal coronary angiop!asty and the other coronary 
artery bypass grafting. Three (13%) patients showed 
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FIGURE 2. Streptokinase resistance titer in both treatment 
groups. Note logarithmic ordinate. 0 = reperiused; • = not re-
perfused (at 90 minutes). 
reocclusion, 2 of whom had anterior infarcts and I an 
inferior infarct (Table V). 
Coagulation and fibrinolytic assays: The changes in 
the most important parameters, plasma fibrinogen con-
centration and euglobulin clot lysis time, are given in 
Figure I. Fibrinogen rapidly decreased in both groups 
after therapy, reaching minimal levels 90 minutes after 
the start of therapy. In the APSAC treated patients the 
mean fibrinogen concentration at this time (33 ± 31 
mg/ dl) was lower than that in the patients treated with 
streptokinase (50± 34 mgjdl) (analysis of variance not 
significant). Thereafter, fibrinogen levels increased and 
returned toward pretreatment values between 24 and 48 
hours after treatment. 
The euglobulin clot lysis time sharply decreased; i.e., 
total fibrinolytic activity in plasma increased, reaching a 
minimum 90 minutes after dosing and thereafter gradu-
ally increasing in both groups. The euglobulin clot lysis 
time was significantly lower among patients treated 
with APSAC, both at 24 hours (p <0.02, analysis of 
variance) and at 48 hours (p <0.005, analysis of vari-
ance) after lytic therapy, reflecting the sustained fibri-
nolytic activity of APSAC. 
The streptokinase-inhibiting capacity of plasma, 
measured as streptokinase resistance titer in pretreat-
ment plasma, was identical in both groups (Figure 2): 
mean 148 U/ml (range 20 to 1,000) in the APSAC 
treated patients and mean 148 U/ml (range 13 to 
1,000) in the patients who received streptokinase. There 
was no correlation between pretreatment streptokinase 
resistance titer and occurrence of reperfusion in either 
group, as indicated in Figure 2. More detailed results of 
coagulation and fibrinolysis studies in these patients 
have been published elsewhere.IO 
DISCUSSION 
In nearly 90% of patients, coronary arterial occlu-
sion is likely to be present in the first 4 hours after the 
onset of symptoms of AMI. 1 However, in an individual 
patient it is not possible to be certain that occlusion and 
subsequent reperfusion have occurred unless coronary 
angiography has been performed before and after lytic 
therapy. 
The importance of thrombolytic therapy in the treat-
ment of AMI has been confirmed by recent studies car-
ried out in Europe and the US using intracoronary 
streptokinase. In the Western Washington TriaJI1.1 2 a 
reperfusion rate of 69% was achieved after thrombolytic 
therapy, although there was no significant difference in 
patient survival I year after therapy between these pa-
tients and a control group who received nonthromboly-
tic therapy. These results are comparable with those of 
the Interuniversity Cardiology Institute of the Nether-
lands Study Group,6 which found an 85% patency rate 
in infarct-related vessels after thrombolytic therapy and 
a significantly higher survival rate I year after therapy 
among the patients who received thrombolytic treat-
ment (90 vs 84% in the control group). Simoons et al13 
have noted a similar decrease in mortality rates in-
hospital after thrombolytic therapy. Verrneer6 suggests 
that the differences in long-term mortality rates be-
tween the Interuniversity Cardiology Institute of the 
Netherlands Study Group findings and those in the 
Western Washington Trial are partly attributable to the 
greater delay between onset of symptoms and start of 
therapy in the latter trial. The benefits of early throm-
bolytic therapy have been demonstrated in the GISSI14 
trial (1.5 X 106 U streptokinase by intravenous infusion 
vs placebo), when a marked reduction in hospital mor-
tality was seen in patients who received thrombolytic 
therapy within 4 hours of the onset of symptoms, com-
pared with those whose treatment was more delayed. 
The largest decrease in mortality was seen among pa-
tients treated within I hour of the onset of symptoms. 
The present study shows that 30 U of APSAC by 
intravenous injection is as effective as 250,000 IU of 
streptokinase by intracoronary infusion in producing re-
perfusion in occluded coronary arteries within 90 min-
utes of treatment. Futherrnore, the administration of 
APSAC as a single intravenous injection in 5 minutes is 
easier and quicker than intracoronary infusion of strep-
tokinase in patients with AMI because of the delay 
caused by the catheterization of the patient for the in-
tracoronary procedure. 
After streptokinase therapy, fibrinogen decreased to 
about 22% of pretreatment values, which was close to 
the values found in other studies on intracoronary strep-
tokinase15.16 In the APSAC treated patients there was 
a marked reduction in fibrinogen to 15% of pretreat-
ment values, a result identical to our earlier findings. 17 
When given in equally effective doses, both drugs 
systemically activate the fibrinolytic system in most pa-
tients (93%) to similar degrees, without causing signif-
icant bleeding. The differences in euglobulin clot ly-
sis time between the treatment groups indicate that 
APSAC has a more sustained fibrinolytic activity than 
streptokinase. In the present study, reocclusion occurred 
in more patients treated with streptokinase (3 patients, 
13%) than in the APSAC group (I patient, 5%). How-
ever, the small number of patients in this trial should be 
noted. 
We believe that APSAC is well suited for rapid 
thrombolysis of relatively fresh clots, as evidenced by 
the 77% of patients in this study treated within 2.5 
hours of the onset of symptoms of AMI who showed 
reperfusion 90 minutes after dosing, compared with 
56% of patients whose treatment was more delayed. In 
contrast, the difference in reperfusion rates between pa-
tients who were treated early and those treated late with 
streptokinase was far less marked. 
APSAC can be given successfully and safely as a 
single intravenous injection. These are advantages that 
the other known plasminogen activators, which are ei-
ther hypotensive at high doses or are cleared too rapid-
ly, are not likely to have. 
APSAC apparently reduced the incidence of early 
reocclusion observed by most investigators after throm-
bolytic therapy with streptokinase in AMI. This can be 
explained by APSAC's prolonged fibrinolytic activity, 
resistance to autodegradation and strong fibrin affinity. 
However, further trials are needed to confirm that the 
incidence is, indeed, lower. 
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CHAPTER 2 
Systemic Effects of Thrombolytic Drugs in Acute Myocardial Infarction: 
Comparison oflntravenous APSAC (BRL 26921) and Intracoronary 
Streptokinase 
J. J. M. L. Hoffmann, J. J. R. M. Bonnier, J. B. R. M. De Swart 
SUMMARY. The systemic effects of intravenous anisoylated plasminogen-streptokinase activator complex 
(APSAC; BRL 26921; 30 U) and intra coronary streptokinase (250 000 U) were compared in 70 patients with acute 
myocardial infarction. In 5 patients no signs of a systemic lytic state were observed. In all other patients, significant 
consumption of coagulation and fibrinolytic factors occurred: fibrinogen levels decreased by 85% in the APSAC 
group and 78% in the streptokinase-treated patients. For plasminogen the decreases were 68% and 64% and for 
a 2-antiplasmin activity >95% and 87% (APSAC and streptokinase, respectively). Fibrin(ogen) degradation prod-
ucts were generated t" mean levels of 739 mg/L and 355 mg/L, respectively. Although there was a trend for the lytic 
state to be more profound in the APSACwtreated patients, no difference with the streptokinase group was observed 
with regard to bleeding complications or therapeutic efficacy, which was 64% and 68% respectively for APSAC and 
streptokinase. The total fibrinolytic activity, measured as euglobulin clot lysis time, sustained longer in the APSAC 
group, which might be the reason for the low reocclusion rate (4.5%) in comparison with the SK group (13%). 
KEYWORDS. Acyl-enzymes. APSAC. Myocardial infarction. Systemic lytic state. Streptokinase. Thrombolysis. 
Acyl~enzymes with plasminogen activator potency 
constitute a new approach in the field of dinical fibrin-
olysis.!. 2 Their principle of action is that the acyl form 
of the enzyme, which is catalytically inactive, will be 
hydrolysed under physiological conditions according 
to first-order kinetics. By this spontaneous deacyla-
tion an active plasminogen activator is generated in 
the circulation with a controlled rate, so that a long-
acting fibrinolytic activity will be obtained. 
Of the acyl-enzymes available, the anisoylated 
plasminogen-streptokinase activator complex 
(APSAC; formerly BRL 26921) has been best investi-
gated. From prior investigations in limited numbers of 
patients with acute myocardial infarction it appears 
that APSAC is an effective thrombolytic agent. 3- 6 
Unfortunately, its relative fibrin-selectivity present in 
animal systemsL 2 . 7 has not been found in humans. 
probably because of interspecies differences in plas-
minogen activation kinetics2 or in binding to fibrin. 
Because of its efficacy and its favourable kinetic 
properties, which allow iv bolus administration. 
J. J. M. L Hoffmann. Hemostasis Division. Department of Clinical 
Laboratories. J. J. R. M. Bonnier. on behalf of the Dutch IRS 
group, Department of Cardiology. Catharina Hospital. Eindhoven, 
J. B. R. M. De Swart, Department of Cardiology. University Hospi-
tal, Maastricht, The Netherlands. 
APSAC is considered as a promising thrombolytic 
drug. Several clinical trials in patients with acute myo-
cardial infarction are at present in progress in order to 
assess its value in clinical practice. 
Up to now there are no studies published in which 
APSAC was compared with the standard drug for 
thrombolytic treatment, namely streptokinase (SK). 
Therefore we studied 85 patients with acute myo-
cardial infarction in an open, randomised multicentre 
trial comparing SK (250 000 U by intracoronary in-
fusion) and APSAC (30 U by rapid intravenous injec-
tion); this dosis of APSAC contains approximately 1 
million units of SK, complexed to plasminogen and 
inactivated by active-site acylation. The aim of this 
study was to compare both drugs with respect to their 
effect on major components of the coagulation and 
fibrinolytic systems and to investigate possible rela-
tions between the systemic lytic state and clinical items 
as reperfusion. reocclusion and bleeding complications. 
PATIENTS AND METHODS 
Patients 
Eighty five patients with acute myocardial infarction 
entered the study. There were 14 females and 71 males. 
7 
39 with anterior and 46 with inferior myocardial 
infarction. The age of the patients ranged from 36 to 
70 years, mean age 54.8 years. All patients gave their 
informed consent for participating in the study, which 
had been approved by the local ethical committee. 
Study Protocol 
In the patients fulfilling the inclusion criteria, angio-
graphy was performed to document occlusion of one 
or more coronary vessels. Then, the patients were ran-
demised to either of two treatment regimens: APSAC 
(30 U; equivalent on a molar basis to about I million 
U of SK) by single intravenous injection during 2-
4 min or SK (250 000 U) by intracoronary infusion for 
60 min. Thrombolytic therapy was always started 
within 4 h from the onset of chest pain. The adminis-
tration of heparin was allowed as a catheter flush 
(5000 U by bolus injection) at the insertion of cath-
eters and heparin was mandatory after thrombolytic 
therapy (1000 Ujh as a continuous infusion): in the 
APSAC-treated patients it started 4 h after starting 
thrombolytic therapy and in the SK-group as soon as 
the thrombin time decreased below twice the upper 
normal limit (usually 3-5 h after starting SK). In all 
cases heparin infusion was maintained up to 24 h after 
starting thrombolysis; thereafter oral anticoagulants 
were given if necessary. Repeat coronary angiograms 
were made at 15 min intervals during the first 1 h 
30 min and 24 h after starting therapy for assessing 
coronary reperf)Jsion and reocclusion, respectively. 
The study was carried out by members of the Dutch 
IRS group (see appendix) in three hospitals in the 
south-eastern part of the Netherlands. 
Methods 
Blood for coagulation and fibrinolysis studies was col-
lected in plastic syringes containing 1/10 volume of 
0.1 M sodium citrate (for a 2-antiplasmin, euglobulin 
clot lysis time and streptokinase resistance titer deter-
minations) and 0.1 M sodium citrate plus 0.07 M 
e-aminocaproic acid for all other determinations. 
Blood was centrifuged immediately at 4°C and plasma 
was snap-frozen and stored at - 70"C until testing. All 
analyses were carried out in the central coagulation 
laboratory. From 15 patients no or insufficient plasma 
was available for testing. Fibrinogen concentration 
was measured with the clotting-rate method (Clauss): 
prothrombin time (PT). activated partial thrombo-
plastin time (APTT), thrombin time (IT) and rep-
tilase time (RT) according to standard metnods using 
commercial reagents. APTTs were measured without 
and with addition of Polybrene for heparin neutralisa-
tion.8 Serum fibrin/fibrinogen degradation products 
(FDPjfdp) were estimated semi-quantitatively using a 
latex agglutination assay (Thrombo-Wellcotest; Well-
come Diagnostics). Plasminogen and a2-antiplasmin 
activities were determined using the chromogenic sub-
strates S-2251 (Kabi) and euglobulin clot lysis time 
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Table 1 Patient Characteristics and Outcome of Thrombolytic 
Therapy. Non-evaluable Patients have been Omitted 
Number of patients 
sex(M:F) 
age. mean ±SD (y) 
Systemic lytic state 
reperfusion 
no reperfusion 
No systemic lytic stafc 
reperfusion 
no reperfusion 
Reperfusion 
Major bleeding 
Reocclusion 
APSAC SK 
36 
30o6 
54.6±8.1 
33f36 (9!.7%) 
23/33 
10/33 
3j36 (8.1%) 
0/3 
3/3 
23j36 (63.9%) 
None 
1/22 (4.5%) 
34 
27:7 
54.8±10.1 
32/34 (94.1%) 
21/32 
II/32 
2/34 (5.9%) 
2/2 
0/2 
23/34 (67.7%) 
None 
3/23 (!3.0%) 
(ECL T) according to Nilsson et al9 Streptokinase 
resistance titers in plasma were measured using the 
technique ofDeutsch. 10 
A systemic lytic state was defined as a decrease in 
fibrinogen concentration after thrombolytic therapy 
by at least 10% of the pretreatment value. 11 
Statistics 
For statistical evaluation we used analysis of variance, 
if indicated after logarithmic transformation of the 
data. P values <0.05 were considered significant. 
RESULTS 
The patient characteristics and clinical findings are 
summarised in Table 1. The composition of the two 
treatment groups was closely comparable. The efficacy 
of APSAC, expressed as reperfusion rate at 1 h 30 min 
was 64%, not significantly different from 68% for SK. 
The incidence of reocclusion of initially reperfused 
coronary arteries was 4.5 and 13%, respectively. 
Minor bleeding from puncture sites occurred fre-
quently in both groups, but major bleeding did not 
occur in this study and no patient required blood 
transfusion. 
In 5 out of the 70 patients of whom adequate 
samples were available for testing, no signs of a sys-
temic lytic state could be observed (3 APSAC and 
2 SK). In both SK-treated patients, successful roper-
fusion was achieved, in the 3 others, treated with 
APSAC, it was not. The data of these 5 patients have 
been excluded from the statistical analysis. The course 
of the coagulation parameters of the remaining 
patients is shown in Figure 1. The pretreatment values 
were identical in both groups and only slight devi-
ations from the normal range were seen in some 
patients. After therapy, however, considerable changes 
became apparent: fibrinogen concentration fell to very 
low levels, while the Polybrene-APTT. PT (not 
shown). thrombin time and reptilase time were 
strongly prolonged during the early post-treatment 
period. 
The nadir of fibrinogen was approximately 15% 
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Fig. I Course of coagulation parameters during thrombolytic therapy with APSAC ( 0) and SK ( 0). Mean± SD is shown. *p<0.05. 
(APSAC) and 22% (SK) of the respective pre-
treatment values, and it was normal again at 48 h; the 
differences between both groups were never statistic-
ally significant. The course of the other coagulation 
parameters was also comparable between the two 
groups, except significant differences in PT and rep-
tilase time at 1 h 30 min and 12 h post-treatment. 
The course of the fibrinolytic parameters is shown 
in Figure 2. In the APSAC group, significantly more 
FDP/fdp were generated during therapy than in the 
SK group. Plasminogen was consumed to about one 
third its original level in both groups. txrAntiplasmin 
activity became undetectably low in all but 1 APSAC-
treated patients, but in only a part of the patients in 
the SK-group. The difference in a2-antiplasmin at 1 h 
30 min was significant (p<0.005) between both 
groups. The total fibrinolytic activity in euglobulin 
fractions sharply increased (i.e. ECL T decreased) after 
therapy and then slowly decreased. The differences in 
ECL T between both groups at 24 and 48 h were statis-
tically significant (p < 0.02 and p < 0.005, respectively), 
indicating that APSAC has a more sustained fibrin-
olytic effect than SK. The streptokinase-inhibiting ac-
tivity in plasma, measured as SK-resistance titer 
(SKRT), was identical in both groups: mean 148 
(range 15-1000) U/mL in the APSAC group and 
mean 148 (range 13-1000) in the SK group. The de-
gree of fibrinolysis as a function of pretreatment 
SKRT is shown in Figure 3: the correlation coefficient 
(by linear regression) was 0.173 (not significant). 
DISCUSSION 
Although APSAC is much less fibrin-selective in 
humans3- 6 than in animals..:!:. 7 · 12 it might be better 
suited for clinical usage than SK, due to the possibility 
of rapid intravenous administration. Then. APSAC 
should not cause more side effects. mainly systemic 
lysis, than SK does. These systemic effects of APSAC 
were the subject of this comparative study with intra-
coronary SK, which is considered as the standard for 
thrombolytic treatment of acute myocardial infarc-
tion.13 
A major problem in assessing the coagulation sys-
tem during thrombolytic therapy is that the fibrinoly-
tic activity will continue in vitro after blood collection, 
thereby giving falsely low results for fibrinogen and 
other factors and falsely elevated levels of FDP/fdp." 
In order to prevent in vitro fibrinogenolysis to go on, 
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we have collected blood in anticoagulant containing 
.::-aminocaproic acid for those determinations, in 
which this inhibitor had been shown not to interfere 
(unpublished results). Only >,-antiplasmin, euglobu-
lin clot lysis time and streptokinase resistance had to 
be determined in plain anticoagulated plasma. 
After SK therapy. fibrinogen decreased to about 
22% of pre-treatment values in our patients (Fig. 1), a 
value close to that of other studies on intracoronary 
SK. 15• 16 In the APSAC group the fall in fibrinogen 
was marked. to 15% of baseline values, which is ident-
icai with our earlier observations, 5 but clearly lower 
than in two recent studies on intravenous 
APSACP· 18 This discrepancy is probably caused by 
the different methods used: we used the Clauss tech-
nique. which reflects rapidly coagulable fibrinogen 
and can be negatively influenced by higher levels of 
FOP. The methods used by the other authors measure 
total clottable protein and may include some slowly-
coagulable fibrinogen fragments. In any case, all 
available studies with SK and APSAC. administered 
locally or systemically, indicate that after administra-
tion of therapeutically effective doses, fibrinogen will 
fall to low levels, often below 0.5 g/L, but rapidly in-
creases to normal values within 48 h (Fig. 1). 5 • 6 · 1.1-18 
From Figure I it is concluded that global coagula-
tion tests provide little, if any additional information 
during thrombolytic therapy. In order to appreciate 
the effect of thrombolytic therapy on these global 
assays without the effect of heparin interfering, we in-
cluded two heparin-insensitive coagulation assays, the 
Polybrene-APTT8 and the reptilase time. Even with 
these tests the information obtained is limited. As 
Figure I shows, the reptilase time is probably the best 
global test for monitoring thrombolytic therapy! 
although fibrinogen concentration alone appears to 
be sufficient for this purpose. 
As a consequence of fibrinogenolysis FDP/fdp in-
creased to very high levels in both treatment groups 
(Fig. 2). The peak level of FDP/fdp in the APSAC 
group (739 mg/L) corresponds to about 30% of the 
pretreatment fibrinogen concentration, a value ident-
ical with that found in high-dose (1.5 million U) intra-
venou~ SK therapy. 14 
In line with expectations, the ECLT fell extremely 
after therapy in both groups. In most patients, the clot 
in the euglobulin preparation dissolved immediately, 
as has been described by others. 17· 18 In the early post-
therapy period we found no difference in ECL T 
between APSAC and SK, but the fibrinolytic activity 
in the SK group was approximately normal at 24 and 
48 h, while in the APSAC group it was still elevated 
(Fig. 2). This sustained fibrinolytic activity might be 
speculated to be a factor of importance in preventing 
early reocclusion. A similar suggestion on a relation 
between the lytic state.and reocclusion has been made 
by others:~· 1 7 
Plasminogen activities were identical in both 
groups throughout therapy; the lowest activity, about 
30% of the pretreatment level, is in reasonable agree-
ment with data from studies on APSAC*· 18 and SK. 14 
but the minimum was not as low as in our earlier 
study:5 the reaso•. wr this remains unexplained. 
Functional :x 2-antiplasmin decreased to undetect-
able levels in the majority of patients, both in APSAC 
and SK (Fig. 2). This is fully in keeping with the con-
cept that fibrinogenolysis only occurs once the plasmin 
generated has completely exhausted circulating free cxr 
antiplasmin. This process is much better reflected by 
measurement of cx2-antiplasmin activity than by an 
immunological assay. 5 Data on cx2-antiplasmin during 
thrombolytic therapy are rather scarce: Walker et al 3 
observed a mean decrease to 28% of the baseline value 
after APSAC in varying doses, but there was no sys-
temic lysis in all of their patients and if it was, not as 
profound as in our study (mean decrease in fibrinogen: 
44%). The results on ~,-antiplasmin reported by 
Collen et al 14 in patients treated with high-dose 
intravenous SK are not easily explained: fibrinogen 
fell to below 10% of its initial concentration, but :x 2-
antiplasmin had decreased to only 24/~ of its pretreat-
ment activity, while one should expect extremely low 
levels with such a degree of fibrinogenolysis. The re-
sults shown in Figure 1 and 2 indicate only a few 
statistically significant, but clinically hardly relevant 
differences between the systemic effects of APSAC and 
SK, while their clinical efficacy and safety was ident-
ical (Table 1). The degree of systemic lysis appeared to 
be somewhat more profound in the APSAC group, 
but one should realise that 30 U of APSAC is equiva-
lent to approximately I million U of streptokinase. 
Table 1 shows a correlation between reperfusion 
and the occurrence of a systemic lytic state, especially 
in the case of APSAC, while a truly local effect of SK 
was observed in two patients who had reperfusion 
without a systemic lytic state. However, the small 
number of patients does not allow to draw a firm con-
clusion on this subject. In agreement with others we 
found no correlation between presence of systemic 
lysis and major bleeding complications.6 • 18 
The significance of anti-SK antibodies has up to 
present not been investigated in detail and certainly 
not so in APSAC therapy. The effect of SK-resistance 
on systemic lysis is difficult to interpret from the re-
sults of Walker et a1 3 because of the low number of 
patients and the wide range of doses applied. Figure 3 
indicates that the effects of APSAC may be modulated 
by anti-SK antibodies: high SK-resistance titers some-
times prevent a systemic lytic state to occur, but there 
is no significant correlation between these parameters. 
Reperfusion appears not to be related at all with SK 
resistance titers, irrespective whether APSAC or SK 
was the thrombolytic drug administered. 
In conclusion, the results of our present investi-
gation can be summarised as follows: when adminis-
tered in equally effective doses, intravenous APSAC 
and intracoronary SK both will give rise to systemic 
activation of the fibrinolytic system in the majority 
(93%) of patients, to a closely comparable degree, but 
without the systemic lysis causing significant bleeding. 
Since early thrombolytic treatment can substantially 
reduce early mortality from acute myocardial infarc-
tion 19 and time-consuming cardiac catheterisation is 
obviated, intravenous APSAC seems one of the better 
thrombolytic drugs currently available. 
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APPENDIX 
The members of the Dutch Invasive Repcrfusion Study (IRS) 
Group arc: J. J. R. M. Bonnier (study coordinator). M. L H. El 
Gam::>l. H. R. Michels. J. B. R. M. de Sw::>rt (C::>tharina Hospital 
Eindhoven): A. H. Bosma. M. C Huigc, P. Slcgcrs. R. F. Visser (St 
Joseph Hospital, Eindhoven): H. Klomps and H. Penn (St Jan's 
Hospital. Weert): J. J. M. L. Hoffmann (central coagulation laborat-
ory) and D. A. L. G. Aclvoet (organisation). 
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CHAPTER 3 
Significance of Antibodies to Streptokinase in Coronary Thrombolytic 
Therapy with Streptokinase or APSAC 
J. J. M. L. Hoffmann, R. Fears. J. J. R. M. Bonnier, R. Standring, H. Ferres, J. B. R. M. De Swart 
SU 1\11\1 AR Y. In 61 patients with acute myocardial infarction, who received thrombolytic therapy with intra-
coronary streptokinase (250 000 U) or intravenous anisoylated plasminogen-streptokinase complex APSAC (30 U), 
the concentration of IgG antibodies to streptokinase (IgG anti-SK) was measured using a recently developed micro-
radioimmunoassay technique. The distribution of lgG anti-SK in the patients was approximately log-normal with a 
geometric mean of 0.84 !lg/mL The correlation with the streptokinase resistance titer was statistically significant, 
but there was a wide scatter of individual results. 
In both drug regimens a significant correlation was found (r = 0.51 and 0.67) between degree of systemic lytic 
state, expressed as residual fibrinogen 1.5 h after dosing, and pretreatment IgG anti~SK, as well as between post-
treatment euglobulin clot lysis time and pre-treatment lgG anti-SK (p < 0.025). Comparable, angiographically-
defined reperfusion rates were obtained for intravenous APSAC (66%) and intracoronary SK (69%). For both 
APSAC and SK there was no significant difference in initial IgG anti-SK between the patients who achieved reper-
fusion and those who did not. However, the rarity of patients with very high antibody levels in this study precludes a 
definitive conclusion on reperfusion success in such patients. There was no correlation between time at which sus-
tained reperfusion was achieved (mean interval 45 min for APSAC a!'ld 47 min for streptokinase) and baseline IgG 
anti-SK levels. The incidence of side effects of APSAC and SK was too low to examine in relation with antibody 
levels. 
The time course of changes in IgG anti-SK during the first 48 h after therapy was independent of drug regimen and 
pre-treatment antibody leveL The maximum decrease in IgG anti-SK concentration after dosing was approximately 
1.0 l'gfml. This is less than the amount expected by stoichiometic binding of APSAC with antibody and indicates 
that APSAC might be poorly bound by antibodies to streptokinase. 
Although concurrent studies in vitro demonstrate that IgG anti-SK can bind and at high concentrations even cause 
some loss of activity for a streptokinase-containing thrombolytic agent, the present clinical results show that the 
reperfusion response in our population of patients was not significantly affected by IgG anti-SK at therapeutic doses 
of intravenous APSAC or intracoronary SK, while the systemic lytic state was significantly influenced by anti-SK 
antibodies. 
KEYWORDS. Anti-streptokinase antibodies. Intravenous APSAC. Acute myocardial infarction. Reperfusion. 
Intracoronary streptokinase. Streptokinase resistance. Systemic lytic state. 
More than 40 years after the discovery of the fibrinoly-
tic properties of streptokinase (SK). renewed interest 
in thrombolytic agents has arisen after the demonstra-
tion that SK could effectively restore the blood flow in 
occluded coronary arteries of patients with acute myo-
cardial infarction. 1 It recently became evident that 
early thrombolytic treatment with SK significantly 
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Hospital. Eindhoven. The Netherlands. R. Fears., R. Standring. 
H. Ferres.. Beecham Pharmaceuticals, Rc:;;earch Division, Great 
Burgh, Epsom. England. J. B. R. M. De Swart. University Hospital 
Maastricht, The Netherlands. 
reduced the mortality in such patients, 2 · 3 but reperfu-
sion trials indicate that 20-30% of the patients fail to 
respond to thrombolytic treatment. 1 The reasons for 
this failure are largely unknown. 
Some authors have explained at least part of the 
therapeutic failures of SK by high levels of antibodies 
to SK in those patients.'1 · 5 It is known that following 
infections with streptococci and after administration 
of SK. antibodies to streptococcal proteins are 
formed 6 • 7 which are capable of reacting with SK and 
neutralising its potency to activate the fibrinolytic sys-
tem:1·8 However, absence of systemic fibrinolytic 
activity is not necessarily identical with failure to lyse 
13 
coronary thrombi, although there may be a relation-
ship in some patients.9- 11 So, adequate evidence from 
clinical studies that antibodies to SK can prevent suc-
cessful dissolution of thrombi is currently not avail-
able in the literature, certainly not concerning 
thrombolytic therapy in acute myocardial infarction. 
Most authors who reported measurements of anti-
SK activity in blood or plasma have relied upon the 
streptokinase resistance test (SKRT) or some modifi-
cation of it.6 · 7 · 12 However, this functional assay of 
total SK inhibiting capacity is not specific for anti-
bodies to SK, since it also measures other inhibitors, 
such as antiplasmin. 7 Moreover, the SKRT cannot be 
carried out in samples containing SK; therefore, 
studies on antibodies to SK during thrombolytic 
therapy have been impossible. Recently a sensitive 
radioimmunoassay has been described which does not 
have these disadvantages. 13 
We now present results obtained using this assay in 
a recent randomised comparative study on intra-
venously administered anisoylated plasminogen-
streptokinase activator complex (APSAC; BRL 
26921), a novel thrombolytic agent/' and intra-
coronary SK in acute myocardial infarction. 15• 16 
Overall, these drug regimens achieved comparable 
reperfusion rates (64% for APSAC and 68% for SK) 
and the aim of the present study was to investigate the 
significance of anti-SK antibodies in the clinical re-
sponse (reperfusion and haemostatic changes). In 
addition, data are presented on the course ofigG anti-
SK concentrations during the first 48 h after thrombo-
lytic treatment with APSAC or SK, Thus, the study 
was intended to assess the effects of antibodies on 
short term events as reperfusion, reocclusion and 
haemostatic changes and the depletion of antibodies 
in response to drug, but not to examine the induction 
of an anamnestic response and other long term effects. 
PATIENTS AND METHODS 
Patients 
The Dutch Invasive Reperfusion Study 15 is an open, 
randomised, multicentre trial comparing i.v. APSAC 
and i.e. SK in patients with acute myocardial infarc-
tion. Eighty five patients were recruited, but the 
present analysis is confined to 61 patients from whom 
sufficient plasma for measurement of SKRT and lgG 
anti-SK was available. These 61 patients were in no re-
spect different from the entire study group. There were 
50 male and II female patients with a mean age of 54,8 
years (range 37-70 years). Thirty two of them were 
treated with APSAC and 29 with SK. Each patient 
had given his or her informed consent prior to enter-
ing the study, which had been approved by our ethical 
committee. 
Study Protocol 
After angiographical demonstration of coronary 
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artery occlusion, the patients were randomised to 
thrombolytic treatment with either APSAC (30 U by a 
5 min intravenous injection) or SK (250000 U over 
60 min by intracoronary infusion), Administration of 
the thrombolytic drugs was always started within 4 h 
(mean 2.3 h) from the onset of chest pain. Heparin was 
given, when necessary, as a catheter flush (5000 U i.v.) 
and then as a continuous i.v, infusion (1000 U/h), from 
about 4-24 h after initiating thrombolytic therapy, 
Vascular patency was assessed by coronary angio-
graphy every 15 min for L5 h, Ali angiograms were 
read independently by two investigators in a 'blind' 
fashion and classified on a 4-class scale, according to 
the definitions used in the TIM! triaL 17 Reperfusion 
was assumed if at L5 h a sustained change from class 0 
or 1 to class 2 or 3 had occurred. Reocclusion was 
assessed by coronary angiography at 24 h (range 
18-30 h) after starting thrombolytic therapy. 
Methods 
Blood for coagulation studies was collected before and 
L5, 12,24 and 48 h after therapy, 16 ln all patients pre-
treatment plasma was used for measuring SKRT and 
lgG anti-SK; moreover, in 22 patients lgG anti-SK 
was determined also in post-treatment plasma 
samples. SKRT was performed as described by 
Deutsch and Fischer7 The assay of IgG anti-SK was 
carried out according to Moran et al. 13 Briefly, 25J.ll 
of appropriately diluted patient plasma was pi petted 
into the wells of a micro titre plate. Then 25 ~I of 125!-
iabeiied SK dilution (approximately 100 ng SK/ml) 
was added to each well and after 3 h incubation at 
ambient temperature, the lgG anti-SK/ 125!-SK 
immunocompiexes were precipitated by adding 50 ~I 
of a Protein A-Sepharose suspension (50 gj!) in buffer. 
The plate was continuously agitated for 1 hand centri-
fuged (10 min; 1000 rpm). The supernatant was 
removed and the precipitate washed 6 times. Finally, 
each well was cut loose from the plate and counted for 
radioactivity. The results were expressed in ~g SK 
bound per ml plasma (~gjml), 
Inhibition of fibrinolytic activity in vitro in a model 
system was measured using a semi-purified IgG pre-
paration. Sera containing high anti-SK binding levels 
were obtained from individuals previously treated 
with APSAC and lgG-enriched serum fractions were 
prepared by salt-fractionation. The fibrinolytic activ-
ity of a range of concentrations ofSK and APSAC was 
measured by the fibrin plate assay using a range of 
anti-SK antibody concentrations. The inhibition (%) 
was calculated by measuring the amount of activator 
required to produce an equivalent lysis area in the 
presence of antibody as that produced in the absence, 
Thus, the inhibition by a range of antibody concentra-
tions over a range of activator concentrations was 
quantified and a plot made of relative inhibition ver-
sus fold excess of antibody (that is, ratio of antibody to 
antigen), 
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Fig. I Histogram oft he distribution of IgG anti-SK concentrations 
in a population of patients with acute myocardial infarction (total 
n = 61). 
Statistics 
Standard methods were used for the statistical evalu-
ation of the results, as indicated in the results section. 
In case of non-normal distributions, the data were 
transformed prior to testing. Significance was assumed 
at p values < 0.05. 
RESULTS 
Distribution of lgG Anti-SK in Patients 
The distribution of pre-treatment IgG anti-SK con-
centrations in our population of patients with acute 
myocardial infarction is shown in Figure 1. The arith-
metic mean was 1.39 p.gjml and the geometric mean, 
after logarithmic transformation of the data, 0.84 ~g/ 
mi. The tenth and ninetieth percentile values were 0.21 
and 2.67 Jl£/ml, respectively. There was no difference 
in IgG anti-SK between the patients who were treated 
with i.v. APSAC and i.e. SK (p>0.5; Student t-test). 
The level of lgG anti-SK appeared to be dependent 
on age: younger patients had significantly higher levels 
than older ones (p<0.02; linear regression). The high-
est values of lgG anti-SK (4.7-5.5 Jlg/ml) were found 
in 5 patients whose mean age was only 44.4 years as 
compared to a mean age of 55.7 years in the other 
patients, whose IgG anti-SK concentration was below 
3.0 Jlg/ml (p<0.005: Student t-test). There was no sex-
dependent difference apparent in our population. 
The relation between lgG anti-SK and SKRT, both 
in pre-treatment plasma, is demonstrated in Figure 2. 
When calculated from log-log regression analysis, the 
coefficient of correlation was statistically significant 
(r = 0.43: p < 0.001: 95% confidence limits of r: 0.18-
0.61). However, a very wide scatter of data in indi-
vidual patients was obvious. 
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treatment plasma. Correlation coefficient r = 0.43 (p<O.OOI). 
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Fig. 3 Effect oflgG antibodies to SK on in vitro fibrinolytic 
activity of APSAC (0) and SK (G) in a fibrin plate assay. 
Inhibition of Fibrinolytic Activity in vitro 
Results from the fibrin plate assay, comparing the in-
hibition of fibrinolytic activity of SK and APSAC by 
partially purified preparations of lgG anti-SK, are 
shown in Figure 3. At an antibody: antigen ratio of 1.0 
(equivalence), SK was rather more inhibited than was 
APSAC. At excess antibody levels, the inhibition of 
SK and APSAC became similar, but for both agents a 
large excess of antibody was required to produce an 
appreciable inhibition of fibrinolytic activity in the 
fibrin plate. 
lgG Anti-SK and the Systemic Lytic State 
Figure 4 shows the degree of systemic lysis, expressed 
as residual fibrinogen at 1.5 h, as a function of pre-
treatment lgG anti-SK. In both groups the best fit of 
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correlation was described by a linear regression func-
tion. The coefficient of correlation was 0.51 (p < 0.005; 
95% confidence limits: O.l9<r<0.73) in the APSAC 
group (Fig 4A) and 0.67 (p<O.OOl; 95% confidence 
limits: 0.41 <r<0.83) in the SK group (Fig. 4B), re-
spectively. On the contrary, the relation between 
SKRT and residual fibrinogen was not significant, 
neither in the patients treated with i.v. APSAC 
(r=O.IO: n.s.), nor in those treated with i.e. SK 
(r=0.19: n.s.). 
The relationship between pre-treatment lgG anti-
SK and euglobulin clot lysis time (ECLT) at 1.5 h after 
initiation of therapy, was also assessed. In both 
therapy regimens. the post-dosing ECL T became very 
short (I 0--20 min) in the majority of patients. More 
prolonged ECL T"s were nearly exclusively found 
amongst those patients with a relatively high pre-
treatment antibody level (Table). although of those 5 
patients with the highest pre-treatment lgG anti-SK, 
only 2 patients (both receiving SK) demonstrated a 
substantially prolonged ECL Tat 1.5 h. 
lgG Anti-SK and Reperfusion 
The distribution of pre-treatment lgG anti-SK 
according to whether successful reperfusion was 
achieved or not. is shown in Figure 5. For both 
APSAC and SK there was no significant difference 
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Table Euglobulin clot lysis time (ECL T) at 1.5 h in patients with 
low and high pre-treatment IgG anti-SK levels. 
Baseline 
IgG anti-SK ECLT(min) 
Treatment n (pgjml) (mean±SEM) 
i.v.APSAC 23 ~2.0 10.4+ 0.4] 
5 >2.0 57.2±35.3 
i.c.SK 20 ~2.0 16.0+ 3.91 .. 
8 >2.0 82.5±32.2 
'" P <0.025 and ,.,. p < 0.005 by Wilcoxon signed rank test 
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Fig. 5 Distribution of pre-treatment lgG anti-SK concentrations in 
both patients groups relative to repcrfusion success: r = reperfused. 
nr = not repcrfuscd at 1.5 h. Median values are indicated by 
horizontal lines. 
(Mann-Whitney U-test) in pre-treatment lgG anti-SK 
between the groups of patients who reperfused and 
those who did not. Also, there was no statistically sig-
nificant correlation between pre-treatment IgG anti-
SK concentration and time to sustained reperfusion 
for those patients who reperfused within the 90 min 
study period: r = 0.20 (n.s~ linear regression analysis) 
for APSAC and r = 0.17 (n.s.) for SK. We also found 
no significant difference in reperfusion rate between 
patients with high and low SKRT, irrespective of the 
type of drug given (not shown). 
In the entire group of patients studied, reocclusion 
of an initially reperfused coronary artery at 24 h was 
documented in only 4 cases: one patient had been 
treated with i.v. APSAC and 3 with i.e. SK. In 3 of 
these 4 patients plasma was available for measuring 
pre-treatment IgG anti-SK~ the concentrations were 
1.54 ~g/mL (APSAC) and 1.10 and 1.39 ~g/mL (SK) 
respectively. Adverse side-effects were mild and of low 
incidence: hypotension. vomiting and haematomas 15 
and so it was impossible to investigate a relationship 
with anti-SK levels. 
lgG Anli-SK after Therapy 
The course of lgG anti-SK during the first 2 days after 
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Fig. 6 Course of IgG anti-SK concentrations after thrombolytic 
therapy in patients with pre-treatment levels above(---) and 
below(--) 2.0 1-lg/mL Differences between both groups were 
significant (p <0.001) at all post-treatment moments. 
treatment was determined in 22 patients, 11 of whom 
had received APSAC and II SK. There was no differ-
ence between these two groups with respect to change 
in IgG anti-SK concentration: in all patients it de-
creased significantly (p<O.OO!: paired t-test) imme-
diately after therapy, remained more or less constant 
up to 24 hand began to rise slowly on the second day. 
However, within both groups, two entirely different 
patterns emerged, when the proportional decrease in 
lgG anti-SK was calculated (Fig. 6): in 14 patients (8 
APSAC. 6 SK) there was a considerable decrease to 
Only 17% of baseline on the average, while in the 
remaining patients (3 APSAC. 5 SK) the mean 
residual IgG anti-SK concentration was still 70% of 
baseline. This significant difference was closely related 
to the patients' pre-treatment antibody level: the for-
mer pattern was confined to patients with IgG anti-
SK concentrations < 2.0 llg/ml, while 7 of the 8 
patients exhibiting the latter pattern had lgG anti-SK 
levels above this value. 
Upon plotting the post-treatment lgG anti-SK 
value as a function of the pre-treatment level, as 
shown in Figure 7, it became clear that up to a base-
line level of approximately l.O 11g/ml nearly all lgG 
anti-SK had disappeared after therapy, but in patients 
with initial concentrations above this value, the deple-
tion in IgG anti-SK was independent of pre-treatment 
level and amounted to approximately 1.0 11g/ml. This 
was observed for the APSAC-treated patients as well 
as for those who had received i.e. SK (Fig. 7). 
DISCUSSION 
High reperfusion rates can often be achieved with cur-
rent regimens of thrombolytic agents, but reasons for 
failure in approximately 1 in 4 patients are not usually 
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Fig. 7 Post-treatment IgG anti-SK as a function of pre-treatment 
concentration in patients treated with i.v. APSAC (0) or i.e. SK 
(8 ). Slope of regression line 1.03 and intercept on x-axis L061lgjml 
(c ~ 0.98). 
clear. 1 Resistance to lysis may be related to location, 
age and composition of the thrombus, but also, per-
haps, to variations in the circulating level of substrate 
and inhibitors. One of the theoretical explanations for 
the failure of SK-containing thrombolytic drugs is the 
inactivation by antibodies to streptococcal proteins. 
Reports on the role of anti-SK in thrombolytic 
therapy are scarce and are predominantly confined to 
older studies in patients with deep venous thrombosis 
or thrombophlebitis, who were treated with intra-
venous SK.4 • 5 • 8 Moreover, in the few patients with 
acute myocardial infarction described, the effect of 
anti-SK on systemic lysis rather than on reperfusion 
was reported! It is highly questionable whether such 
results can be extrapolated to intracoronary SK 
therapy or to reperfusion in acute myocardial infarc-
tion. Only two recent reports on anti-SK in acute 
myocardial infarction thrombolysis are available. The 
study by Rothbard and colleagues, describing 15 
patients receiving i.e. SK, showed no correlation 
between anti-SK, measured as SKRT, and presence of 
lytic state or between SKRT and reperfusion; how-
ever, the patient with the highest SKRT in their study 
did not show systemic lysis or reperfusion. 11 Lew et al 
described a single patient who failed to develop a sys-
temic lytic state and did not reperfuse after high dose 
i.v. SK 18: this patient had an extremely high anti-SK 
antibody titer, measured using a semiquantitative 
electrophoresis method. Thus, there is no convincing 
evidence that anti-SK antibodies can prevent coron-
ary reperfusion within a normal population. In the 
present report we describe the relevance of antibodies 
to SK. measured using a new and specific assay for 
IgG anti-SK, in patients with acute myocardial infarc-
tion who were treated with intravenous APSAC or 
intracoronary SK. Only short term effects, e.g. on 
reperfusion success and the systemic lytic state, were 
examined in this study; we did not investigate the 
longer term effects such as the anamnestic rise in anti-
17 
bodies6 and the consequences thereof for possible re-
treatment. 
The distribution of IgG anti-SK concentrations in 
our patient population was most probably log-normal 
(Fig. !). which is in agreement with that in healthy 
volunteers. 13 Since the distribution of SKRT is also 
known to be Iog-normal,8 the statistical correlation of 
lgG anti-SK and SKRT is not surprising. However. 
the inconsistencies amongst individuals described by 
Moran et al 13 were also present in our patients (Fig. 2) 
hence there is a poor association between SKRT and 
IgG anti-SK concentration for the individual patient. 
The mean concentration of IgG anti-SK in our 
patients ( 1.4 llg/ml) is comparable with a mean of 
0.9 llg/ml. found in a small group of patients in Scot-
land,19 but much lower than in English volunteers, 
being approximately 3.3 11g/ml.13 Similar geograph-
ical differences have been reported for SKRT and are 
postulated as resulting from differences in exposure to 
streptococcal infections.*· 5 The age-dependence in 
lgG anti-SK (higher levels in younger subjects) has 
not been reported previously, but might also account 
for the difference between the mean values in Dutch 
and Scottish patients compared to English volunteers. 
In the present study none of the 5 younger patients 
exhibiting higher levels had a history of recent infec-
tion, but 1 had been treated with intracoronary SK 2 
years previously. 
We evaluated the potential influence oflgG anti-SK 
in a model system in vitro. Although the fibrin plate 
method provides an insight into the effect of anti-
bodies on fibrinolytic activity, it requires an incuba-
tion time of 24 h and it is possible that antibody 
exchange could occur, leading to overestimation of the 
inhibition. Our results in vitro suggest that for the 
antibody: antigen ratio expected in a normal popula-
tion of patients receiving thrombolytic therapy for 
acute myocardial infarction, the inhibition of SK 
might be rather greater than that of APSAC. but for 
both drugs the net inhibition is small (Fig. 3). For 
example. for APSAC there might be 10% inhibition of 
the dose at an lgG anti-SK concentration of 3.3 )lg/ml. 
i.e. above the ninetieth percentile in the current study. 
Although in vitro methods can only provide a partial 
estimate of what might happen in vivo, our use of a 
specific assay for lgG anti-SK allows a more precise 
prediction of the role of antibody in the response to 
SK-containing thrombolytic agents than has been 
possible previously. 20 
When the clinical response to i.v. APSAC and i.e. 
SK therapy was examined, there was a statistically sig-
nificant relationship found between pre-treatment 
IgG anti-SK concentration and residual fibrinogen (at 
I .5 h post-dosing) in both groups (Fig. 4). This is con-
sistent with the correlations noted previously between 
SKRT and systemic lysis in patients receiving intra-
venous SK.*· 5 · 8 · 20 but not after intracoronary SK. 11 
It is most likely that increasing levels of antibody bind 
and inactivate increasing proportions of the SK-
containing plasminogen activators administered and 
18 
thus modulate the circulating fibrinolytic activity and 
the development of the systemic lytic state. These in 
vivo results are comparable with the in vitro results 
described above (Fig. 3) and those of Matsuo et al.21 
It is also interesting to note the correlation between 
pre-treatment lgG anti-SK and post-dosing ECL T 
(Table). Since post-treatment ECLT is mainly deter-
mined by the residual levels of fibrinogen and plas-
minogen a~ wei! as by the circulating amount of 
plasminogen activator, where present, the relationship 
between lgG anti-SK and ECL T presumably reflects 
the same process as the correlation between IgG anti-
SK and residual fibrinogen. However, it is also con-
ceivable that because APSAC is cleared much slower 
from the circulation than SK-plasminogen, the contri-
bution of APSAC to the ECL T at 1.5 h is still con-
siderable and therefore that in the APSAC group the 
ECLT is less dependent on pre-treatment lgG anti-SK 
than in the SK group. In addition we feel that caution 
must be advised in interpreting this correlation 
because under the acidification conditions involved in 
measuring ECL T. we cannot exclude the possibility 
that not all complex is precipitated or the possibility 
that the complexes may dissociate. 
With regard to thrombolytic efficacy. when the 
patients response to APSAC and SK was examined 
there was found to be no significant correlation 
between pre-treatment anti-SK concentration and 
reperfusion success. Because patients with high IgG 
anti-SK levels were rare in our population, any pos-
sible effect of high antibody concentrations on reper-
fusion remains to be established using larger groups of 
patients. 
In the patients in whom successful recanalisation 
was achieved there was no correlation found between 
pre-treatment lgG anti-SK level and time at which 
sustained reperfusion was achieved, neither for SK 
(mean interval47 min). nor for APSAC (mean interval 
45 min). Furthermore. we found no statistically signi-
ficant correlation between residual fibrinogen at 1.5 h 
and time interval to sustained reperfusion. This find-
ing contrasts with a recent study22 using 750 000 U of 
SK i.v., where both high residual fibrinogen concen-
tration and delayed reperfusion were attributed to a 
high pre-treatment antibody level. The difference 
between our results and this conclusion22 might be 
explained by an augmented delivery of the throm holy-
tic drug to the thrombus or to a suboptimal dose of 
SK used in the previous study. Furthermore, Lew et al 
employed only a semiquantitative estimate of anti-SK 
concentration and recognised reperfusion by non-
angiographic criteria.22 
The very small number of patients who reoccluded 
within 24 h does not permit any conclusions to be 
drawn. However. it would be improbable that lgG 
anti-SK would affect reocclusion; the 3 reoccluded 
patients had only averaged lgG anti-SK levels. even in 
comparison with those who reperfused successfully 
without reocclusion. Reocc1usion beyond 24 h after 
dosing would be very unlikely, since there will be no 
longer SK or APSAC in the circulation by that time. 
in view of the half-life of the drugs. 
The course of lgG anti-SK after administration of 
the thrombolytic drug is compatible with binding of 
antibody to SK or APSAC and clearance of the com-
plexes. as has been suggested by others.4 · 8 · 18 Some-
what surprisingly. it was found that the clearance of 
antibody-SK and antibody-APSAC complexes ap-
parently became saturated at approximately !.0 ~g/ 
mL lgG anti-SK (Fig. 7) and thus gave rise to two dif-
ferent patterns of antibody depletion (Fig. 6), depend-
ing on the pre-treatment IgG anti-SK concentration. 
In theory. the dose of SK applied in the present study 
(250 000 U) should deplete lgG anti-SK by about 
0.8 ~g(ml. assuming a normal plasma volume. 13 Thus. 
in the SK-treated patients. the results are compatible 
with the theoretical calculation. On the contrary, the 
quantity of SK complexed in the dose of APSAC 
applied. would theoretically be expected to deplete 
IgG anti-SK by more than 3.0 ~g(ml, since 30 U of 
APSAC is equivalent to approximately 1 million U of 
SK on a molecular basis. In fact, APSAC depleted IgG 
anti-SK to the same level as occurred in the SK group, 
thus to only 25% of the theoretical value. These data 
on decrease in IgG anti-SK after APSAC are similar 
to those from the only other report available on this 
subject. 19 In that study, 6 patients were treated with 
i.v. APSAC (30 U) and from the data an average dep-
letion of IgG anti-SK of 0.80 ~/ml can be derived, 
similar to the mean in our APSAC group (0.90 ± 
0.42 ~g/ml). Only partial disappearance of IgG anti-
SK after APSAC therapy might be explained by circu-
lation of antigen-antibody complexes after dosing if 
the clearance process was saturated. However, we 
searched for such complexes in plasma taken 1.5 h 
after dosing, using an immunoblotting trechniquc, but 
without success (R. Standring. unpublished result). 
The steric conformation of the APSAC molecule may 
also be important. For example the plasminogen moi-
ety or the anisoyl-group might render the SK part less 
accessible for antibody binding than in the unmodified 
SK molecule. 
In conclusion. although the degree of systemic lysis 
(residual fibrinogen) was shown to correlate with pre-
treatment IgG anti-SK, most patients could still be 
defined as exhibiting a systemic lytic state after treat-
ment with SK or APSAC. Whether or not APSAC is 
relatively protected from binding to and inhibition by 
IgG anti-SK, it is concluded from the present results 
that such antibodies. at least in the range studied here. 
have little effect on the reperfusion success in a normal 
population of patients with acute myocardial infarc-
tion who are treated with therapeutic doses of intra-
venous APSAC or intracoronary SK. 
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CHAPTER4 
Effects of anistreplase on blood 
viscosity and platelet function in 
patients with acute myocardial 
infarction 
J.J.R.M. BONNIER1 ,J.J.M.L. HOFFMANN 1• P.G. MELMAN 1• I. BARTHOLOMEUS~ 
The effect of thrombolysis on viscosity and platelet function in vivo is not exactly known. 
Reduction in viscosity could be beneficial in acute myocardial infarction by facilitating 
myocardial blood flow. Effect on platelet function could cause reocclusion or bleeding. 
The present study was performed in order to assess the effects of anistreplase (APSAC: 
anisoylated plaminogen streptokinase activator complex), 30 U intravenously~ on these 
parameters in ten patients with acute myocardial infarction not receiving any anti-platelet 
drug therapy- We measured platelet aggregation_ plasma and blood viscosity and cardiac 
output. 
There was a rapid and significant decrease of 13 percent in plasma viscosity at 90 minutes_ 
parallel to a 97 percent decrease in fibrinogen. Blood viscosity at high and low shear rates 
was significantly decreased~ reaching the lowest value after 24 hours~ due to the reduction 
in plasma viscosity and haematocrit. Platelet aggregation rapidly decreased within 30 
minutes and fully recovered after 24 hours in most patients; it showed hyper-aggregation 
at 48 hours_ which disappeared after one week. No correlation was found between cardiac. 
output and blood viscosity (high and low shear rate)_ plasma viscosity. or fibrinogen 
concentration. Whether there would be a beneficial effect from reduced viscosity due to 
thrombolytic therapy during acute myocardial infarction needs further investigation. 
Keywords: thrombolytic therapy- blood viscosity- platelet function -platelet aggrega~ 
tion- acute myocardial infarction 
Introduction 
In the last decade several clinical trials 
have clearly demonstrated that early ad-
ministration of a thrombolytic agent to 
patients with acute myocardial infarction 
significantly reduces mortality and morbi-
dity.1-7 The reduction in mortality is simi-
lar for several thrombolytic agents used. 
such as streptokinase anisoylated plasmi-
nogen streptokinase activator complex 
(anistreplase) and tissue-type plasmino-
gen activator ( alteplase). 
Anistreplase is a combination of strepto-
kinase and plasminogen with an anisoyl 
group reversibly placed within the cataly-
tic centre of the plasminogen moiety. In 
the circulation anistreplase is de-acylated 
at a controlled rate. This produced a more 
sustained fibrinolytic activity compared to 
streptokinase. which might be an advanta-
ge with respect to reocclusion rates. It can 
be given as an intravenous injection over 4 
to 5 minutes. 
The lack of success of thrombolytic thera-
py in a considerable percentage of acute 
myocardial infarction patients indicates 
that the underlying mechanisms responsi-
ble for recanalization. preservation of left 
ventricular function and improved survi-
val are still not clearly understood. Fac-
tors such as early and late reocclusion. 
platelet activation and effect on blood 
flow still require further research. 
In this pilot study some of these factors 
were addressed in more detail. namely: 
the effect of anistreplase on blood and 
plasma viscosity. platelet function and any 
possible influence on the cardiac output 
during administration of this drug to pa-
tients with acute myocardial infarction. 
Patients and methods 
Patients 
Between April and December 1990 ten 
patients with an acute first myocardial 
infarction. who were not receiving any 
antiplatelet drugs such as aspirin or dipy-
ramidoL were treated with anistreplase 
(table 1). 
Methods 
After establishing the diagnosis of acute 
myocardial infarction by the usual inclu-
sion and exclusion criteria and excluding 
the use of aspirin or other anti-platelet 
drugs for ten days before admission. ani-
streplase (30 U.) was slowly given intrave-
nously over five minutes. The lytic thera-
This study was presented during the American Heart 
Association Scientific Sessions. Anaheim. Nov. 13. 
1991. 
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Fig. I. Mean blood 
viscosity, measured 
arborh high ( 128.5 
S-1) and low (1.3 S· 
1) shear raresand 
corrected for hema-
tocrit, at critical rime 
points. The differ-
ences with pretreat· 
ment are indicated 
bv an asterisk 
r* P<D.os.-
n=S-10). 
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Table I 
Patients characteri~tics 
patients 
sex (malc/female) 9/1 
age (yrs) mean 
± SD 60.0 ± 6.4 (range 50-6S) 
weight (kg) 74.4 ± 10.5 (range 53.0-84.3) 
height (m) 1.75 ± 0.04 (range 1.70-1.78} 
history of AMI none 
location of 
infarction 
anterior/inferior 119 
infarct-related 
vessel 
RCA s 
RDA 1 
ex 1 
time chest pain 
to alteplase (hrs} 2:23 ± 1:03 (range 1:10- 4:15) 
days in hospital 13.8 ± 5.2 (range 8- 24) 
py was started within four hours after 
onset of symptoms. Patency of the infarct 
related coronary artery was assessed by 
angiography after 60, 75 and 90 minutes 
and again after 4S hours: left ventriculo-
graphy was also performed after 60. 90 
minutes and 48 hours. 
Cardiac output was measured by thermo-
dilution technique after 90 minutes and 48 
hours. Intravenous heparin was started 
three hours after the administration of 
anistreplase. The dosage was adjusted ac-
cording to the activated partial thrombo-
plastin time (target value: 2-3 time base-
line). Blood was collected before adminis-
tering anistreplase and at regular intervals 
over the next two days. for laboratory 
examination through a venous catheter or 
by venepuncture. An additional sample 
was taken after 7-9 days. prior to dischar-
ge from hospital. Blood and plasma visco-
sity were determined at low (1.3 s-1) shear 
rate (representing small venules) and high 
(128.5 s-1) shear rate (representing arte-
ries and large veins). Shear rate can be 
Table 2 
An~iographic characteristics 
TIM I grading 
0 (no perfusion) 
1 (penetration) 
2 (partial perfusion) 
3 (normal perfusion) 
diameter of stenosis 
<50% 
50-70% 
70-90% 
90-100% 
filled collateral 
60 
min. 
2 
1 
7 
3 
5 
75 
min.* 
2 
7 
4 
3 
90 
min.* 
9 
4 
3 
48 
hrs'' 
9 
4 
3 
2 
* One patient excluded after 60 min. because of 
PTCA. 
defined as the velocity gradient over 
fluid.8 Platelet aggregation in platelet rich 
plasma was measured in an optical aggre-
gometer using ADP as inducer. 
Statistical analysis 
Statistical evaluation of the data was per-
formed using paired and unpaired Stu-
dent's t-test. considering p values <0,05 
as significant. For measurements of a nor-
mal distribution. mean ± SD is given and 
in case of abnormal distribution. median 
and range, unless stated otherwise. 
Results 
Infarct characteristics 
The angiographic results are shown in ta-
ble 2. Protocol violation occurred in one 
patient. in whom PTCA was performed 
after 60 minutes. It is interesting to note 
that in this small series all patients had 
reperfusion. while none had reocclusion, 
within 48 hours. 
Viscosity 
Fig. 1 gives a graphic representation of the 
values found for blood viscosity at high 
Blood viscosity 
t- 0 t- 90' t-48 h 
• 
t- 8 d 
~ High shear rate 
0 Low shear rate . 
Fig. 2. Courseo_f 
mean plasma viSco-
sity and plasma [lbri-
no!!en. relative to 
pr~treatment values 
(*P<O.OSand 
** P<O.Ol: 
n=6-!0). 
Fig. 3. Mean platelet 
aggregation, indu-
ced with 2.4 muM 
PDP at different ti-
mes. Difference with 
pretreatment is indi-
cated(* P< 0.05; 
n=6-10). 
110 Plasma viscosity 
105 
* 
100 
95 
90 
85 
80 
and low shear rates. with correction for 
the hematocrit which showed no differen-
ce. This correction had to be done because 
hematocrit is the most important factor 
influencing blood viscosity especially un-
der low shear conditions occurring in par-
tially or completely occluded vessels dur-
ing acute myocardial infarction. 
Fig. 2 shows plasma viscosity and fibrino-
gen values. There was a rapid and signifi-
cant decrease in plasma viscosity during 
the first 48 hours. associated with a mar-
ked decrease in fibrinogen concentration. 
After eight days viscosity in blood. plasma 
and fibrinogen levels were within normal 
range. 
Platelet aggregation 
Fig. 3 shows effects on ADP-induced pla-
telet aggregation. A biphasic response in 
ex vivo platelet aggregation was observed 
after anistreplase. After an immediate in-
hibition for 6-12 hours. full recovery of the 
platelet aggregation was attained within 
24 hours. Then a phase of hyper-aggrega-
tion became apparent. lasting for at least 
c: 140 Fibrinogen 
(!) 
E 
'"120 2! 
~ 100 ,... ····-························-·-··--·--·· .. _ ....... 
-0 
'$. 80 
• 
60· 
40 
20 
~ OLL~ ~~~-J~-
t=O t=90' t=48h t•8d 
24-48 hours after the administration of 
anistreplase. This effect disappeared after 
one week. 
Cardiac output 
Table 3 shows cardiac output after 90 
minutes and 48 hours. There was no rela-
tion between cardiac output and either 
blood viscosity (high shear rate). blood 
viscosity (low shear rate). plasma viscosity 
or fibrinogen concentration (Pearson "s 
correlation coefficient r < 0.51). 
Discussion 
Several large-scale clinical trials have 
demonstrated that all thrombolytic agents 
administered to patients with acute myo-
Table3 
Cardiac output 
Cardiac output (1/min): 
90min. 
4S hrs 
mean ± SD range 
6.49 ± 2.04 (4.1- 10.2) 
4.91 ± 1.16 (3.5- 6.0) 
ADP-induced aggregation 
23 
24 
cardial infarction reduce mortality and 
morbidity. 1-7 
There are still. possible mechanisms for 
improved survival that have not been 
studied. We examined three factors which 
may improve survival: namely the effect 
of anistreplase on blood viscosity, platelet 
function and cardiac output. 
The importance of blood and plasma vis-
cosity in acute myocardial infarction was 
first described by Chmiel et al. in 1973:9 
after their publication a few authors focus-
sed solely on the role ofviscosity. 10• 12 Jan 
et al. concluded in a well documented 
study on blood viscosity in patients with 
acute myocardial infarction who received 
no thrombolytic therapy. that the increas-
ed viscosity at the onset was mainly due to 
high hematocrit, and the subsequent in-
crease in viscosity. which peaked at about 
the fourth day. resulted from elevation of 
plasma fibrinogen. This impaired the 
rheological properties of blood. especially 
in the coronary microcirculation distal to 
the occluded vessel. Because oxygen sup-
ply to myocardial tissue is greatly depen-
dent on this blood rheology. at least a part 
of the mvocardial damage can be attrib-
uted to i~creased viscosity .13 
In our study we investigated the role of 
anistreplase in patients receiving this drug 
during their acute myocardial infarction. 
These patients had a significantly decreas-
ed blood and plasma viscosity. as weU as 
fibrinogen levels. which may be responsi-
ble for a reduced myocardial workload 
and oxygen consumption. 
Moriarty et al. studied patients with acute 
myocardial infarction receiving streptoki-
nase. and found similar findings to ours 
for anistreplase. although he did not know 
if this contributed to preservation of myo-
cardial function and improved survival. 14 
GISSI-2.6 ISIS-37 and the Bassand study15 
show no difference between the effects of 
streptokinase. anistreplase and alteplase 
on mortality. As we know. alteplase does 
not influence viscosity and has only a very 
small effect on fibrinogen levels: it also 
gives a higher initial patency and a higher 
reocclusion rate. Therefore the nett effect 
on mortality is probably the same for the 
three thrombolytic agents. A possible 
benefit of lowering viscosity therefore re-
quires further investigation. 
Since the research by De Wood et aL the 
role of thrombus formation in the patho-
genesis of acute myocardial infarction is 
well established. 16 We use agents which 
induce lysis of fibrin in thrombus but the 
role of platelets in this process has not 
been thoroughly investigated. Some stud-
ies however demonstrated platelet aggre-
gation in patients with unstable angina 
pectoris and evolving myocardial infarc-
tion.l7-21 
The available literature on the effects of 
thrombolytic therapy on platelet function 
yields highly conflicting data.3 · 22-27 In our 
study we found a biphasic response in ex 
vivo platelet aggregation. an immediate 
inhibition lasting about 6-12 hours. fol-
lowed by a phase of hyper-aggregation 
during day 1 and 2 after thrombolysis. 
This hyper-aggregation may play a role in 
a higher reocclusion rate of the infarct 
related vessel. As known from the litera-
ture, PTCA during acute myocardial 
infarction has a higher reocclusion rate 
compared to this procedure in stable angi-
na pectoris. This may be the explaination 
of this phenomenon.28 Our hypothesis 
that there is a correlation between viscosi-
ty and cardiac output (measured at 90 
minutes and after 48 hours. because we 
expected on theoretical grounds the lar-
gest difference) was not confirmed. Al-
though it seems that cardiac output after 
90 minutes was higher than after48 hours. 
the difference was not statistically signifi-
cant. probably because of the small num-
ber of patients. 
The beneficial effect of reduced viscosity 
during acute myocardial infarction still 
requires further investigation. Additional 
research is also needed to establish the 
role of platelets in patients treated with 
the thrombolytic agent anistreplase. 
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CHAPTERS 
HEMORHEOLOGICAL EFFECTS OF A NONIONIC CONTRAST MEDIUM: 
AN EX VIVO STUDY 
J_J_M_L_ HOFFMANN•, J.J.R.M. BONNIERb and L BARTHOLOMEUSc 
•Department of Clinical Laboratories, Hemostasis Division,and bDepartment of Cardiology, 
Catharina Hospital, P.O.Box 1350,5602 ZA Eindhoven, the Netherlands and 
cSmithKiine Beecham,Medical Department, Rijswijk, the Netherlands. 
ABSTRACT 
Blood and plasma viscosity were measured in 10 patients, before and after 
administration of the nonionic contrast medium Iopromide for coronary 
angiography_ In all patients the hematocrit dropped markedly; the mean (±SD) 
value decreased from 0.425 ± 0.036 to 0.386 ± 0.037 (p<0.001). The mean blood 
viscosity also decreased significantly, in a dose-dependent way; this effeCt could be 
entirely explained by the change in hematocrit. Plasma viscosity remained constant 
despite the high viscosity of the contrast medium. The drop in hematocrit was 
caused by the volume of the contrast medium plus a shift of water from 
extravascular spaces to plasma, due to the high osmolarity of the contrast agent. 
The contrast medium studied is unlikely to cause cliLically relevant late effects on 
blood rheology other than hemodilution. 
INTRODUCTION 
Intravascular radiodiagnostic procedures are associated with the administration of 
sometimes considerable volumes of contrast media (CM) to patients. CM are iodinated 
derivatives of benzoic acid which are used in highly viscous, hyperosmolar solutions (1,2). With 
regard to its chemical nature, a CM can be either an ionic or a nonionic molecule. Most ionic 
CM are extremely hyperosmolar, while the nonionic CM have a much lower osmolarity, but still 
higher than plasma. All CM are known to cause adverse reactions, which are partially related to 
their osmolarity and thus the nonionic CM generally display less toxic side-effects than ionic 
agents do (1,2). 
One of the adverse reactions of CM is their ability to induce red cell aggregation, at least 
in vitro and again nonionic CM appear to have the milder effects (2-5). The in vivo 
significance of red cell aggregation due to CM is supposed to be limited or even absent, because 
the red cells would be rapidly disaggregated under the shear conditions in blood, flowing in the 
KEY WORDS: Blood viscosity - contrast agents - hematocrit - hemorheology - Iopromide -
plasma viscosity 
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vessels ( 4,5). To our best knowledge there are no published cata supporting this assumption. 
Another effect of CM, also at least in vitro, is due to their high osmolarity; they cause a 
pronounced shift of water from the red cells to plasma, which leads to a decrease in hematocrit, 
a decrease in mean red cell volume and a decline in red cell fluidity by stiffening of the red cell 
membranes (6). All these factors contribute to whole blood viscosity but their net effect on 
blood viscosity in vivo is entirely unpredictable, because some of these factors are highly 
variable or even impossible to measure (6). 
Since there are very few reports concerning the effects of CM on ex vivo hemorheology, 
we designed a study for documenting the rheological effects of Iopromide, a nonionic CM, in 
patients receiving a relatively large dose of CM during diagnostic coronary angiography. 
PATIENTS AND METHODS 
Patients 
We studied 10 patients, 1 female and 9 males, with a mean age of 54.7 y (range 30-75 y), 
who underwent coronary angiography for angina pectoris or coronary artery disease. Just before 
angiography, blood was collected for measuring baseline rheological parameters. During the 
procedure, the cardiologist determined the amount of CM necessary for each individual patient. 
The CM used was the nonionic, low osmolar Iopromide (Ultravist-300~; Schering AG, Berlin, 
FRG). The mean duration of the angiographic procedure was 31.7 min (range 20-65 min) and 
immediately after completion, another blood sample was taken from all patients. 
Methods 
Blood for rheology measurements was collected into evacuated, siliconized glass tubes 
containing liquid K3-EDTA (final concentration 1.5 mg/mL; 4.00 mL blood to 0.045 mL of 
anticoagulant, a dilution by 1.1 %; Monoject~, Sherwood, Ireland). Rheological testing was 
always performed within 1 hour from venepuncture; meanwhile the samples were kept at 
ambient temperature (19-22.C). All viscosity determinations were carried out at 37.o·c in a 
Couette-type rotational viscosimeter (Contraves LS-30; Contraves AG, Zurich, Switzerland), 
according to the ICSH recommendations (7), at two different shear rates: 1.3 s-1(1ow) and 128.5 
s-1 (high), respectively. Standardized blood viscosity, corrected to an hematocrit of 0.45, was 
calculated using the formula described by Matrai et a! (8). Hematocrit was measured in an 
automated impedance-type cell counter (Model S +; Coulter Inc., Hialeah, Fl., USA), which was 
calibrated with fresh blood from normal subjects against the microhematocrit reference method. 
Total protein and albumin concentrations in plasma were determined using standard biochemical 
methods (biuret and bromocresol green, respectively). 
Statistical evaluation was done using the two-sided paired t-test or Spearman's rank 
correlation test, regarding p values < 0.05 as significant. 
RESULTS 
The mean volume of CM administered to our patients was 152 mL, ranging between 110 
and 260 mL. The osmolality of Iopromide was 616 ± 8 mmol/kg (mean ± SD; n = 3) and its 
viscosity at 37•c was 4.94 ± 0.09 mPa.s (n = 4). 
Before angiography, the rheological parameters of all 10 patients were within the 
reference ranges ruling in our laboratory. In all patients the hematocrit decreased significantly 
after angiography (Table I), as did the native blood viscosity, measured at low and high shear 
rates. The decrease in high-shear blood viscosity was significantly correlated with the dose of 
CM administered (r= 0.86; p < 0.01 by Spearman's rank test). The relationship between low-
shear blood viscosity or hematocrit and the CM dose did not reach statistical significance. The 
viscosity of plasma did not change and neither did the calculated standardized (i.e. corrected to 
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hematocrit 0.45) blood viscosity. The concentrations of total protein and albumin in plasma 
decreased by approximately 12% of the baseline value, which was highly significant (Table I). 
When CM was added to whole blood in vitro, there was a gradual, small but significant 
increase in high shear blood viscosity (from 0 to 5% v fv CM: 4.36 to 4.51 mPa.s at 128.5 s·1; 
p=O.Ol), and a decrease in low-shear blood viscosity (mean 17.7 to 14.2 mPa.s at 1.3 s-1 from 0 
to 5% CM). The mean hematocrit dropped slightly, but the decrease did not reach statistical 
significance if corrected for the dilution with CM (results not shown). As expected, the viscosity 
of plasma, to which 5% (v fv) of CM had been added, significantly increased from 1.40 ± 0.03 
to 1.51 ± 0.01 mPa.s (p < 0.01). 
TABLE I 
Rheological Parameters before and after Angiography with CM. 
Mean ± SD is given; n = 10 
parameter baseline after CM p 
hematocrit (L/L) 0.425 ± 0.036 0.386 ± 0.037 < 0.001 
plasma viscosity (mPa.s) 1.37 ± 0.11 1.35 ± 0.21 NS' 
plasma total protein (g/L) 72.6 ± 3.0 64.3 ± 3.9 < 0.001 
plasma albumin (g/L) 45.7 ± 3.6 40.8 ± 3.8 < 0.001 
at high shear rate (1285 s-1) 
native blood viscosity (mPa.s) 4.50 ± 0.44 3.89 ± 0.38 om 
standardized blood viscosity 
at low shear rate (1.3 s-1) 
(mPa.s) 4.83 ± 0.22 4.67 ± 0.46 NS 
native blood viscosity (mPa.s) 15.2 ± 3.7 10.9 ± 1.9 < 0.001 
standardized blood viscosity (mPa.s) 17.3 ± 3.0 15.7 ± 2.9 NS 
*NS : not significant 
DISCUSSION 
Despite the notion that intravascular CM may influence blood rheology because all CM 
are highly viscous solutions, surprisingly few literature has been published on this subject. The 
available studies almost exclusively fucused on the in vitro effects of ionic and nonionic CM on 
red cell morphology and red cell aggregation (2-6). Some authors believe that the aggregation 
phenomenon is unimportant for the in vivo situation (4) and that it is unlikely to pose any 
threat to the patient (5). However, evidence for this from clinical studies is lacking and yet such 
studies are necessary because it is impossible to estimate the effects of CM on blood rheology 
by simple in vitro experiments. 
The results from the present study indicate that the fall in native blood viscosity after CM 
administration depends largely if not entirely upon the decrease in hematocrit. After correction 
to a standard hematocrit of 0.45, the change in blood viscosity, both at low and at high shear 
rate, was very small and of no statistical significance (Table I). Indirectly, this means that red 
cell aggregation by CM is unlikely to be of clinical relevance, at least some time after CM 
administration (4,5). A similar decrease in blood viscosity has been described by Acciavatti et 
a!., who observed a small lowering of blood viscosity, only at high shear (150 s-1), after giving 
100 mL of the nonionic CM Iopamidol to patients (9). These authors were unable to make any 
hypothesis on a possible effect of CM on red blood cells. Acute effects of CM on red cell 
rheology were not investigated in this study and neither in the present one. This leaves the 
possibility that CM can affect red cell rheology immediately after injection; probably, such 
effects would be rapidly reversible. 
The lack of a significant change in plasma viscosity after 30 min is in agreement with a 
previous study in which 80 mL of the ionic and high-osmolar CM diatrizoate was given without 
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any effect on serum viscosity (10). Apparently this can be explained by a balance between 
increase in plasma viscosity due to the CM's own viscosity (see in vitro results) and a 
concomitant decrease in viscosity as a consequence of hemodilution (see below). 
The above results all indicate that the hematocrit is the parameter of central importance 
in this study. The change in hematocrit must have been caused by at least two factors: the 
volume of CM and the osmolarity of CM. If only the volume of CM administered (mean 152 
mL) was of influence, a 3% decrease in hematocrit would have been expected in the average 
patient with an estimated blood volume of 5.0 L (2.1 L red cells plus 2.9 L plasma). From the 
total protein and albumin concentrations in plasma before and after CM, it can easily be 
inferred that the mean plasma volume increased with about 350 mL (or 12%), which is far more 
than the volume of CM used. This difference is explained by a shift of extravascular water to the 
plasma space in order to compensate for the much higher osmotic pressure of CM as compared 
with plasma osmolarity. A similar phenomenon has been described in vitro, where the water 
shifted from the red cells to plasma (6). In our study we unfortunately did not record red cell 
volumes and therefore we cannot give an opinion on a possible loss of water from red blood 
cells in vivo. However, if such a loss would have been present, it was of very limited size 
(about 2% of red ceil volume), since there was hardly any difference between the mean 
hematocrit observed after CM (0.386; see Table I) and the value expected on the basis of the 
decrease in plasma protein concentrations (0.397, on the average). Anyhow, the shift of water 
from red cells to plasma in vivo was considerably smaller than found in vitro (6); of course in 
the latter case there was no other source of water available for compensating the high osmotic 
pressure induced by CM. 
Some limitations of our study have to be mentioned. Because there were no blood samples 
taken immediately after giving the CM, conclusions regarding any acute effects on blood 
rheology are not justified. Such acute effects might bee expected in view of the very high local 
concentrations of CM, close to the site of injection. Further, we had no opportunity to directly 
measure parameters of red cell aggregation or fluidity and our conclusions based on indirect 
measures need to be interpreted with some caution. 
In conclusion, it has been shown that all hemorheological changes observed about 30 min 
after the administration of the nonionic CM Iopromide, can be explained by hemodilution due to 
the high osmolarity and the volume of the CM. It is unlikely that by this time other effects of 
CM on blood rheology are of clinical importance. 
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CHAPTER 6 
Value of immediate angioplasty after 
intravenous streptokinase in acute myocardial 
infarction 
To improve reperfusion, immediate percutaneous transluminal coronary angioplasty (PTCA} was 
considered after intravenous streptokinase (0.75 to 1.5 million U) was administered to 98 
patients with acute myocardial infarction less than 4 hours after the onset of chest pain. 
Thirty-four culprit arteries were occluded (group A); 42 arteries were patent with residual stenosis 
of more than 70% (group 8). Twenty-two patients had residual stenosis of less than 70% (group 
C); eight of these had severe disease of the remaining vessels. Group C patients were either 
treated conservatively or underwent bypass surgery. Immediate PTCA was attempted in 74 
patients (32 in group A, 42 in group B) and was successful in 68 (g2%). Emergency bypass 
surgery for acute occlusion after PTCA was required in two patients. Follow-up averaged 23 
months (range, 16 to 47 months). Asymptomatic occlusion recurred in three patients. Restenosis 
occurred in five patients: four had early restenosis (one in group A, three in group B) and one had 
late restenosis (group B). These arteries were successfully redi!ated. late reinfarction occurred 
in two patients. They were treated with intravenous urokinase and repeat PTCA. Elective bypass 
surgery was performed in three patients because of recurrent angina. They had severe 
three-vessel disease as revealed by control angiography. The mortality rate was 2.7% (two 
patients; one in group B had early reinfarction, and one patient in group A died suddenly after 17 
months). Eighty-five percent of patients treated with PTCA alone remain free of symptoms. This 
approach has a high success rate and low morbidity and mortality rates. long-term results are 
superior to thrombolysis alone. (AM HEART J 1990;119:786.) 
Fekry El Deeb, MD, Renzo Ciampricotti, MD, 
Mamdouh El Gamal, MD, FRCP (Edin), Rolf Michels, MD, 
Hans Bonnier, MD, and Berry Van Gelder, BE. Eindhoven, The Netherlands 
It is now well established that the earlier throm-
bolytic therapy is given in patients with acute myo-
cardial infarction (AMI), the more myocardial tissue 
and function can be preserved.1-10 Intravenous strep-
tokinase (SK) is widely accepted as a rapid, conve-
nient, and easy means of administration. Throm-
bolytic therapy, however, is not always effective or 
successful in restoring blood flow_n. 12 A significant 
residual stenosis usually remains at the site of initial 
occlusion after successful thrombolysis.13 This can 
result in an unfavorable clinical course with recurrent 
ischemic events or myocardial infarction.14-16 Percu-
taneous transluminal coronary angioplasty (PTCA) 
has been used to open occluded coronary arteries, to 
restore blood flow when thrombolytic therapy fails, 
and to dilate vessels with severe residual stenosis af-
ter thrombolytic therapy.14·17 Combined throm-
bolytic therapy and PTCA could be very effective in 
achieving optimal perfusion; however, the procedure 
is longer and the risk of acute occlusion after angio-
plasty is higher than when PTCA is used for stable 
angina. We report our early and late results of the 
combined use of intravenous SK and PTCA. 
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METHODS 
The study population consisted of 98 patients who were 
admitted to the coronary care unit of the Catharina Hos-
pital within 4 hours after the onset of symptoms of AMI. 
Diagnosis was based on acute typical chest pain that lasted 
for more than 30 minutes and was unrelieved by sublingual 
nitroglycerin and persistent ST segment elevation of more 
than 2 mm in two or more leads. Exclusion criteria included 
cardiogenic shock (defined as sustained systolic pressure of 
90 mm Hg or less that lasted for 1 hour or more), recent SK 
therapy, previous coronary artery bypass surgery, bleeding 
diathesis, recent surgery, recent cerebrovascular accident, 
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Acute Myocardial Infarction 
I 
98 patients 
i.v. SK ( 0.75-1.5 x 1 o6JU/30 min.) 
I 
Immediate Angiography 
--------- I -----------Total occlusion 
Group A 
34 
Open with > 70% 
residual stenosis 
Group B 
Open with < 70% residual 
stenosis 3 V D 
Group C 
42 22 
l l ~ 
Emergency PTCA 
32 
Emergency PTCA 
42 
Conservative CABG 
14 8 
3 V D"' three vessel disease; PTCA= percutaneous trans!umina! coronary 
angioplasty; IV::. intravenous: SK"' streptokinase; CABG = coronary artery bypass grafting. 
Fig. 1. Treatment regimen. 
recent prolonged cardiopulmonary resuscitation, age 
greater than 75 years, significant hepatic disease, and 
pregnancy. 
Treatment regimen (Fig. 1). Mter informed consent was 
obtained, patients received intravenous nitroglycerin (0.3 
to 5.0 mg/hr). They were then given premedication that 
consisted ofl2 mgdexamethasone,and after this 0.75 to 1.5 
million units SK was infused intravenously over 30 min-
utes. Meanwhile, arrangements were made to transport 
each patient to the catheterization laboratory for emer-
gency angiography. After placement of vascular sheaths, 
5,000 U heparin was administered. A pacing catheter was 
positioned in the right ventricle. Selective arteriography of 
the infarct-related artery was performed in multiple views, 
followed by visualization of the other coronary artery. Bi-
plane left ventriculography was performed in the 30-degree 
right anterior oblique and SO-degree left anterior oblique 
projections. Global and regional left ventricular perfor-
mance was analyzed with a VAX computer (Digital Equip-
ment Corp., Maynard, Mass.). Patients with complete oc-
clusion of the infarct-related artery were considered for 
emergency mechanical reperfusion and angioplasty. Pa-
tients with 70% or more residual stenosis were also 
considered for immediate PTCA. 
Definitions. The determination of the patency of the in-
farct-related artery was made according to the classifica-
tion of the Thrombolysis in Myocardia! Infarction (TIM!) 
tria!.18 As defined by the TlMl study group, TIM! grade 
0 = "no perfusion" with no anterograde flow beyond the 
point of occlusion; TIMI grade 1 = "penetration without 
perfusion," contrast fails to opacify the coronary bed dis-
tal to the obstruction; TIMI grade 2 = "partial perfusion," 
contrast filling or clearance is delayed but there is complete 
opacification of the distal coronary bed; and TIM! grade 
3 ="complete perfusion," showing a normal pattern of 
contrast filling clearance. Vessels that show TII.\11 grade 0 
or grade 1 flow were considered to be occluded. Angie-
graphic exclusion criteria for PTCA were defined as left 
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main stem stenosis, less than 70% stenosis of a single ves-
sel, severe disease of the remaining vessels(:=::: 70% steno-
sis), and distal coronary occlusive lesions unsuitable or not 
amenable for PTCA. 
RESULTS 
The baseline characteristics of the 98 study pa-
tients are listed in Table I. They were divided into 
three groups according to the degree of stenosis of the 
infarct-related coronary artery after the administra-
tion of intravenous streptokinase: group A (34 pa-
tients) had totally occluded infarct-related vessels, 
group B (42 patients) had patent infarct-related ves-
sels with residual stenosis of more than 70%, and 
group C included patients with residual stenosis of 
less than 70% with TIMI grade 3 flow, of whom 
eight had severe disease of the remaining vessels. The 
median age was 54 years, and 78.5% of the patients 
were men. The median time from onset of pain to 
administration of SK was 2.1 hours, whereas the me-
dian time from onset of pain to PTCA was 2.8 hours. 
The angiographic date of patients are shown in Ta-
ble II. Eighty-three percent of the patients had one-
vessel disease; 5% had two-vessel disease; 10% had 
three-vessel disease. In 2% of the patient population 
it was not possible to define the site of the lesion in 
the culprit artery. Patients in group C were either 
treated conservatively (14 patients) or underwent 
coronary artery bypass grafting (eight patients). 
Thirty two patients in group A and 42 patients in 
group B underwent immediate coronary angioplasty 
(total= 74 patients). 
The results of coronary angioplasty are summa-
rized in Table III. Angiop!asty was attempted imme-
diately after intravenous infusion of SK and angiog-
Table !. Patient characteristics 
No. of patients 
Mean age (yr) 
Range (yr) 
Sex ratio (M:F) 
Previous MI 
Congestive heart 
failure 
Obstruction of 
Group A 
34 
54.7 
(34-72) 
26:8 
2 
0 
100 
GroupE Group C 
42 22 
53.5 56.1 
(40-72) (25-76) 
34:8 17:5 
4 1 
0 0 
> 70-99 <70+3VD 
IRA after SK (%) 
Time from onset 2.37 (1.1-4.3) 2.11 (1.0-3.3) 1.96 (1.3-3.3) 
of pain to 
SK (hr) 
Time from onset 
of pain to 
PTCA (hr) 
2.91 (2.2-5.6) 2.78 (2.1-5.3) 
SK. Streptokinase; PTCA, percutaneous transluminal coronary angioplas-
ty: 3 VD, three-vessel disease; Ml, myocardinl infarction; IRA, infarct-
related artery. 
Table II. Angiographic data 
Group A Group B Group C Total 
Infarct location 
Anterior 16 19 9 44 
Inferior 18 23 13 54 
Infarct-related artery 
LAD 16 19 9 44 
LC 6 2 4 12 
RCA 12 21 9 42 
Extent of _coronary disease 
None 0 0 2 2 
One-vessel 31 39 11 81 
Two-vessel 2 2 1 5 
Three-vessel 1 1 8 10 
LVEDP (mm Hg) 18.2 15.6 16.1 
Range (8-24) (5-30) (4-25) 
LV Ejection fraction (%) 54.8 56.2 56.9 
Range (37-69) (49-63) (51-62) 
LAD, Left anterior descending; LC, left circumflex artery; RCA, rigltt cor-
onary artery; LV,left ventricular; EDP, end-diastolic pressure. 
raphy in 7 4 patients in groups A and B. PTCA was 
successful in 68 patients (92% ). PTCA was at-
tampted in 32 of the 34 group A patients and was 
successful in 28 (87.5% ). Inability to cross the occlu-
sion (three patients) or a guiding problem (one 
patient) were the causes of failure. PTCA was not 
performed in two patients because the sites of occlu-
sion were considered unsuitable. PTCA was at-
tempted in all patients in group B (42) but was suc-
cessful in 40 (95%). 
Complications during PTCA. Acute reocclusion oc-
curred in two patients (group B); they underwent 
emergency bypass surgery. Two patients had ven-
tricular tachycardia and fibrillation; both were suc-
cessfully defibrillated. One patient had transient 
atrial fibrillation. Another patient had severe tran-
sient hypotension that responded to inotropic ther-
apy. The early and late follow-ups of both groups are 
shown in Table IV. One patient died 5 days after the 
procedure because of reinfarction and sustained 
ventricular tachycardia followed by asystole. Four 
patients (three in group B, one in group A) had 
recurrent angina. They were found to have resteno-
sis and underwent successful repeat PTCA. Coronary 
angiography was repeated before discharge in all pa-
tients in whom initial PTCA was successful (68). 
Asymptomatic reocclusion was found in two patients 
(group B). 
Long-term follow~up. All patients were seen at the 
outpatient clinic regularly for 16 to 47 months 
(mean; 23 months). They were evaluated clinically 
and by routine exercise testing on a bicycle ergome-
ter. Thirty-seven symptom-free patients consented 
to have routine repeat angiography after 6 months. 
Thirty-six were found to have patent vessels with re-
sidual stenosis (<50%); one had total occlusion with 
collaterals (group A). Recurrent angina due to re-
stenosis occurred in one patient (group A). The ves-
sel was successfully redilated. Three patients (two in 
group A, one in group B), in whom angina developed, 
had restenosis of the infarct-related vessel but were 
found to have severe three-vessel disease and under-
went elective coronary bypass surgery. One patient 
(group A) died suddenly after 17 months. Fourteen 
patients (group C) made uneventful recoveries and 
are free of symptoms at follow-up. An invasive regi-
men to maintain myocardial perfusion during hospi-
talization was also followed after discharge. Patients 
who had late infarction with reocclusion of the 
infarct-related artery were treated with thrombolytic 
agents followed by PTCA. Patients with angina and 
severe three-vessel disease underwent coronary ar-
tery bypass surgery. With the application of this pol-
icy, 63 out of 74 patients (85%) who underwent 
PTCA after thrombolysis remained improved (Ca-
nadian Cardiovascular Society classes I and II) dur-
ing follow-up. 
DISCUSSION 
Limitation of myocardial infarct size by salva,oing 
ischemic myocardial tissue in the area that undergoes 
necrosis is the most important aim in the manage-
ment of patients with acute myocardial infarction in 
order to preserve cardiac fnnction and improve 
prognosis. Intravenous SK has been approved as a 
standard treatment for AMI because of the ease and 
rapidity of administration 19• 20 and its efficacy in re-
ducing mortality. 21 However, regardless of the route 
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of administration, recanalization may not occur. In 
addition, SK has no effect on an underlying severely 
stenotic lesion. The presence of severe residual steno-
sis increases the incidence of reinfarction and/or 
postinfarction angina.13· 22· 2S In our patient series, a 
patent infarct-related vessel after administration of 
intravenous SK was present in 64 patients (65% ); 
this is similar to the outcome of other studies.26· 29 
Thus many of these patients achieved early reperfu-
sion, most probably as a result of the thrombolytic 
agent, but, as expected, most of the recanalized in-
farct-related arteries had high-grade residual stsno-
sis (77.5% ). PTCA was successful in 68 of the 74 pa-
tients (92%) in whom it was attempted. The success 
rate was high both in patients with totally occluded 
arteries (87.5%) and in those with significant resid-
ual stenosis (95.2% ). The presence of a systemic lytic 
state did not adversely affect the outcome of PTCA, 
as other studies have also shown.14• 15 
The present study shows that a therapeutic inter-
vention for the treatment of AMI that combines ad-
ministration of intravenous SK and emergency an-
gioplasty is effective in achieving a high level (85%) 
of early and sustained coronary perfusion. Patients 
who were treated with this regimen had a very low 
rate of cardiac complications (including death) at 
both short-term and long-term follow-up. The effec-
tiveness of a combined medical and mechanical reca-
nalization in increasing coronary reperfusion and in 
improving left ventricular function has already been 
reported. 29·31 In a recently published study of 342 
patients with AMI, who were treated with the same 
regimen as in our study, Stack et al.3o reportsd a sig-
nificant number of interventional complications and 
an 11% in-hospital mortality rate. The better results 
obtained in our study group are due to the following 
differences. First, we excluded from our series pa-
tients in cardiogenic shock. Second, the mean inter-
val between onset of pain and performance of PTCA 
in our series was .:::; 3 hours in contrast to 4.5 hours 
in the other series. Conceivably, as a result of a 
shorter ischemic time, the mean global left ventricu-
lar ejection fraction of our patients was 10% higher 
than in the patients reported on by Stack et al.30 It 
has been demonstrated that the duration of ischemia 
before reperfusion is achieved is of paramount im-
portance in the determination of myocardial salvage 
and in the clinical outcome of patients with 
AMP· 19· 25 In spite of the encouraging results 
achieved with a combination of thrombolysis and 
PTCA, the role and timing of angioplasty in the 
management of AMI is still a matter of controversy. 
A recent study32 that compared immediate angio-
plasty with delayed elective angioplasty showed no 
advantages of immediate angioplasty. However, 
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Table iii. Results of PTCA 
Group A Group B 
Successful PTCA 28/32 (87.5%) 40/42 (95.2%) 
Severity of stenosis 100 95 
in initial CAG 
(mean){%) 
Stenosis 40 30 
after PTCA (mean)(%) 
PTCA. Percutaneous translumino.l coronary angioplasty; CAG. coronary 
arteriography. 
Table IV. Early and late outcome in the PTCA patients 
groups 
Group A GroupE 
(N = 32) (N = 42) 
Outcome Early Late Early Late 
Death 1 1 
Emergency CABG 2 
Elective CABG 2 1 
Asymptomatic reocclusion 1 2 
Late MI (reocclusion) 1 1 
Restenosis requiring 1 1 3 
emergency PTCA 
PTCA. Percutaneous transluminal coronary angioplasty; CABG. coronary 
artery bypass grafting; MI. myocardial infarction. 
among the patients who were selected for elective 
angioplasty (7 days), 18% had recurrent ischemia 
(most of which occurred within 24 hours of admis-
sion) that required crossover to urgent PTCA, and 
the global ejection fraction was significantly im-
proved in the immediate PTCA group. 
These findings indicate that after successful intra-
venous thrombolysis, careful monitoring of patients 
is mandatory for consideration of angioplasty if 
ischemia recurs. In another recently published mul-
ticenter study,33 the authors recommended that im-
mediate coronary angioplasty after thrombolysis 
should not be performed as a routine procedure in all 
cases, and they claimed that this had no additional 
benefit over thrombolysis alone. However, it should 
be noted that the combination of recombinant tissue 
plasminogen activator and coronary angioplasty was 
not addressed in this study. This combination may be 
the cause of the high acute and early reocclusion rate, 
which may differ from treatment with SK followed by 
PTCA, because of the long-acting systemic effect of 
SK. 
Limitation of the study. The number of patients in 
our study was small, and there was no control group. 
However, the data from this study compare favorably 
with the results from recently published randomized 
trialsY-17•3° Furthermore, the good long-term prog-
nosis in our series could be related to the large num-
ber of patients with one-vessel disease rather than to 
early and maintained perfusion of the culprit vesseL 
Conclusions and recommendations. This study has 
shown that early administration of intravenous SKin 
AMI followed by emergency angioplasty is feasible 
and safe. This strategy is associated with a high 
reperfusion rate, a low mortality rate, and low recur~ 
renee of cardiac events at both short-term and long-
term follow-up. Early reperfusion is the main goal in 
treating patients with evolving myocardial infarc-
tion. An intravenous thrombolytic agent should be 
administered as soon as possible, preferably before 
hospitalization. Careful monitoring for ischemia is 
also required. Angiography can be postponed only 
when clinical signs of reperfusion have appeared, 
such as sudden relief of chest pain and normalization 
of the ST segment. Further studies should be di-
rected to identification of patients at high risk of re-
occlusion after successful thrombolysis so that timely 
angiography and subsequent angioplasty or coronary 
bypass surgery can be performed. 
The authors express their appreciation to Mrs. G. Odenthal and 
Mrs. M. v.d. Broek for their secretarial assistance. 
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CHAPTER 7 
Long-term follow-up of 100 patients with left anterior 
descending artery lesions treated with percutaneous 
transluminal coronary angioplasty 
H. BONNIER, P. BRONZWAER, R. MICHELS AND M. EL GAMAL 
Catharina Hospital, Eindhoven, The Netherlands 
KEY WORDS: Percutaneous transluminal coronary angioplasty. long-term follow-up. left anterior 
descending artery. 
In order to analyse late outcome. we reviewed the data on the first 100 patients who underwent percutaneous 
trans luminal coronary angioplasty ( PTCA) of the left anterior descending artery (LAD) in our institution. 
Their ages ranged between 40·0 and 82·3 years (mean 66·6. males 75%Jemales 25% ). All patients were 
treated with the non-steerable system between September 1980 and February I983, and followed upfor6· 2-9·6 
years (mean8·5 years). 
The primary success rate was 73%. We were unable to cross the lesion in 19%. and 8% of the patients 
required emergency bypass surgery because of acute occlusion or dissection. Elective bypass surgery was 
required in I8% of the patients. The clinical restenosis rate was 22%. Risk factors in this patient group were: 
smoking 66%: hypertension 37%: elevated serum cholesterol 32% and diabetes mellitus in 7%. After an 
initially successful PTCA, 12 out of 73 patients required a second PTCA of the same vessel because of 
restenosis and three, PTCA of a new lesion in another vessel because of recurrence of angina. Fifty-four 
patients were asymptomatic during the follow-up period of 8·5 years. Ninety-four of the 100 patients are still 
alive. 
Canadian Heart Association anginal classification of the study group was: class 0: 80 patients; class 1: 1 I 
patients; class If: three patients; class III and IV: no patient. Six patients died, there were four non-cardiac 
deaths because of cancer; one patient died 24 h after a myocardial infarction as a result of cardiogenic shock 
and ventricular septal rupture and one died suddenly 6 years after the initial PTCA. 
Thus, PTCA of the LAD is a safe procedure with excellent long-term results during an average 8·5 years' 
follow-up. More than half of the patients are totally asymptomatic after the initial PTCA. 
Introduction 
The clinical value and use of PTCAill is judged by 
its long-term effect on symptoms, the need for 
medication. return to work and the cost of medi-
cal care. In this article we will review the clinical 
outcome of our initial experience with percu-
taneous transluminal coronary angioplasty 
(PTCA) of the left anterior descending artery 
(LAD) in order to evaluate its long-term benefit. 
We will compare our results with those of the 
National Heart, Lung and Blood Institute PTCA 
Registry and the first 169 patients who underwent 
PTCA by Andreas Gruntzig121 in Zurich between 
1977 and 1980. 
Address for correspondence: H. Bonnier M.D., Catharina Hospital. 
Postbox 1350. 5602 ZA Eindhoven. The Netherlands. 
Methods 
PATIENT POPULATION 
The first 100 patients (75 men and 25 women) 
aged 40·0-82·3 years, (mean 66·6 years) with a sten-
osis in the LAD anatomically suitable for PTCA 
participated in this evaluation. All patients had 
angina pectoris Canadian Heart Association class 
Ill or IV in spite of adequate medical therapy. 
DILATATION EQUIPMENT 
The guiding catheter used in this initial patient 
group was a 9-F left Judkins polyurethane catheter 
made by Schneider Medintag, Zurich, or a 9-F El 
Gamal catheter when the orifice of the left main 
coronary artery was high and the left Judkins did 
not provide adequate engagement. 
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Initial PTCA 
---- n = 1 00 ----------Unsucces;ful Successful 
/n=27~ Death..----- n=73' \ n=1 t . ------.... after 24 h Myocardial Asymptomatic 
"'/\ /\' A~T" w:??f\~ 
PTCA (other late late PTCA (other PTCA (other RePTCA late RePTCA late Asympto-
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Figure I Follow-up data in 100 patients who underwent PTCA of the LAD. CABG: coronary artery bypass grafting. 
The balloon dilatation catheter used in this study 
was the Gruntzig DG and DJ Schneider, Zurich. 
Neither are steerable, that is, the dilatation cath-
eters did not allow directional control. Only 
shaping the short wire at the tip of the balloon and 
turning it facilitated entry into the vessel and across 
the stenosis. The diameters used were 2·0, 3·0 or 
3·7 mm. A Myler temporary pacemaker catheter 
was positioned in the pulmonary artery in all 
patients. 
MEDICATION 
All patients routinely received I 0 000 U heparin 
during the procedure, as well as calcium-channel 
blockers, nitrates and dextran. After the pro-
cedure aspirin or coumarin, dipyridamole and 
calcium-channel blockers were given for 6 months. 
RISK FACTORS 
66% of all patients were smokers; 37% had 
systemic hypertension; 37% had elevated serum 
cholesterol and 7% suffered from diabetes mellitus. 
Results 
The acute results and follow-up data of our first 
100 patients, who underwent PTCA of the LAD 
between September 1980 and February 1983, are 
shown in Fig. 1. Early and late mortality are sum-
marized in Table I. PTCA was successful in 73 
patients and failed in 27 patients. After an initial 
successful PTCA, one patient died after 24 h in 
cardiogenic shock after ventricular septal rupture. 
He had undergone PTCA during evolving acute 
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Table I Mortality after PTCA 
A Cardiovascular 
I patient 24 h after PTCA during acute myocardial infarction 
with ventricular septal rupture 
1 patient suddenly after 6·2 years. at home 
B Non-cardiovascular 
1 kidney tumour after 5·9 years 
1 carcinoma of the stomach after 3·2 years 
I carcinoma of the rectum after 7·4 years 
I carcinoma of the pancreas after 2·1 years 
myocardial infarction. Eight patients had a myo-
cardial infarction after apparently successful PTCA 
(cardiac enzymes were elevated at least twice the 
normal value). Three of these patients remained 
asymptomatic; four patients underwent repeat 
PTCA within 6 months because of restenosis. Sub-
sequently, two remained asymptomatic and two 
underwent CABG. There was one late death, after 
3·2 years, from carcinoma of the stomach. 
In the 64 patients initially asymptomatic after 
PTCA. restenosis occurred in eight within 2·3-5·2 
months (mean 4·5 months), who underwent a 
second PTCA. Subsequently four of these patients 
underwent elective CABG because of recurrence of 
angina but four remained asymptomatic. There 
were two late deaths, one patient died suddenly at 
home after 6· 2 years and one died of a kidney 
tumour after 5·9 years. Fifty-four out of the 64 
patients initially asymptomatic remained asympto-
matic and required no further treatment during 
long-term follow-up. 
Of the 27 patients in whom PTCA was initially 
unsuccessful. seven were treated conservatively. At 
follow-up a single patient later underwent success-
ful PTCA of the circumflex artery. and there was 
one late mortality, after 2·1 years. as a result of 
carcinoma of the pancreas. Twelve patients under-
went elective CABG. A single patient had success-
ful PTCA of the right coronary artery after 5·2 
years and another died of carcinoma of the rectum 
after 7·4 years. Eight patients underwent emerg-
ency CABG because of acute occlusion or dissec-
tion of the vessel during PTCA. Four developed 
acute mycardial infarction with moderate elev-
ation of cardiac enzymes while four patients did 
not develop peroperative myocardial infarction. 
Subsequently a single patient had successful PTCA 
of the right coronary artery after 4·7 years. Ninety-
two per cent of all patients had repeat coronary 
angiography at 6 months. All patients underwent 
exercise stress testing on a bicycle ergometer and 
were re-evaluated between November 1988 and 
February 1989. The follow-up period ranged from 
6·2 to 9·6 years (mean 8·5 years). Sixteen patients 
had mild disease in another vessel that did not 
require intervention at the time of the initial PTCA. 
Ninety-four patients are alive after a mean follow-
up of 8·5 years. Eighty patients are in Canadian 
Heart Association anginal class 0. II patients in 
class I. and three in class II. There are no patients in 
class Ill or IV. 
Discussion 
Though our cohort is relatively small, the results 
of our first 100 patients who underwent PTCA of 
the LAD with the non-steerable system demon-
strate the safety of the procedure. The six late 
deaths were unrelated. The long-term follow-up is 
excellent even though 26 patients underwent coron-
ary artery bypass grafting, eight acute and 18 elec-
tive. Eighty patients remain asymptomatic, in 54 
cases. after initial PTCA alone. 
In comparison with the initial 169 patients 
reported by Gruntzig121. in whom other vessels as 
well as the LAD were dilated. 83 out of the !33 
patients with successful PTCA were in functional 
class 0, and no patients were in class Ill or IV after I 
year. 
The PTCA Registry131 has reported similar 
figures. as has the group from the Mayo Clinicl41. 
Restenosis occurred in 22% in our series. while 
Gruntzig reported 31% and the PTCA Registry 
33·6%. However, in the PTCA Registry 72% of the 
initially successful patients remained improved 
after 4 years and did not require further inter-
ventions. The annual mortality rate in their patients 
with PTCA and single-vessel disease was less than 
I% per annum. 
Conclusions 
Although patients who had PTCA required 
many interventions during the first 6 months. such 
as re-PTCA because of restenosis and coronary 
artery bypass grafting, subsequent interventions 
and clinical events were rare. Interventions were 
considered safe since there was no mortality. Thus 
the long-term outcome after PTCA is excellent in 
patients with left anterior descending artery sten-
osis. More than 50% of the patients remained 
totally asymptomatic after the initial PTCA. after a 
mean follow-up of8·5 years. 
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CHAPTERS 
Initial and long-term results of coronary 
angioplasty and coronary bypass surgery in 
patients 75 years or older 
Hans Bonnier, Cornelis de Vries, Rolf Michels, Mamdouh El Gamal 
ABSTRACT 
Objective- To evaluate the clinical outcome after 
percutaneous transluminal coronary angioplasty 
(PTCA) or coronary artery bypass grafting (CABG) in 
patients 75 years or older who underwent either proce-
dure between 1980- 1987 in our institution. 
Patients and methods - Ninety three patients. 
between 75-89 years. suffering from angina pectoris. 
all in class III or IV C.C.S .. out of whom 79 patients 
(85%) had three vessel disease underwentPTCA. while 
81 patients 75 - 89 years. all in class III or IV C.C.S .. 
out of whom 62 patients (77%) had three vessel dis-
ease. underwent CABG. Follow-up: after PTCA 8.2 
years. after CABG 8.3 years. 
Results - Primary success rate in 93 PTCA pa-
tients was 84% (78 patients). In 72% of patients only 
one vessel was dilated in spite of the fact that three 
vessel disease was present. 
There were 4 major cardiac events: 2 emergency 
bypass operations and 2 deaths. Other complications 
were: myocardial infarction in 3 patients and CV A in 1 
patient. It was impossible to dilate the lesion in seven 
patients (5 underwent elective CABG. 2 were treated 
conservatively). Median hospital stay was 4.3 days. 
In 81 CABG patients 53 (63%) made an uneventful 
recovery. 
Death occurred in 6 patients: 24 patients developed 
other complications: CV A in 2 patients. myocardial 
infarction in 8 patients. 10 patients needed a re-thora-
cotomy and 4 patients required prolonged ventilation 
because of adult respiratory distress syndrome. Median 
hospital stay was 14.2 days. 
During follow-up after PTCA there were 8 deaths. 
Three patients suffered a non-fatal myocardial infarc-
tion. two patients required elective CABG and 10 
patients underwent repeat PTCA because of recurrence 
of severe angina. Four patients had recurrence of mild 
angina medically treated. Sixty-four patients were free 
of angina without any complications (69%). During 
* Submiur:d for publication. 
follow-up after CABG. there were 8 deaths. One devel-
oped a non-fatal myocardial infarction: 6 patients re-
quired PTCA and 3 had recurrence of mild angina 
during follow.:.up received medic-al treatment. Thus 57 
patients were free of angina without other complica-
tions (70%). Actuarial survival after PTCA was 92% 
after 10 years and 91% after CABG (excluding four 
deaths after emergency CABG for complications of 
coronary angiography). 
Conclusions- PTCA is a safe procedure in elder-
ly patients. 
Dilatation of the culprit lesion relieves symptoms. 
The complication rate is lower and the hospital stay is 
significantly shorter when compared to CABG (p < 
0.05). Long-term follow-up did not show a significant 
difference between PTCA and CABG. Therefore 
PTCA is preferable in patients 75 years or older. when 
the culprit lesion is suitable for PTCA. 
iNTRODUCTiON 
The population is ageing and the percentage and 
number of patients 75 years or older is increasing. In 
this patient population a conservative medical manage-
ment is often chosen for those suffering from ischemic 
heart disease. However when symptoms are not ade-
quately relieved. the options for revascularizaton 
should be considered. A number of reports have docu-
mented the efficacy ofPTCA in elderly people [1-18]. 
but also CABG can be performed in this group with 
increasing safety [18-28]. In this observational study 
we report our experience between 1980 and 1987 in 
patients 75 years or older. who underwent PTCA or 
CABG. 
PATIENTS AND METHODS 
Between September 1980 and December 1987, 3142 
patients underwent PTCA in our institution. Ninety 
three patients were 75 years or older (3% ). In the same 
period 3657 patients underwent CABG. of whom 81 
patients (2%) were 75 years or older. 
Follow-up was available up to June 1991 for all 
patients. Information was obtained from the referring 
physician. from the patients at out -patient visits. or by 
telephone. 
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PROCEDURE 
PTCA was performed via the femoral artery in 98% 
of the cases. In the majority (72%) an ··over the wire" 
balloon system was used. Angioplasty was considered 
successfuL when the stenosis was reduced to less than 
fifty percent of the luminal diameter. without major 
complications (myocardial infarction. cerebrovascular 
accident. emergency coronary artery bypass surgery or 
death). Ten thousand units of heparin were given at the 
onset of the procedure and 5000 units at the end. 
Aspirin . 250 mg intravenously. was given after the 
procedure. if the patient was not already receiving the 
drug before PTCA. In addition during a six month 
period after PTCA 300 mg dipyridamole per day and 80 
mg Aspirin were prescribed. Up to 1985 a calcium 
entry blocker was also prescribed. Complete revascu-
larization was not necessarily the goal in these elderly 
patients undergoing PTCA. In CABG patients. how-
ever. complete revascularization was performed if pos-
sible. Cardiopulmonary bypass with moderate hypo-
thermia and cristalloi"d cardioplegia was used. 
Postoperatively all patients received Aspirin 300 mg 
daily or coumadin up till 1984. combined with 300 mg 
dipyrimadole a day for at least one year. After 1984 the 
combination of 80 mg Aspirin combined with 300 mg 
dipyrimadole daily was prescribed routinely to all pa-
tients. 
STATISTICAL ANALYSIS 
Continuous variables are expressed as median ± 
standard deviations. Student" s t -tests were performed 
to determine whether there was a significant difference 
between mean values. 
RESULTS 
The age range for PTCA patients was 75- 89 years 
(median 80)). forCABG patients 75-84 years (median 
77) (table 1). Fifty eight percent (54 patients) in the 
PTCA group were males. and 66% (53 patients) in the 
group that underwent CABG. There were no differen-
ces in smoking habits. hypertension. diabetes. anginal 
classification. prior myocardial infarction or prior 
CABG. There was also no difference in severity of 
coronary artery disease: 85% of the PTCA patients had 
three vessel disease while 77% of the CABG patients 
had three vessel disease. No difference was found in 
left ventricular ejection fraction. angiographically de-
termined. in both groups. There were only a few pa-
tients with very poor left ventricular function in either 
group. In total 122 vessels were dilated in the PTCA 
group (table 2): left anterior descending artery or a 
graft to the left anterior descending artery in 66 patients 
(54%). left circumflex coronary artery in 24 patients 
(20%). right coronary artery in 22 patients (18%). 
diagonal branch in 7 patients (6% ). An unprotected left 
main stem was dilated in 3 patients (2% ). These 3 
patients had class IV angina and were not suitable 
candidates for CABG. One vessel was dilated in 67 
patients (72%). two vessels in 23 patients (25%) and 
three vessels in 3 patients (3% ). In the CABG group 3 
patients (4%) had a single distal anastomosis; 15 pa-
tients (19%) had two distal anastomoses: 12 patients 
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Table 1. 
Clinical profile of 174 patients, 75 years of age and older 
undergoing coronary angioplasty or coronary artery bypass 
graft surgery. 
PTCA (n~93) CABG (n~81) 
Male 54 53 
Female 39 28 
Mean age 80 77 
Smoking history, former 17 14 
current 37 31 
Hypertension 47 40 
Diabetes 5 3 
Anginal class (CCS) 0 
I 
II 0 2 
Ill 43 37 
IV 50 42 
Prior Ml 36 30 
Prior CABG 9 13 
Diseased vessels 1 4 3 
2 10 16 
3 79 62 
LVEF >45% 69 62 
25-45% 22 18 
<25% 2 1 
Abbreviations: 
PTCA= percutaneus transl uminal coronary ang·loplasty 
CABG= coronary artery bypass grafting 
LVEF= left ventricular ejection fraction 
Ml =myocardial infarction: 
n = number of patients 
n.s =not significant 
Table 2. 
Extent of procedure in ninety three patients undergoing percu-
taneous transluminal coronary angioplasty and eighty one 
patients undergoing coronary artery bypass grafting. 
PTCA (n~93) CABG (n~81) 
one vessel/distal anastomosis 67 (72%) 
two vessels/distal anastomoses 23 (25%) 
three vessels/distal anastomoses 3 (3%) 
four or more distal anastomoses 
Abbreviations: 
As in Table 1. 
3(4%) 
15(19%) 
12 (15%) 
51 (62%) 
(15%) had three distal anastomoses and 51 patients 
(62%) 4 distal anastomoses or more (table 2). 
Complete revascularisation was performed more fre-
quently in the surgical patients as compared to PTCA 
patients in whom in the majority of cases only the 
culprit lesion was dilated. 
Median follow-up after PTCA was 8.2 years. range 
3.5- 10.9 years and after CABG 8.3 years. range 3.5-
11.2 years. 
PERIPROCEDUF!Al RESULTS 
PTCA was successful in 78 out of93 patients (84%). 
In 7 patients it was impossible to cross the lesion: 5 
patients underwent CABG on an elective basis and 2 
were treated conservatively. 
There were four major complications: two deaths 
and two emergency CABG. One patient underwent 
PTCA during cardiogenic shock after an acute myocar-
dial infarction. The stenosis was adequately dilated. 
but the patient died within 24 hours from progressive 
shock. The second patient developed dissection of the 
left main coronary artery. induced by the guiding 
catheter and died during the procedure. CABO was 
uncomplicated without myocardial infarction in the 2 
emergency procedures. In addition there were 4 other 
complications: one patient had a cerebrovascular acci-
dent. but recovered without residual symptoms and 
three patients suffered a myocardial infarction in the 
first 24 hours after PTCA. Hospital survival for the 
whole PTCA group was 96% (91 patients). The median 
hospital stay was 4.3 days (2-15 days). 
CABG was uneventful in 53 out of 81 patients 
(63%). There were 6 deaths. all procedure related. Four 
died during emergency surgery from evolving myocar-
dial infarction as a result of complications during 
coronary angiography elsewhere. Two other patients 
sustained a myocardial infarction during the operation 
and died on the second and third day after the procedure 
respectively. In addition 24 patients developed non-
fatal complications within 30 days including two cere-
brovascular accidents, which recovered uneventfully. 
Eight patients had an uncomplicated myocardial inf-
arction, ten patients required re-thoracotomy because 
of excessive bleeding and 4 patients required pro-
longed ventilation (more than 3 days) because of adult 
respiratory distress syndrome. Hospital survival was 
92% (75 patients). The median hospital stay was 14.2 
days (8-53 days). Figure I shows an overview of the 
initial results of PTCA and CABO. 
100 
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40 
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survival 
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D CABG (n=81) 
Fig. 1 Initial results of percutanous transluminal core~ 
nary angioplasty and coronary artery bypass grafting in 
174 patients, 75 years or older. 
lONG-TERM FOllOW-UP 
Follow-up was available in all patients. Table 3 
shows the late outcome of these patients. 
In the PTCA group median follow-up was 8.2 years 
(3.5 -10.9 years). Actuarial survival was 92% after 10 
years. There were Slate deaths: 2 sudden cardiac deaths 
after 3 and 6 years and 6 non-cardiac from cancer. 
Three patients had a non-fatal myocardial infarction. 
Elective coronary bypass surgery was performed in 2 
patients because of recurrence of angina and repeat 
PTCA was performed in I 0 patients. Thus in the PTCA 
group 68 patients (76%) had event free long-term 
survival. Four of these patients had angina pectoris 
C.C.S. class II or III which was treated conservatively. 
so 64 patients (70% of the initially surviving group) 
were free of angina. 
Table 3. Outcome of patients 75 years or older after successful 
percutaneous coronary angioplasty (PTCA) or coronary artery 
bypass grafting (CABG). 
PTCA (n=93) CABG (n=81) 
Median hospital stay (days) 4.3 14.2 p < 0.05 
In hospital deaths 
Late, cardiac deaths 
Late. non-cardiac deaths 
Survival 
Follow-up (1 0 years) 
Non-fatal Ml 
Survival no Ml 
Elective CABG (PTCA group) 
Survival no Ml or (re) CABG 
Repeat PTCA (PTCA group) 
PTCA (CABG group) 
Survival no MI. CABG or PTCA 
Recurring angina 
2 
2 
6 
83 (89%) 
92% 
3 
80 
2 
78 
10 
68 
4 
Survival no MI. CABG or PTCA 64 (70%) 
and angina free 
Abbreviations: 
As in Table 1. 
6" 
3 
5 
67 (83%) 
91% 
66 
66 
6 
60 
3 
57 (76%) 
• Four patients were operated on an emergency base after 
complicated coronary angiography elsewhere 
In the CABO group median follow-up was 8.3 years 
(3.5- 11.2 years). Actuarial ten year survival was 91% 
(excluding the four early deaths during emergency 
surgery). There were 8 deaths: one patient died after a 
myocardial infarction after 5.4 years and two patients 
died suddenly at 2.4 and 6.8 years after operation. 
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while 5 patients died from cancer. Only 1 patient had a 
non-fatal myocardial infarction. Elective PTCA was 
performed in 6 of the patients who had prior CABG 
because of recurrence of angina. 
Thus in the CABG group 60 patients (80%) had 
event free long-term survival. Three of these patients 
had angina pectoris C.C.S. class li-lli and were treated 
conservatively. thus 57 patients (76% of the initial 
group) survived free of angina. 
Figure 2 shows the total survival calculated by the 
Kaplan-Meier method32 for all patients 75 years or 
older. who underwent PTCA or CABG. The four pa-
tients referred to our institution for emergency bypass 
surgery, due to complications during coronary angi-
oplasty elsewhere. and died, are not included. There is 
no statistical difference between both groups. 
DISCUSSION 
Patients of75 years or older form a considerable and 
rapidly growing part of our popul3.tion. In 1995 the 
number of elderly citizens(> 65 years) in The Nether-
lands will increase to two million and it is calculated 
that in 2030 one million Dutch citizens will be 75 years 
or older. Already more than fifty percent of patients 
admitted to the department of cardiology of the Tho· 
raxcenter in Rotterdam in 1990 are older than 65 
years. 33 Cardiovascular disease remains the main cause 
of morbidity and mortality in this group29 and an 
increasing number of elderly patients unresponsive to 
medical therapy for angina pectoris will be referred for 
PTCA or CABG. 
CABG in this patient population is associated with 
an increased mortality and morbidity. 18-28 In a recent 
review of the influence of age on the results of coronary 
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artery surgery. Weintraub et al.27 reported the highest 
mortality in the group of patients 80 years or older. 
followed by the group of70-79 years. Wound infection 
and neurological events were higher in these groups. 
compared to younger patients. In contrast several re-
ports indicate that the results of PTCA in elderly pa-
tients are comparable to those obtained in younger 
patients30• although other authors report lower success 
rates and increased morbidity'' Thus PTCA may be an 
attractive alternative to surgery. 1· 17• 31 
The PTCA and CABG results. in this retrospective 
study are similar to those published in the literature. 
The percentage of complications. tended to be higher in 
the CABG group. Furthermore the hospital stay after 
CABG was significantly longer. Late outcome was 
excellent in both groups. although there was a trend 
towards more cardiac events neccessitating repeated 
interventions after PTCA to achieve similar late out-
come. It is interesting to note that mortality during 
follow-up in both groups was mainly due to cancer and 
not. to coronary artery disease. Another observation 
from this study was that dilating the culprit lesion in the 
majority of PTCA patients appeared sufficient to 
achieve a similar late outcome as the completely revas-
cularized CABG patients. So in selected cases dealing 
with the culprit lesion only in patients selected for 
PTCA is often sufficient. It is notal ways neccessary to 
operate on patients with three vessel disease to achieve 
freedom from angina and long-term survival. 
A point of criticism of this study is the selection of 
patients. since it was a non-randomized series and it 
was not recorded in detail why PTCA was done in a 
certain cohort of patients and CABG in the other group 
(indication bias). 
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Fig. 2 Kaplan 
Meier curve of 
total survival time 
[Ill PTCA £ CABG] 
for patients 75 
years or older, 
who underwent 
PTCA or CABG. 
Vertical lines are 
95% confidential 
intervals. The 
numbers indicate 
patients 'at risk'. 
Four patients had 
complications 
during coronary 
angiography 
elsewhere and 
were referred for 
emergency bypass 
surgery. They died 
during the 
procedure and are 
not included in the 
curve. 
In conclusion, PTCA and CABG in patients 75 years 
or older can be performed with an acceptable incidence 
of complications. In the elderly, dilatation of the culprit 
lesion often provides adequate symptomrelieve in the 
majority of patients selected for PTCA. The complica-
tion rate for PTCA was lower and the hospital stay was 
shorter compared to CABG. These observations sug-
gest. that PTCA in patients 75 years or older is prefer-
able to CABG, when the culprit lesion is suitable for 
PTCA. If the culprit lesion is not identified or unsuit-
able for PTCA, CABG can be performed with an 
acceptable result. 
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CHAPTER 9 
Acute myocardial ischaemia and cardiogenic shock after 
percutaneous transluminal coronary angioplasty; risk 
factors for and results of emergency coronary bypass 
1. 1. BREDEE*, J. H. BAVINCK*, E. BERREKLOUW*, H. J. BONNIERt, C. VAN DOORN*, 
M. I. EL GAMALt, P. N. HENDEL*, Y. A. MASHHOUR*, H. R. MICHELSt, T. H. RELIKt, 
J.P. SCHONBERGER*, 1. STEENBRINK*, R.N. VAN WANDELEN* AND F. J. TER WOORST* 
Departments of Cardiopulmonary Surgery* and Cardiologyt. Catharina Hospital, Eindhoven, 
The Netherlands 
KEY WORDS: Acute myocardial ischaemia, cardiogenic shock, PTCA, risk factors, emergency CABG. 
Between I September, I980 and I January, I989, 4I42 patients underwent percutaneous transluminal 
coronary angioplasty ( PTCA). We retrospectively studied the I 55 [3·7%; II9 males. mean age 53·4 years, 
(range 33-78 years) and 36 females, mean age 59·6 years (range 40-7 4 years) J who required urgent coronary 
artery bypass grafting (CABG) (Group I) and a select control group of I 55 patients, in whom PTCA was 
performed without complications (Group II). 
Before PTCA, 14 Group I and 42 Group II patients had angina Class II, and 78 Group I and 49 Group II 
patients had angina class IV (x'-test, P<0-05). There were445 complications in the I 55 group I patients: 303 
(68%) early (during PTCA) and 14I (32%) late (within 24 h). On arrival in the operating room I26 patients 
were stable;five were in cardiac arrest and I9 in cardiogenic shock (AS-group; 24 patients). In the AS-group 
and control group, respectively, angina Class II occurredin2j24 (8·3%) and42/ I 55 (27-I%) patients, angina 
Class IV in I4/24 (58·3%) and49j I 55 ( 3I·6%) (P <0·05) ,single-vessel disease in 8/24 (33·3%) and85J I 55 
(54·8%), triple-vessel disease in 7/24 (29·2%) and 23JI55 (14·9%) (P<0-05); elective PTCA in 11/24 
( 45·8%) and92j I 55 (59·4%), urgent PTCA in I2/24 (50%) and48/ I 55 ( 30·9%) (P<0·05), PTCA of the 
left anterior descending artery (LAD) in I8/24 (75%) and 86/ I66 (5I·8%), PTCA of the right coronary 
arteryin2/24 (8·3%) and47JI66 (28·3%) (P<0-05). 
Angina pectoris Class IV, triple-vessel disease. urgent PTCA and PTCA of the LAD were risk factors for 
development of cardiac arrestjcardiogenic shock after PTCA. 
Of the I 55 Group I patients ,four (2·6%) died. The myocardial infarction rate was 62/ I 55 ( 40% ). Of the 
24 AS-group patients, the myocardial infarction rate was 10/24 (4I·7%). although the time to revascu-
larization was significantly shorter (median I03 min; range 73-I85 min) than in the I26 patients who were 
in good condition preoperatively (median I35 min; range 80-235 min) (Wilcoxon's rank sum test, 
P<O·OOI). 
Introduction 
Eleven years after the introduction of percutaneous 
transluminal coronary angioplasty (PTCA) by 
Griintzig et a/. in 197?1'1, a Task Force of the 
American College of Cardiology J American Heart 
Association (Subcommittee on PTCA) formulated 
internationally recognized guidelines for the pro-
cedurel'i, thus emphasizing the rapid acceptance of 
this method for revascularization of jeopardized 
myocardium. In the Special Report of the Sub-
Address for correspondence: J. J. Bredee. Department of Cardio-
pulmonary Surgery. Catharina Hospital. P.O. Box 1350. 5602 ZA. 
Eindhoven. The Netherlands. 
committee is underscored the importance of weigh-
ing beforehand the likelihood of a successful PTCA 
against the likelihood of failure and the risk of 
complications (abrupt vessel closure, morbidity, 
mortality and restenosis). 
Despite the enthusiasm for the benefits of PTCA 
there is concern for the hazardous aspects of the 
method: 'Although there is a tendency to categorize 
angioplasty procedures as having low, moderate or 
high risk, situations do occur in low risk procedures 
that lead to catastrophic complications'i3] The 
retrospective study presented here, based on 
data from more than 4000 consecutive patients 
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Table I Number of procedures from I September, 1980-J 
January,l989 
Emergency CABG 
Year PTCA afterPTCA 
(n) (n) (%) 
1980 20 0 0 
1981 86 9 10·5 
1982 144 15 10-4 
1983 217 19 8·7 
1984 328 22 6·7 
1985 595 26 4-4 
1986 779 23 2·9 
1987 992 24 2-4 
1988 981 I:Z. 1·7 
Total 4142 !55 
PTCA =percutaneous transluminal coronary angioplasty: 
CABG =coronary artery bypass grafting. 
undergoing PTCA in one institution, concentrates 
on the potentially lethal sequelae ofPTCA, on their 
possible prevention and on the results of their surgi-
cal treatment. 
Materials and Methods 
DEFINITIONS 
Angina Pectoris (AP) was graded according to 
Canadian Cardiovascular Society Classes L II, Ill 
and JVI4] PTCA 's were classified as elective 
(according to the waiting list), urgent (within 48 h 
of diagnostic cardiac catheterization), and emerg-
ency (as an extension of the initial diagnostic cath-
eterization). Complications of PTCA leading to 
emergency CABG were denoted early when they 
occurred during PTCA and late when they occurred 
within 24 h of the start of the procedure. The types 
of dilated lesions were morphologically classified, 
according to Rosch and Rahimtoolal'l, as short 
( < 5 mm long), concentric or eccentric; tubular 
(5-20 mm long), regular, irregular or with ulcerating 
plaque, and diffuse ( > 20 mm long). 
MATERIALS AND METHODS 
From I September, I 980 to I January, 1989 in the 
Catharina Hospital in Eindhoven, PTCA was per-
formed in 4142 patients. An emergency operation 
was necessary in 155 of these patients (3·7%). The 
complication rate decreased from 10·5% in 1981 to 
I ·7% in 1988 (Table 1). 
From the introduction of PTCA to our insti-
tution in 1980, the data on every candidate for 
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Table 2 Operations in 155 patients of group I 
Operation Patients (n) (%) 
No history of previous CABG !52 98·1 
History of previous CABG 3 1·9 
Total 155 100 
of which 
CABGI 61 39-4 
II 62 40 
Ill 17 II 
IV 12 7·7 
v 3 1·9 
Total !55 100 
CABG=coronary artery bypass grafting. I-V=number of 
grafts. 
PTCA have been formally discussed by a cardiolo-
gist and a surgeon. A surgical team stood in 
readiness for every PTCA performed. 
In addition to our study group (I) we studied a 
select control group (group II) of I 55 patients. in 
whom PTCA was performed without compli-
cations. The control group was selected from the 
PTCA Patient Registry using the patient immedi-
ately following each patient who needed operation. 
of the same sex and the same age (±4 years). In 
groups I and ll the mean ages of the men were. 
respectively, 53·4 years (range 33-78 years) and 54·8 
years (range 34-76 years), of the women, 59·6 years 
(range 40-74 years) and 58·9 years (range 44-74 
years), and of all patients 54·8 years (range 33-78 
years) and 55·7 years (range 34-76 years). In the 155 
patients of group I a history of previous coronary 
surgery was absent in 152 patients and present in 
three. Usually one or two venous bypasses were 
constructed (Table 2). In no case was the internal 
thoracic artery used as bypass graft in these often 
critically ill patients. The mode of myocardial pro-
tection during operation was intermittent cross-
clamping in 38 patients. cristalloid cardioplegia in 
97 patients and (in the last 2 years) blood cardio-
plegia in 20 patients, according to Buckberg's 
protocol ofreperfusion strategyl'i. 
'Time to revascularization' was designated the 
time elapsed between notification by the cardiolo-
gist that a complication necessitating emergency 
operation had occurred to the moment after com-
pletion of both distal and proximal anastomoses. In 
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Figure 1 Indications for percutaneous transluminal coron-
ary angioplasty in 155 patients of group I(~. surgical group) 
and !55 patients of group II ( 0, control group). Angina pec-
toris was graded according to the Canadian Cardiovascular 
Society classification. 
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Figure 2 Distribution of dilated vessels in 155 patients of 
Group I (Ill, surgical group) and !55 patients of Group II (0, 
control group). LAD=left anterior descending coronary 
artery. CX =circumflex coronary artery. RCA= right coron-
ary artery. 
the cases where blood cardioplegia was used, this 
included up to 20 min of warm regional reperfusion. 
Perioperative myocardial infarction was considered 
to be present when the postoperative ECG, 12 h 
after the operation, showed new Q-waves and 
simultaneously an elevation of the serum-level of 
glutamic oxaloacetic transaminase (GOT) to at 
least twice normal. 
To analyse the statistical significance of the datz; 
the x'-test, the Z-norm test and Wilcoxon's rank 
sum test were used. 
Results 
The indications for PTCA in group I (surgical 
group) and in group II (control group) are depicted 
in Fig. I. Only 14 patients were AP Class II in group 
I. compared with 42 in group II; on the other hand, 
there were 78 patients with AP Class IV in group I 
compared with only 49 in group II (x2-test, 
P<0·05). 
Figure 2 shows the distribution of dilated vessels 
in groups I and II; it is significantly different (x2-test, 
P < 0·05), but the difference in this distribution is 
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Figure 3 Classification of percutaneous coronary angio-
plasty in 155 patients of Group I (gj. surgical group) and 155 
patients of Group II ( ::J. control group). For explanation, see 
text. 
Vessel d1sease 
Figure 4 Distribution of coronary artery disease in 155 
patients of Group I ( ~. surgical group) and 155 patients of 
Group II (D. control group). I =single-vessel disease. II= 
double-vessel disease, III= triple-vessel disease. LMT =left 
main trunk lesion. 
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Figure 5 Types of dilated lesions in 155 patients of group I 
(Ill, surgical group) and !55 patients of Group II (0, control 
group). SC =short concentric. SE =short eccentric. TR = 
tubular regular. TI =tubular irregular. TU =tubular with 
ulcerating plaque. DI =diffuse.# = obstructed. For expla-
nation see text. 
mainly caused by the small number of PTCAs in 
grafts and double PTCAs. 
Figures 3-5 show the respective distributions of 
classification of PTCA, of coronary artery disease 
and of types of dilated lesions in groups I and II. 
In none of these variables was there a significantly 
different distribution between groups. The 
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Table 3 Complications of percutaneous rransluminal coronary angioplasty in 155 patients of group I, leading to emergency 
coronary artery b_1:pass grafting. and in ]55 patients of group II 
Early 
(during PTCA) 
Complication 
Group I Group II 
(n) (%) (n) (%) 
Persistent chest pain 62 
ECGchanges 
indicative of 
myocardial ischaemia 62 
Inability to cross 30 4 
Inability to dilate 26 4 
Spasm 6 3 
Dissection 59 25 
Perforation 2 
with 
haemopericardium 
Occlusion 27 
Asystole 5 
Ventricular tachy-
cardia/fibrillation 7 2 
Cardiogenic shock 14 
Total 303 68 38 79 
PTCA =Percutaneous transluminal coronary angioplasty. 
complications ofPTCA in the I 55 patients of group 
I, leading to emergency operation, and in the !55 
patients of group Il are listed in Table 3. In group I 
there were 445 complications, 303 (68%) early and 
141 (32%) late; in group II there were 48 compli-
cations, 38 (79%) early and lO (21 %) late. In 34 
patients of group I and in three patients of group 
IL the late complication was documented by 
recatheterization. 
In Fig. 6 the type of stenosis and the type of 
concomitant complications are indicated. Most 
complications of all types of lesions were early. 
Early dissection was prominent, especially in 
tubular regular lesions (43%). Similar numbers of 
occlusions were early and late, in all types of lesion 
(Fig. 7). 
On arrival in the operating theatre, 126 of the !55 
group I patients were stable. Five had a cardiac 
arrest and needed continuous cardiopulmonary 
resuscitation, 19 were in cardiogenic shock and 
needed intermittent resuscitation (24 patients, 
AS-group- arrest or shock). In five patien.ts the 
condition was not documented. 
The postoperative cardiac complications are 
listed in Table 4. Myocardial infarction occurred, 
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Late Total 
(within 24 h) 
Group I Group II Group I Group II 
(n) (%) (n) (%) (n) (%) (n) (%) 
48 5 110 5 
45 2 107 2 
I 31 4 
2 28 4 
2 8 3 
13 72 25 
2 
I 
27 3 54 3 
5 
7 2 
3 17 
141 32 10 21 445 100 48 100 
overall, in 40% of cases, and in the patients with 
intermittent crossclamping, cristalloid cardioplegia 
and blood cardioplegia the incidence was 39-4%, 
42·2% and 30%, respectively. There was no relation 
of myocardial infarction rate to the mode of pero-
perative myocardial protection (Z-norm test). In 
the 24 patients of the AS-group, myocardial infarc-
tion occurred in I 0 ( 41· 7%) cases; although the time 
to revascularization was significantly shorter in 
these patients (median 103 min, range 73-185 min) 
than in the 126 patients who arrived in the operating 
room in good condition (median !35 min, range 
80-235 min) (Wilcoxon's rank sum test, P<O·OOI), 
this did not result in a lower myocardial infarction 
rate. 
The non-cardiac complications are given in Table 
5. The pulmonary complications were acute respir-
atory distress syndrome, necessitating prolonged 
mechanical ventilation, and airway infection and 
atelectasis, necessitating bronchoscopy. 
Four patients died: 2·6% (Table 6). Three of 
them had AP Class IV preceding PTCA and had 
urgent PTCA for this. Three were in cardiogenic 
shock when they arrived in the operating room and 
notwithstanding cardiopulmonary resuscitation 
tOO E L E L E L E L E L E L E L 
"' "' 0 
c 
"' l:
"' 0. 
., 
c 
0 
:g_ 50 
"'" c 0 
:g 
·" c.
E 
0 
(.) 
0 S C S E T U D I N D 
48 52 28 15 6 5 5 
Stenosis type and number 
~igure 6 Type of stenosis and type of complication in 155 
patients of group I (surgical group). Stenoses: SC =short con-
centric. SE=short eccentric. TR=tubular regular. TI= 
tubular irregular. TU =tubular with ulcerating plaque, DI = 
diffuse. ND=not documented. Complications: E=early. 
L=late. IC =inability to cross. ID =inability to dilate. SP= 
spasm. DI =dissection. PE=perforation. OC =occlusion. 
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Figure 7 Type of complication and type of stenosis in 155 
patients of Group I (surgical group). Abbreviations as in 
Fig.6. 
and the use of !ABP in two patients, they all devel-
oped a lethal perioperative myocardial infarction. 
In the group of 24 patients arriving in the 
operating room in cardiac arrest or cardiogenic 
shock (AS-group) we studied the following vari-
abies, probably contributing to the development of 
these pathological states. In the AS-group there 
were 11/24 (45·8%) patients with a history of pre-
vious myocardial infarction compared with 53/155 
(34·2%) in the control group (statistically non-
significant difference;x2-test, P> 0·05). The follow-
ing factors however were of importance (Figs 8, 9) . 
In the AS-group there was a low incidence of AP 
Class II (2/24; 8·3%) vs the control group (42/!55; 
27·1 %) and a high incidence of AP Class IV (14/24; 
58·3%) vs the control group (49/155; 31·6%) (X2-
test, P<0·05). Single-vessel disease was seen only 
in 8/24; 33·3% of patients in the AS-group and in 
85/155; 54·8% in the control group, as opposed to 
triple-vessel disease, which occurred in 7/24; 29·2% 
of the AS-group and in only 23/155; 14·9% of the 
control group Cx'-test, P < 0·05). Elective PTCA 
was performed in 11/24 patients; 45·8% in the 
AS-group and in 92/155; 59-4% in the control 
group; urgent PTCA however was performed in 
12/24; 50% of cases in the AS-group and in only 
48/155; 30·9% in the control group Cx'-test, 
P<0·05). Finally, PTCA of LAD occurred more 
frequently in the AS-group (18/24; 75%) than in the 
control group (86/166; 51·8%) and PTCA of RCA 
occurred less frequently in the AS-group (2/24; 
8·3%) than in the control group (47/166; 28·3%) 
(x'-test, P < 0·05). 
Thus AP-class IV, triple-vessel disease, urgent 
PTCA and PTCA of LAD were risk factors for the 
development of cardiac arrest/cardiogenic shock 
after PTCA. In the 24 patients of the AS-group no 
risk factor was present in one patient, one risk 
factor in seven patients. two risk factors in five, 
three in ten patients and four in one patient. Among 
the four patients who died. one risk factor was 
present in one, two risk factors in two and three risk 
factors in one. 
Discussion 
Early in our experience with PTCA. we realized 
that a clear understanding of which patients were 
predisposed to acute myocardial ischaemia after 
PTCA, was lacking. In recent years, several authors 
have addressed this questionJ7-IO] Vlietstra stated 
that: 'the major risks of PTCA are myocardial 
infarction and death. usually a consequence of cor-
onary artery thrombotic occlusion or dissectionl'l·. 
He adds: ·when one considers the risk of mortality 
in patients with stable angina having percutaneous 
transluminal coronary angioplasty, the assumption 
generally made is that the observed mortality 
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Table 4 Postoperative cardiac complications in 155 patients of group I 
Complication 
New low output 
Ventricular tachycardia/ventricular fibrillation 
Atrioventricular block (pacemaking) 
New Q-wavesand SGOT;.2 N (>60 U ml-') 
Any of the above 
SGOT =Serum glutamic oxaloacetic transaminase. 
Table 5 Postoperative non-cardiac complications in 155 
patients of group I 
Complication 
Bleeding (resternotomy) 
Wound infection 
Pulmonary 
Renal (dialysis) 
Liver 
Sepsis 
Cholecystitis 
Intestinal obstruction 
Incarcerated hernia 
Any of the above 
Patients 
(n) (%) 
6 
3 
ll 
3 
3 
2 
26 
3·9 
1·9 
7·1 
1·9 
1·9 
1·3 
0·6 
0·6 
0·6 
16·7 
directly reflects procedure related mortality. This 
assumption is not true when dealing with very ill 
patients (e.g. patients with cardiogenic shock). For 
them, the observed mortality is the net result of the 
hazards and benefits imposed by the underlying ill-
ness, and the treatments that have been used. Under 
these circumstances, the effects of treatment might 
only become evident when there is comparison with 
the outcome in a control group'l'l. The obvious 
drawback of a retrospective study of patients 
undergoing PTCA and emergency operation from 
1980-1989 is that in this period rapid developments 
have taken place in the indications for, the tech-
nique and procedure of PTCA and in methods of 
myocardial protection, once acute myocardial 
ischaemia has occurred. This makes cohorts of 
earlier years incomparable with those oflater years. 
However the inclusion in the study of a time-
matched control group makes it possible to draw 
certain conclusions. 
From 1981 to 1988 in our institution, the 
incidence of PTCA leading to emergency CABG 
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Patients 
(n) (%) 
5 3·2 
19 12·3 
2 1·3 
62 40·0 
70 45·2 
decreased from 10·5% to 1·7%; overall it was 3·7%. 
This is in accordance with data in other published 
large seriesl"·"] 
For this stepwise improvement two factors seem 
important: increased operator experience and 
improvement of technology; an increasing under-
standing of when PTCA is indicated may also have 
contributed. Holmes et a/. found that despite a 
higher risk patient population in the cohort of 
patients undergoing PTCA between 1985-1987 vs 
the 1977-1981 cohort, the overall complication 
rate in the recent cohort was either unchanged or 
decreased from that in the earliercohorti"] Regard-
ing early (during PTCA) and late ( <24 h) occlusion 
we saw exactly 50% early and 50% late occlusion. It 
underscores the message of Page et a/.[1~ that the 
risks of PTCA do not end when the patient leaves 
the catheterization laboratory and that 'Patients 
with a severe intimal dissection and a significant 
amount of myocardium at risk should be monitored 
closely and sent immediately to surgery ifischaemic 
symptoms occur•IJS] 
In a detailed account of risk factors for acute 
closure after coronary angioplasty and the associ-
ated in-hospital cardiac mortality, given by Ellis et 
af['-81, clinical variables associated with increased 
procedural mortality were age > 65 years, female 
gender, a history of hypertension, diabetes, prior 
myocardial infarction, prior bypass surgery, multi-
vessel disease, left main coronary disease, a large 
area of myocardium at risk, impairment of left 
ventricular function, and collateral vessels that sup-
ply significant areas of myocardium and originate 
distal to the segment to be dilated. 
Our finding that angina Class IV carries a higher 
risk of acute myocardial ischaemia than lower AP 
classes is in accordance with the findings of others. 
De Feyter et a/. concluded that coronary angio-
plasty for unstable angina can be performed with a 
Table 6 Postoperative mortalit_v in 155 patients of group I 
Age Previous AP Vessel Complication ACBG Peri operative Other (years), myocardial Class disease PTCA ofPTCA plus myocardial complications 
sex infarction IV infarction 
56, M + LAD/UR Chest pain: !ABP + RenaL 
ECGchanges Pulmonary 
60, M + + II CX/UR Inability to IABP + 
cross: shock 
67, F II LADjEL Occlusion; + Incarcerated 
shock hernia 
69, M + II RCA/UR Occlusion: CPR + Renal 
shock 
M =Male, F =female. -=absent. +=present. UR =urgent. EL =elective. LAD= left anterior descending coronary artery, 
CX =circumflex coronary artery. RCA= right coronary artery. ECG =electrocardiographic. ACBG =aorta-coronary bypass 
grafting. CPR= cardiopulmonary resuscitation, IABP= intra-aortic balloon pumping. 
100,---------------------------------, 
90 
n ill Ill II ill LMT 
AP class Vessel disease 
Figure 8 Incidence of factors contributing to development 
of cardiac arrestjcardiogenic shock in 24 patients (AS-group) 
of Group I. LMT =left main trunk lesion. f2 =arrest/shock 
(n~24); Ill ~control group (n~ 155). 
UR EM 
PTCA 
LAD CX RCA Grafts 
PTCA 
Figure 9 Incidence of factors contributing to development 
of cardiac arrestjcardiogenic shock in 24 patients (AS-group) 
of group I. PTCA =percutaneous transluminal coronary 
angioplasty. EL=elective. UR=urgent. EM=emergency. 
LAD=left anterior descending coronary artery. CX= 
circumflex coronary artery. RCA=right coronary artery. 
ill ~arrest/shock (n ~ 24); Ill ~control group (n ~!55). 
high initial success rate but at an increased risk of 
major complicationsl"l, In cases of unstable angina, 
Di Marco et a/. reserve PTCA for patients with 
single-vessel disease and no evidence of previous 
myocardial infarction120] 
Our results showed that the morphological type 
of lesion, as classified by Rosch and Rahimtoola I~ 
was not a determinant of complications of PTCA 
necessitating emergency surgery. It should be added 
that this classification was not devised to this end. 
The lesion-specific classification of types A, B and 
C, as proposed by the ACC/AHA Task Forcel'l 
appears to take into account better the uniquely 
technical aspects of PTCA for risk stratification, 
but must stand the test of time. 
Study of the subset of24 patients who arrived in 
the operating room in the haemodynamically very 
unstable state of cardiac arrest or cardiogenic 
shock, candidates for 'desperate' operation accord-
ing to Pagel171, gave valuable information. The risk 
factors identified were: AP Class IV; triple-vessel 
disease; urgent PTCA; and PTCA of LAD. In the 
presence of one or more of these risk factors, the 
cardiologist should be aware of the increased 
possibility of a serious complication after PTCA 
and take this into account in his choice of invasive 
procedure. 
Only one of the 24 AS-group patients was free 
of risk factors and none of the four patients who 
died was free of risk factors. We cannot suggest, 
however, that the absence of risk factors implies 
a PTCA without the possibility of a serious com-
plication; our data confirm that the occurrence 
of complications after PTCA remains unpredict-
able. Thus we should not refrain from surgical 
standby. 
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Our finding of 2·6% postoperative death is 
roughly in accordance with other published studies 
of emergency revascularization for complications 
of PTCAIII-Is] 
Von Segesser and Turina point to the fact that 
myocardial infarction can be prevented in a 
substantial proportion of patients when revascular-
ization is performed within 1 h of coronary 
occlusion118] The relatively good results in the 
24 patients in cardiac arrest/cardiogenic shock may 
be partly explained by their shorter mean revascu-
larization time vs patients who arrived in the 
operating room in good condition. As in Page's 
experience[!~, the surgical team moves faster in 
these cases, the patient usually being on cardio-
pulmonary bypass within 20 min. It was our experi-
ence that we lost valuable time by installing lABP 
and by the more complicated transport of the 
patient to the operating room as a consequence. 
Nowadays we prefer the rapid institution of 
cardiopulmonary bypass. 
We thank the cardiologists who referred patients for PTCA 
for their permission to include data on their patients. We 
thank the anaesthesiologists, the collaborators of the 
Heart Catheterization Laboratory. the Department of Extra 
Corporeal Circulation and the nursing staff for very effective 
action. The advice of Prof. Dr J. Lubsen and the statistical 
calculations by Drs A. P. M. Scbellekens are gratefully 
acknowledged. We also thank Mrs Mara Siemonsma for 
fine secretarial assistance and Mr Guy van Dael for the 
illustrations. 
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CHAPTER 10 
Myocardial Protection by Intravenous Diltiazem 
During Angioplasty of Single-Vessel 
Coronary Artery Disease 
Johannes J.R.M. Bonnier, MD, Tom Huizer, MSc, Roel Troquay, MD, Gerrit Anne vanEs, PhD, 
and Jan Willem de Jong, PhD 
The possible cardioprotective effect of diltiazem 
during ischemia caused by percutaneous trans· 
luminal coronary angioplasty was tested. Electro· 
cardiograms and myocardial lactate, hypoxanthine 
and urate production were determined in 26 pa-
tients with a stenosis in the left anterior descending 
artery without angiographically demonstrable col· 
laterals. Measurements took place before angio-
plasty, after each of 4 occlusions and 15 minutes 
after the last balloon inflation. Patients were ran· 
domly given placebo or Dl·diltiazem (0.4 mg)kg as 
a bolus intravenously, followed by an infusion of 15 
mg/hr). During angiopiasty the ST -segment eleva· 
tion for the anterior wall leads 'II 2 , V 4 and V "' and 
the intracoronary lead was similar for both groups, 
as was lactate release. Diltiazem significantly re· 
duced cardiac hypoxanthine release immediately 
after angioplasty from 63 to 118% (p <0.05). The 
drug diminished urate production after the last dila· 
tation by 82% (p <0.05). In conclusion, intrave· 
nous infusion of diltiazem reduced cardiac adeno-
sine triphosphate breakdown during angioplasty as 
shown by diminished hypoxanthine and urate pro· 
duction. In contrast, diltiazem was unable to atten· 
uate ST -segment elevation and lactate release. 
(Am J Cardio! 1990;66:145-150) 
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I n the last decade, calcium antagonists have proven to be effective in the treatment of many cardiovascu-lar disorders. A few of these drugs, including diltia-
zem, have been successful in the management of angina 
pectoris. One of the advantages of diltiazem is its abil-
ity to delay ischemic ventricular arrhythmias. 1 In addi-
tion, calcium antagonists may improve the protection 
afforded by potassium-cardioplegia for heart surgery2 
They may also be useful for local cardioplegia during 
coronary angioplasty. 3-8 Diltiazem delayed the onset 
of pacing-induced ischemia9 .1° In isolated hearts and 
open-chest animals, diltiazem11 - 15 and other calcium 
antagonists14J6- 19 exert an energy-sparing effect during 
ischemia. In this study, we tested whether diltiazem 
could minimize adenosine triphosphate-breakdown dur-
ing angioplasty and thus serve as a potential cardia-
protective agent during the procedure. 
METHODS 
Patients: The study involved 26 patients with !-ves-
sel coronary artery disease undergoing percutaneous 
transluminal coronary angioplasty. The following char-
acteristics were observed for each patient. Coronary ar-
tery disease was limited to an isolated proximal stenosis 
<l em in the left anterior descending artery (narrowing 
> 70%) and no collateral filling was seen angiographi-
cally in the region supplied by this artery. There was no 
history of previous myocardial infarction, and nitrates 
were not required during the dilatation procedure (Ta-
ble I). Antiplatelet drugs (including aspirin) and other 
cardioactive medications except short-acting nitrates 
were discontinued :1::48 hours before the procedure. 
With the exception of heparin, no drugs were given be-
fore completion of data acqnisition. This research proj-
ect was approved by the institutional committee on pa-
tient research. All patients gave informed consent be-
fore the study, and no complications related to the 
protocol were observed. 
Coronary angiop!asty: A normal El Gamal diagnos-
tic 7Fr catheter (Cordis) was introduced through the 
right femoral vein in the great cardiac vein. Its position 
was confirmed with the injection of a small volume of 
nonionic contrast medium (Isopaque Coronar 370). An 
8Fr guiding catheter was introduced percutaneously 
and advanced to the aortic root through the right fern-
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TABLE I Clinical Characteristics of the Study Groups 
Placebo Group Diltiazem Group 
(n = 13) (n = 13) 
Age (yrs). average 58 58 
Range 43-72 37-74 
Sex: M/F 10(3 11(2 
Patients in CCS 
Grade II 4 4 
Grade Ill 7 6 
Grade IV 2 3 
Average severity of stenosis(%) 
Before angioplasty 79 82 
After angioplasty 37 35 
Average ejection fraction (%) 64 66 
Mean aortic pressure during 102 97 
transluminal occlusion 
(mmHg) 
Mean heart rate during 74 68 
transluminal occlus·1on 
{beats/min) 
None of the differenC(!s reached Slgnrficonce at p <0.05. 
ccs =canadian Gardiovascu~r Society. 
10 intracoronary 
:: : - : - : : 
- -
' ' ' ' ' ' ' ' 
-
"! ~ 
-";" 0 ~ 
5 0 
~ 
E 
E 
-
c:: 0 
0 
:;:::: 
Cl! 10 > 
'12, '14, 116 <II 
'ii 
I H : • ... : : : : H 
-1-
' ' ' ' ' ' ' ' Ill 
~ 0 0 0 ~ 0 0 0 
0 0 0 
5 
0 
1 2 3 
dilatation 
FIGURE 1. Effect of diltiazem on ST -segment elevation during 
angioplasty, measured with the intracoronary lead (top} and 
the precordial leads (bottom). Bars indicate the median 
values, ranges are given above the columns. Open bars = 
placebo; hatched bars = d!iltiazem. No significant effects 
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oral artery. The left anterior descending artery was 
visualized by injection of contrast medium after the 
first blood samples had been taken. Then, the angio-
plasty balloon (Advanced Cardiovascular System Inc.) 
was introduced. Coronary angioplasty was performed 
according to Simpson et al,20 using a steerable guide-
wire (Advanced Cardiovascular System, high torque 
floppy, 0.014 inch). Balloon diameters were 3.0 or 3.5 
mm. The maximal inflation pressures ranged from 6 to 
12 atmospheres. For each patient, the dilatations were 
sustained for 90 seconds or until the onset of chest pain. 
In each patient, 4 consecutive dilatations were per-
formed, with a 5 minute recovery between inflations. 
Control coronary angiography was then performed. 
Samp5ng: Great cardiac venous and femoral arterial 
blood samples, taken before, immediately after each de-
flation and 15 minutes after the procedure, were treated 
as previously described." 
Ladate and purine analysis: In the deproteinized 
samples, lactate was determined enzyrnatically.22 In ad-
dition, the adeuine nucleotide catabolites hypoxanthine 
and urate were assayed by high-performance liquid 
chromatography,23 as modified by Huizer et al.21 Urate 
was detected at 290 nm. 
Elec:trocardiograms: These were monitored from the 
precordial leads V 2, V 4 and V 6, and from the intracoro-
nary lead, using the guidewire placed in the left anterior 
descending artery. Each lead was calibrated before the 
procedure (10 mm = 1 mV). Maximal ST elevation at 
the end of each inflation was measured 0.80 second af-
ter the J point, with the T-wave-P-wave interval as the 
isoelectric line. 
Experimental regimen: The patients were randomly 
assigned to treatment with placebo or diltiazem ( dou-
ble-blind). Five minutes before the first dilatation, and 
immediately after data collection at rest, they received 
either DL-diltiazem (0.4 mgjkg intravenously [Lorex]), 
or solvent, as a bolus over 5 minutes, followed by a con-
tinuous infusion of either 15 mgjhr diltiazem or solvent. 
Plasma diltiazem was determined with the methodology 
described for verapami!.24 
Stetistical analysis: Results are given as median and 
range, uuless indicated otherwise. Nonparametric statis-
tical methods were used: for within-group analysis the 
Wilcoxon signed rank test, for between-group analysis 
the Mann-Whitney rank sum test. A p value <0.05 was 
considered statistically siguificant. 
RESULTS 
Clinical characteristics: The clinical characteristics 
of the study groups assigned to diltiazem or placebo are 
listed in Table I. Age, Canadian Cardiovascular Society 
grade, severity of the stenosis in the left anterior de-
scending artery and left ventricular ejection fraction in 
the 2 groups were comparable. Inflation time (approxi-
mately 80 seconds), inflation pressure (approximately 9 
atmospheres) and pain symptoms (in 10 or II of 13 
patients) during the 4 consecutive inflations were com-
parable in the 2 groups. Cross-sectional area of the ste-
nosis before and after coronary angioplasty was similar 
in both groups (approximately 80 and 35%, respective-
ly). The baseline values of lactate, hypoxanthine and 
1' ABLE II Effect of Diltiazem on Arterial and Great Cardiac Venous Plasma Lactate Concentrations During Angioplasty 
Lactate Concentration (mM) 
Dilatation 
Sampling 
Site Treatment No. Pee I 2 3 4 Post 
Arterial Placebo 13 0.68 0.65 0.64 0.63 0.57 0.56 
(0.41-1.64) (0.41-1.46) (0.44-1.57) (0.38-1.61) (0.38-1.54) (0.38-1.85) 
Arterial Diltiazem 13 0.73 0.66 0.69 0.66 0.67 0.64 
(0.43-().99) (0.40-0.91) (0.36-{).93) (0.39-0.84) (0.39-0.86) (0.34-0.91) 
Venous Placebo 13 0.53 1.54 1.45 1.46 1.50 0.59 
(0.37-1.65) (0.90-2.56) (0.62-2.34) (0.81-2.67) (0.7 4-2.93) (0.29-1.71) 
Venous Diltiazem 13 0.60 1.47 0.94 1.37 1.05 0.69 
(034-0.86) (0.54-2.39) (0.45-232) (0.41-2.51) (0.43-3.24) (036-{).98) 
No. - number of observations. Medi;:m values a regiven w1th ranges in parentheses. No s•gmficanteffects of treatment were observed. 
TABLE m Effect of Diltiazem on Arterial and Great Cardiac Venous Plasma Hypoxanthine Concentrations During Angioplasty 
Hypoxanthine Concentration ifl.M) 
Dilatation 
Sampling 
Site Treatment No. Pee I 2 3 4 Post 
Arterial Placebo 11 0.60 0.41 0.33 0.25 0.20 0.15 
(0.23-0.96) (0.07 -0.63) (0.07-0.79) (0.06-{).55) (0.06-{).79) (0.02-0.46) 
Arterial Diltiazem 12-13 0.70 0.31 0.34 0.29 0.24 0.16 
(0.25-1.60) (0.11-0.87) (0.08-0.84) (0.09-0.52) (0.06-0.54) (0.08-0.49) 
Venous Placebo 11 0.41 0.94 1.30 1.31 1.04 0.42 
(0.11-0.97) (0.44-5.20) (0.16-2.33) (0.33-2.07) (0.33-2.41) (0.03-0.93) 
pValue 0.017 0.017 0.023 0.017 
Venous Diltiazem 13 0.31 0.42 0.33 0.43 0.37 0.18 
(0.09-0.85) (0.17-2.52) (0.10-4.89) (0.06-5.58) (0.05-3.13) (0.03-0.65) 
No. number of observotions. Med1on volues ore gwen w1th r.:mges 1n porentheses. Where d1fferenccs betv<e<:n plocebo :md dilt•azcm were statistically sigmfocant. p vJiues Jre 
g1ven 
TABLE IV Effect of Diltiazem on Arterial and Great Cardiac Venous Plasma Urate Concentrations During Angiop!asty 
Urate Concentration ifl.M) 
Dilatation 
Sampling 
Site Treatment No. Pee 1 2 3 4 Post 
Arterial Placebo 13 236 224 234 220 212 225 
(192-449) (185-457) (179--431) (177-455) (174-469) (168-462) 
Arterial Diltiazem 12-13 246 244 240 226 243 238 
(138-347) (136-352) (131-351) (128-358) (126-348) (115-348) 
Venous Placebo 13 242 221 217 230 238 221 
(188-495) (181-481) (182-478) (178-480) (174-512) (173-469) 
Venous Diltiazem 13 244 250 251 251 247 238 
(144-342) (131-356) (130-351) (130-352) (128-359) (124-348) 
No. number of observations. Median v<Jiuesare given w1th r<~nges in parentheses. No signrficont effects of tre;Jtmentwere observed. 
urate were similar for both groups (Tables II through 
IV). 
Eleclrocarcliographic measurements: No ST -seg-
ment or T-wave abnormalities were observed before an-
gioplasty. Figure I shows the actual degree of ST-seg-
ment elevation during each occlusion. Electrocardio-
graphic measurements taken from the intracoronary 
lead and the anterior wall leads V 2, V 4 and V 6 show 
that ST elevation tended to be smaller in the placebo 
group, but the differences were not significant. Some 
patients did not develop ST-segment elevation during 
transluminal occlusion. Although they did not show any 
collaterals on pretreatment coronary arteriography, it is 
possible that they developed collaterals during balloon 
occlusion. ST-segment depression during occlusion was 
observed on only I occasion. 
lactate release: The arterial lactate concentrations 
were not affected by diltiazem (Table II). Mter angio-
plasty great cardiac venous lactate increased 2- to 3-fold 
(p <0.01) in both the placebo and diltiazem groups. 
Figure 2 shows the arteriovenous difference of lactate at 
control and after each balloon dilatation. Patients in 
both groups produced lactate immediately after the bal-
loon deflations. Treatment with diltiazem tended to 
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reduce lactate production after angioplasty was per-
formed (p >0.05). 
1-ilfi'Oxanthine metabolism: The hypoxanthine con-
centrations are listed in Table HI. Diltiazem did not af-
fect the arterial values. In the placebo group, the great 
cardiac venous hypoxanthine concentrations increased 
3- to 5-fold (p <0.01) after each dilatation. In contrast, 
only a minor increase was observed in diltiazem-treated 
patients (Table III). In these patients venous hypoxan-
thine was lower (p ~0.02) than that in the placebo 
group. Figure 3 shows the effect of placebo and diltia-
zem on hypoxantllli'1e production by the heart. Samples 
taken directly after the 4 occlusions showed 63 to 88% 
lower hypoxanthine production in the diltiazem group 
than in the placebo group (p <0.05). 
Urate release: Diltiazem had no significant effect on 
the arterial and venous urate concentrations (Table IV). 
Figure 4 shows the effect of placebo and diltiazem on 
urate production by the heart. At rest and directly after 
the first 3 dilatations, there were no significant differ-
ences between the groups. Only immediately after the 
fourth dilatation was urate release smaller (p = 0.047) 
in the diltiazem group. 
Diltiazem levels: The plasma concentrations of dilti-
azem, measured 5 minutes after the last deflation, var-
ied widely (132 to 4,730 l'g/liter, median 902). 
DISCUSSION 
Elec:trocardiographic data: We did not detect a sta-
tistically significant effect of diltiazem treatment on 
ST -segment changes during coronary angioplasty. The 
changes tended to be larger in the diltiazem group. In 
contrast, several investigatorsS-7.8 observed that severity 
and time to onset of ischemic ST- and T-wave changes 
during coronary angioplasty were significantly reduced 
after treatment with this drug. In other studies, the ad-
ministration of diltiazem has also been shown to reduce 
ST-segrnent elevations due to pacing-induced ischemia 
in dogs9 as well as in man. 10 We cannot explain the 
discrepancies between our resnlts and these reports. 
ll..actate produc:lion: In this study, diltiazem tended 
to reduce the amount of lactate produced by the heart 
subjected to coronary angioplasty. However, this effect 
was not statistically significant. Hanet,4 Werner6 and 
their co-workers reported a significant reduction in 
lactate production with other calcium antagonists used 
intracoronarily. Remme et al10 observed that diltiazem 
could attenuate significantly lactate production induced 
by rapid atrial pacing. 
1-ilfi'Oxanthine and urate release: After ischemia the 
human heart releases hypoxanthine due to adenosine 
triphosphate catabolism. This has been demonstrated 
during pacing stress testing,23·25 coronary angioplasty26 
and heart surgery. 2•27 In our study, hypoxanthine pro-
duction was also obvious after each balloon deflation. 
Diltiazem could diminish this production. Based on ani-
mal studies,"- 15 it seems unlikely that the drug influ-
enced purine uptake/release independent of adenosine 
triphosphate hydrolysis. An interesting aspect of the 
present investigation is the production of urate (Figure 
4)." This could be partly suppressed by diltiazern. The 
appearance of urate indicates that the human heart con-
tains xanthine oxidoreductase. This enzyme exists in the 
heart in a number of species, 28 but its presence in hu-
man heart is controversia1.29•30 We cannot exclude that 
the enzyme could be active in the intact human heart, 
generating free radicals in its oxidase form. 
Diltiazem levels: We are puzzled by the large varia-
tion in plasma diltiazem concentrations. The same phe-
nomenon has been noted in other clinical trials (W.J. 
Remme, personal communication). Whether distribu-
tion or metabolism of the drug varies greatly from pa-
tient to patient is not known. We did not see a correla-
tion between diltiazem blood level and suppression of, 
for example, hypoxanthine release. 
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CHAPTER ll 
Effect of Intravenous Metoprolol Given 
During Angioplasty in Patients with Single-Vessel 
Coronary Artery Disease 
Jan Willem de Jong, PhD, FESC, Johannes J.R.M. Bonnier, MD, FESC, Tom Huizer, PhD, 
Renzo Ciampricotti, MD,and Jos R.T.C. Roelandt, MD, PhD, FACC, FESC 
In a double-blind, randomized, placebo-control-
led trial, the possible cardioprotective effect of 
metoprolol during ischemia caused by percutane-
ous transluminal coronary angioplasty was test-
ed. Electrocardiograms, hemodynamics and myo-
cardial metabolism were studied in 27 patients 
with a stenosis in the left anterior descending 
coronary artery. Measurements took place before 
angioplasty, after each of 4 1-minute occlusions 
and 15 minutes after the last balloon deflation. 
Patients were randomly given placebo or meto-
prolol (15mg as a bolus intravenously, followed by 
an infusion of 0.04mg/kg per hour). At the end of 
the procedure, the rate• pressure product had de-
creased by 15% (IllS) and 23% (p = 0.001) in tile 
placebo and metoprolol group, respectively. This 
was mainly due to similar decreases in heart rate. 
Metoprolol tended (p = 0.060) to reduce time to 
recovery of precordial and intracoronary ST -seg-
men_t elevation due to angioplasty. Chest pain 
was lower in the treated group, but the effect was 
not statistically significant. Lactate, hypoxan-
thine and urate release immediately after defla-
tion was similar in both groups. Metoprolol re-
duced the arterial plasma hypoxanthine 
concentration throughout the procedure, by about 
30% (p:S0.02 vs. placebo}. 
Thus, intravenous infusion of metoprolol tend-
ed to attenuate chest pain and ST -segment eleva-
tion, but failed to affect cardiac lactate and oxy-
purine release. It did, however, reduce 
significantly the arterial hypoxanthine concentra-
tions during angioplasty, possibly indicating that 
the B-blocker inhibits extracardiac adenosine-tri-
phosphate catabolism. 
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B eta-blockers protect against unstable angina and reduce the risk for myocardial infarction and sudden deathi-6 In isolated hearts propra-
nolol exerts an energy-sparing effect during ische-
mia.7·8 A beta-blocker. administered intravenously or 
intracoronarily. protects against ischemia during acute 
coronary occlusion in man.9.1° Bonnier et aL showed 
recently that a calcium entry blocker. diltiazem. could 
reduce oxypurine production from high-energy phos-
phates. induced by percutaneous transluminal coro-
nary angioplasty (PTCA). In the present study. pub-
lished in abstract form 12• we tested whether metoprolol 
could further attenuate ischemic injury during this 
procedure. e.g .. by diminishing adenosine-triphos-
phate breakdown. 
EXPERiMENTAl. 
Study population: The trial involved 27 patients 
with 1-vessel coronary artery disease undergoing 
PTCA. They all showed an isolated proximal stenosis 
< 1 em in the left anterior descending artery (narrowing 
>80%). without demonstrable collaterals. Beta-block-
er treatment was discontinued ;;:::: l week before the 
procedure: other cardioactive drugs were withheld 48 
hours before the study. With the exception of heparin. 
no drugs were given during the study before comple-
tion of data acquisition. The institutional committee on 
patient research approved the project. All patients gave 
informed consent before the study: they did not suffer 
protocol-related complications. 
Coronary angioplasty: The procedure has been 
described in detail before. 11 Briefly. a diagnostic cath-
eter was introduced in the great cardiac vein. A guiding 
catheter was introduced percutaneously and advanced 
to the aortic root. The left anterior descending artery 
was visualized with contrast medium after the first 
venous and arterial samples were taken. Then PTCA 
was performed using a standard balloon catheter over 
the guide-wire. with maximal inflation pressures 
ranged from 6 to 12 atmospheres. For each patient. the 
dilatations were sustained for 60 seconds. regardless of 
chest pain: 4 consecutive dilatations were done. with 
;;::::5 minutes between each inflation. and followed by 
control coro'nary angiography. 
Sampling: Great cardiac venous and femoral arte-
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rial blood samples, taken before, immediately after 
each deflation and 15 minutes after the procedure. were 
processed as previously described. 13 
Lactate and purine analysis: In the deprotein-
ized samples. lactate was determined enzymatically. 14 
In addition, the adenosine-triphosphate catabolites hy-
poxanthine and urate were assayed by high-perform-
ance liquid chromatography 15• as modified by Huizer 
et al. 13 Hypoxanthine and urate were detected at 254 
and 290 nm, respectively. 
Electrocardiograms: These were monitored 
from the precordial leads V 2• V 4 and V 6 and the intra-
coronary lead. and analyzed as described before. 11 
Experimental regimen: The patients were ran-
domly treated with placebo or beta-blocker (double-
blind). After baseline arterial and venous samples had 
been taken. 3 loading doses of 5 mg (5 ml) of a racemic 
mixture of S- and R-metoprolol tartrate (SelokenR. 
Astra) or placebo (5 ml saline) were rapidly injected 
intravenously at 2-minute intervals. Then the first dil-
atation took place. The bolus injections were followed 
by a continuous infusion of metoprolol 0.04 mg/kg per 
hour (or placebo) after the second balloon deflation. 
(For continuous use the drug was diluted with saline to 
0.1 mg/m1.) Plasma metoprolol was determined gas 
chromatographically with electron capture detection. 16 
Pain: At the end of each inflation. patient's chest 
discomfort was scored with Borg's new pain-scale. 17 
Statistical analysis: The statistical package for 
social science (SPSS-X) was used for data analysis. 
Adequacy of metoprolol dosing was evaluated by com-
paring the post-PTCA heart-rate and double-product 
values with baseline data (Student's t-test). ECG vari-
ables and arteriovenous differences were expressed as 
changes from baseline before being subject to multi-
variate analysis. Analysis of variance with repeated 
measurements was used. with treatment and time as 
variables. Studenfs t-test was used for the between-
group analysis. except for the comparison of the chest-
discomfortrating scale (Mann-Whitney 2-sample test). 
Unless otherwise stated. results are given as mean ± 
standard error. p <0.05 was considered significant. 
RESULTS 
Clinical characteristics: The study population 
was relatively homogeneous: for example. age and 
severity of the stenosis in the left anterior descending 
artery (Table I), and ejection fraction of the left ventri-
cle (not shown) in the 2 groups were comparable. The 
disease of all patients was classifted as Grade Ill ofthe 
Canadian Cardiovascular Society. They experienced 
angina pectoris only during exercise and received an-
tianginal therapy. 
Inflation time. inflation pressure and pain symptoms 
during the 4 consecutive inflations were comparable in 
the metoprolol group (average 59.8 seconds, II out of 
12 patients with pain) and the placebo group (average 
60.2 seconds, all !5 patients with pain). Cross-section-
al area of the stenosis before and after coronary angi-
oplasty decreased by about 85% in both groups (Table 
1). The baseline values of plasma lactate. hypoxanthine 
and urate were similar for both groups. 
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TABLE I Clinical Characteristics of the Study Groups 
Variable Placebo MetoproJoJ 
Group Group 
n=15 n==12 
Age (yrs), Average± SE 59± 2 57± 2 
Range 46-75 42-72 
Sex: MF 12/3 10/2 
Essential hypertension 1 1 
Hyperlipidemia 0 1 
Smokers (presently) 6 8 
Irregular heart rhythm 0 2 
Diabetes mellitus 1 0 
Severity of stenosis (%) 
Before ang·loplasty 93.0 ± 0.8 92.5 ± 1.3 
After angioplasty 15.6 ± 0.7 15.3 ± 1.3 
None of the differences reached sign"lficance at p <0.05. 
systolic blood pressure (mmHg) 
100 
90 diastolic blood pressure (mmHg) 
70 
50 
100 heart rate (beats I min) ~:~ p < 0.05 vs placebo + p < 0.05 vs placebo 
50 
12 
RPP (mmHg I min, thousands) 
9 
6 
placebo metroprolol 
c:::::J baseline ~ pre PTCA E22ZJ post PTCA 
medication 
FIGURE 1. Hemodynamics before medication, after the 
bolus injections, and 15 minutes after the last deflation. 
Metoprolol treatment (n = 12) induced a larger decrease 
in heart rate than placebo treatment (n = 15} did; how~ 
ever, the drop in rate-pressure product (RPP) did not dif~ 
fer significantly between the groups. 
Hemodynamics: Systolic and diastolic blood 
pressure did not change significantly throughout the 
procedure (Figure 1). In the placebo group. heart 
rate decreased 15% 15 minutes after the last deflation 
(p = 0.007 versus baseline): in the metoprolol group. 
heart rate dropped by 23% (p <0.001 versus baseline. 
1.0 arterial 
0.5 
p = 0.03 versus placebo). The rate· pressure product fell 
significantly only in the latter (by 23%. p = 0.001). 
Metoprolol did not influence this variable significantly ~ 
in comparison with placebo (Figure 1). E 
0.0 
Electrocardiographic measurements: No -Q) 
statistically significant differences were found be- -
1.5 venous 
tween the treatments for the ST -segment changes (as n 
the mean of the anterior wall leads V 2• V 4 and V 6• ~ 
Figure 2). The absolute intracoronary and peak 1.0 
ST -segment changes. as well as for the time to onset 
of the ST -changes. showed similar results. A trend 
(p = 0.060) in reduction in time to recovery of 
ST -changes with metoprolol compared to placebo was 
found (Figure 2): The time to recovery of ST -elevation 
-initially somewhat higher in the metoprolol group-
decreased under the influence of the drug. and in-
creased in the placebo group. 
mean ST-change (mm) 
2 
1 
0 
40 
recovery from ST-elevation (s) 
30 
10 
0 
Borg's chest-pain scale 
0 
PTCA1 PTCA2 PTCA3 PTCA4 
[::J placebo ~ metoprolol 
FIGURE 2. Effect of metoprolol on precordial ST-seg-
ment changes, recovery of ST-elevation, and chest pain 
during angioplasty. The pain scale is in arbitrary units: 
0 = no pain, 10 = extremely strong pain. No significant 
effects of metoprolol treatment were found, although 
there was a trend (p = 0.060) in favor of the drug in time 
to recovery of ST-elevation. n = 9-15. 
0.5 
0.0 
pre PTCA 1 PTCA2 PTCA3 PTCA4 post 
[::J placebo ~ metoprolol 
FIGURE 3. Effect of metoprolol on lactate metabolism 
of the heart. Drug treatment started after collection of 
baseline data. Immediately after angioplasty, lactate 
production was noted, as the great cardiac venous con-
centrations exceeded the arterial ones. No significant 
effects of metoprolol treatment were found. n = 12-15. 
Chest pain: The groups did not differ statistically 
with regard to pain experienced during balloon in-
flation. However. for the metoprolol group consistent-
ly less pain was scored than for the placebo group 
(Figure 2). 
Lactate metabolism: The arterial lactate con-
centrations were lower in the metoprolol group than in 
the placebo group, but the drug did not significantly 
affect them (p = 0.059. Figure 3). The same was true for 
the great cardiac venous lactate concentrations after 
angioplasty. which doubled in both groups. Also the 
arteriovenous difference in lactate was comparable 
between the groups. 
Hypoxanthine metabolism: The arterial and 
venous concentrations of hypoxanthine are given in 
Figure 4 on page 66. In both groups, the arterial con-
centrations fell after the first deflation and remained 
low. After each dilatation. the arterial hypoxanthine 
concentrations in the metoprolol group were about 
30% lower than in the placebo group (p :£ 0.02). The 
great cardiac venous levels remained more or less 
constant during the study. The groups showed no sig-
nificant differences in venous hypoxanthine concen-
trations or hypoxanthine production due to PTCA. 
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1.5 
1.0 
0.5 
~ 
arterial 
"' p < 0.05 
vs placebo 
2o 0.0 
(j) 
" 
.<: 
" "' 1.5 X 
0 
a. 
>-
E. 1.0 
0.5 
0.0 
pre PTCA1 PTCA2 PTCA3 PTCA4 post 
c:::J placebo ~ metoprolol 
FIGURE 4. Effect of metoprolol on arterial and great 
cardiac venous hypoxanthine concentrations. Treat-
ment with B·blocker lowered the arterial concentration 
during the procedure significantly. However, cardiac 
hypoxanthine production due to angioplasty was not 
significantly influenced. n = 12-15. 
Urate release: Metoprolol had no significant ef-
fect on the arterial and venous urate concentrations. nor 
on urate production by the heart (Figure 5). Only 30% 
of the hearts produced (small amounts of) urate before 
PTCA. in contrast to the majority of hearts (usually 
70%) after each deflation. 
Metoprolollevels: The plasma concentrations of 
metoprolol. measured 5 minutes after the last deflation. 
varied relatively little (164 ± 18 nM). 
DISCUSSION 
Metoprolol dosing: The plasma levels measured 
at the end of the procedure were within the therapeuti-
cal range for metoprolol. 18 We observed the expected 
drop in heart rate and double product (Figure 1). indi· 
eating that the drug suppressed partially the beta-
adrenergic system of the patients. The time-effects 
found with some variables is perhaps due to metoprolol 
accumulation in cardiac tissue. 19 
ECG changes and chest pain: The leads used 
included those optimal for monitoring ischemia of the 
area perfused by the left anterior descending coronary 
artery.20 We did not detect a statistically significant 
effect ofmetoprolol treatment on ST-segment changes 
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venous 
200 
100 
0 
pre PTCA1 PTCA2 PTCA3 PTCA4 post 
c:::J placebo ~ metoprolol 
FIGURE 5. Effect of metoprolol on urate production by 
the heart. The drug did not affect the arterial and great 
cardiac venous urate concentrations, nor their differ-
ence across the heart. n = 12·15. 
or chest pain during coronary angioplasty (Figure 2). 
However. the ST -segment changes and chest pain tend-
ed to be smaller in the metoprolol group. Labovitz et 
al. 21 recently observed some decrease of duration and 
extent of maximal ST -segment elevation during angi-
oplasty by ultrashort-acting beta-adrenergic blockade. 
Metoprolol administration is highly effective in reduc-
ing ambulatory ischemia as evidenced by angina pec-
toris during daily life.22 
Lactate production: Metopro1ol was without ef-
fect on cardiac lactate metabolism (Figure 3). The drug 
tended to reduce the arterial lactate levels. which is in 
line with the reduction of arterial hypoxanthine (vide 
infra). 
Oxypurine metabolism: After ischemia. the hu-
man heart releases hypoxanthine due to adenosine-
triphosphate catabolism. This has been demonstrated 
during an atrial pacing stress test 15·23• during coronary 
angioplasty 1L24• and during open-heart surgery.25 In 
contrast to earlierwork1 L24• coronary occlusion did not 
influence venous hypoxanthine. Still the arteriovenous 
difference became negative. because the arterial levels 
fell. The difference with earlier work. the relatively 
short balloon inflation time. could explain the discrep-
arrey. Metoprolol reduced the arterial hypoxanthine 
concentrations during the procedure (Figure 4). This 
could indicate that beta-blockade attenuates extracar-
diac adenosine-triphosphate breakdown. We speculate 
that beta-blockade leads to less anginal attacks22 (cf. 
tendency in Figure 2) by lowering the plasma levels of 
the hypoxanthine precursor adenosine26 (see also 
ref.S). 
The appearance of urate ( cf. ref.27 ) indicates that 
the human heart contains xanthine oxidoreductase. In 
line with in vitro observations28• perfusion of explant-
ed human hearts with hypoxanthine shows little pro-
duction of xanthine and urate in comparison to several 
other species. 29 Harrison et al. 30 demonstrated recently 
that xanthine oxidase. purified from human milk. has 
little affinity for its normal substrate(s). 
However. it has considerable reduced-nicotinamide-
adenine-dinucleotide oxidase activity: this generates 
free radicals. Hopefully future investigations will re-
veal whether or not human heart contains this xanthine 
oxidase (the desulpho form). 
Conclusions: (i) Metoprolol tended to attenuate 
chest pain and ST -segment changes due to coronary 
angioplasty. (ii) Cardiac lactate. hypoxanthine and 
urate release were similar in both groups. (iii) The drug 
lowered the arterial hypoxanthine concentration. pos-
sibly indicating that beta-adrenergic-blockade reduces 
extracardiac adenosine-triphosphate catabolism. 
Acknowledgement: We thank Berry van Gelder 
and the staff of the catheterization laboratory for their 
patient collaboration. We are grateful to Heleen van 
Loon. BSc. for analytical expertise: to Lars Johansson. 
PhD. for the determination of the metoprolollevels: to 
Bert Meems. MSc. and Jan Tijssen. PhD. for statistical 
assistance: and to Carina Poleon for secretarial help. 
REFERENCES 
1. Hjalmarson A. Elmfeldt D. Herlic.~J. Holmberg S, Malek L Nyberg 
G. Rydl:n L. Swedberg K. Vedin A. Waagstein F. Waldenstr6m A. 
Waldenstr6m J. Wedel R Wilhelmsen L. Wilhelmsson C. Effect on 
mortality of metoprolol in acute myocardial infarction: a double-
blind randomi::,ed trial. Lancet 1981:11:823-827. 
2. Norwegian Multicenter Study Group. Timolol-induced reduction 
in mortality and reinfarction in patients surviving acute myocardial 
infarction. N Eng! 1 Med 1981:304:801-807. 
3. Beta-Blocker Heart Att::tck Trial Research Group. A randomi::.ed 
trial of propranolol in patients with acute m_vocardial infarction. I. 
Mortality results. lAMA 1982;247:1707-1714. 
4. The MIAMI Trial Research Group. Metoprolol in acure myocar-
dial infarction. Am 1 Cardiol 1985;56 (Suppl 14): 1G-57G. 
5. ISIS-I Collaborative Group. Randomised rrial of intravenous 
atenoloi among 16027 cases of suspected acute myocardial infarc-
tion. Lancet 1986;11:57-66. 
6. The HINT Research Group. Early rrearment of unstable angina in 
co ronan care unit: a randomise d. double blind. placebo controlled 
comparison of recurrent ischaemia in patients treated with mfed-
ipine or metoprolol or both. Br Heart 1 1986:56:400-413. 
7. Harmsen E. De Tombe PP. DeJong JW. Synergistic effect of 
nifedipine and propranolol on adenosine( catabolite) relr::ase from 
ischemic rat heart. Eur 1 Pharmacal 1983;90:401 -409. 
8. Wangler RD. DeWitt DF, Sparks HY Jr. Effect of hera-adrenergic 
blockade on nucleoside release from the hypoperfused isalated 
heart. Am 1 Phvsiol 1984;247:H330-H336. 
9. Feldman RL: MacDonald RG. Hill JA, Limachcr MC. Conti CR. 
Pcpinc CJ. Effect of propranolol on myocardial ischemia occurring 
during acute coronary occlusion. Circulation 1986:73:727-733. 
10. Zalewski A. Goldberg S. Dervan JP, Slysh S, Maroko PR. 
Myocardial protection during transient coronary occlusion in man: 
beneficial effects of regional j3-adrenergic blockade. Circulation 
1986;73:734-739. 
11. Bonnier JJRM. Huizcr T. Troquay R, VanEs GA. DeJong JW. 
Myocardial protection by intravenous diltia::.em during angioplasty 
of single-vessel coronary artery: disease. Am 1 Cardio/1990;66: 145-
150. 
12. Bonnier JJRM. DeJongJW. HuizerT. Ciampricotti R. Meems B. 
Effect of intravenous metoprolof given during coronary angioplasty 
(PTCA). Eur Heart 1 1990;12 (Abstr Supp/):91. 
13. Huizer T. DeJong JW. Achterberg PW. Protection by bepridil 
aaainst mvocardial ATP-catabolism is probably due to negative i~"atropy. J Cardiovasc Pharmaco/1987:10:55-61. 
14. Gutmann I. Wahlefeld AW. L-(+)-lactate determination with 
lactatedehydrogenaseandNAD.In: Bergmeyer H-U. ed. Methods of 
En::_ymatic Analysis. Vol 3. 2nd edition. Weinheim: Verlag Chemie. 
1974:1464-1468. 
15. Harmsen E. DeJong JW. Serruys PW. Hypoxanthine production 
by ischemic heart demonstrated by high pressure liquid chromatog-
raphy of blood purine nucieosides and oxypurines. Clin Chim Acta 
1981 ;1 15:73-84. 
16. Ervik M. Kylberg-Hanssen K. Johansson L. Determination of 
metoprolol in plasma and urine using high-resolution gas chroma-
tography and electron-capture detection. 1 Chromarogr 
1986;381: 168-174. 
17. Borg G. Holmgren A. Lindblad I. Quantitative evaluation of 
chest pain. Acta Med Scand 1981; Supp/644:43-45. 
18. Sandberg A. Abrahamsson B. Reg:1rdh C-G, Wiesclgren I. Berg-
strand R. Pharmacokinetic and biopharmaceutic aspects of once 
daily treatment with metoprolol CR/ZOK: A review article. J Clin 
Pharmacol 1990:30:S2-S 16. 
19. Ryden L. Tadokoro H. Sjoquist P-0. Kar S. Ervik M. Corday E. 
Pronounced accumulation of metoprolol in ischemic myocardium 
after coronary venous retroinfusion. J Cardiovasc Pharmacal 
1990;15:22-28. 
20. Bush H. Ferguson III JJ. Angelini P. Willerson JT. Twelve-lead 
electrocardiography evaluation of ischemia during percutaneous 
translumina! coronary angioplasr_v and its correlation with acute 
reocclusion. Am Heart 1 1991:121:1591-1599. 
21. Labovitz AJ, Barth C. Castello R. Ojik M. Kern MJ. Attenuation 
of myocardial ischemia during coronary occlusion by ultrashort-
acting beta adrenergic blockade. Am Heart 1 1991:121:1347-1352. 
22. Ardissino D. Savonitto S. Egstrup K Marraccini P. Slavich G. 
Rosenfeld M. Feruglio GA. Roncarolo P. Giordano MP. Wahlqvist L 
Rehnqvist N. Barberis P. Specchia G. L'Abbate A. Transient myo-
cardial ischemia during daily life in rest and exertional angina 
pectoris and comparison of effectiveness ofmetoprolol versus nifed-
ipine. Am J Cardiol 1991;67:946-952. 
23. Remme WJ, Van den Berg R. Mantel M, Cox PH. Van Hoogen-
huyzc DCA. Kraus XH. Storm CJ. Kruyssen HACM. Temporal 
relation of changes in regional coronaryflow and myocardial lactate 
and nucleoside metabolism during pacing induced ischemia. Am 1 
Cardiol1986;58:JJ88-JJ94. 
24. Serruys PW, Suryapranata H. Piscione F. Harmsen E. Van den 
Brand M. De Feyter P. Hugenholtz PG. De Jong JW. Myocardial 
release of hypoxanthine and lactate during percutaneous translumi-
nal coronary angioplasty. Am J Cardiol 1989:63:45E-51E. 
25. Smolenski RT, Skladanowski AC. Perko M. Zydowo MM. 
Adenylare degradation products release from rhe human myocar-
dium during open heart surgery. Clin Chim Acta 1989; 182:63-74. 
26. Crca F. Pupita G. Galassi AR. Eltamimi H. Kaski JC. Davies G. 
Maseri A. Role of adenosine in pathogenesis of anginal pain. Circu-
lation 1990;81:164-172. 
27. Huizer T. DeJong JW. Nelson JA. Czarnecki W. Serruys PW, 
Bonnier JJRM. Troquay R. Urate production by human heart. 1 Mol 
Cell Cardia! 1989:21:691-695. 
28. Podzuwcit T. Beck H. Miillcr A, Bader R. GOrlach G. Scheid HH. 
Absence of xanthine oxidoreductase activity in human myocardium. 
Cardiovasc Res 1991:10:820-830. 
29. DeJong JW, VanderMeer P. Nieukoop AS. Huizer T. Stroeve 
RJ. Bos E. Xanthine oxidoreductase activity in perfused hearts of 
various species. including humans. Circ Res 1990;67:770-773. 
30. Harrison R. Abadah S, Benboubetra. Purification of xanthine 
oxidase from human milk. Biochem Soc Trans 1991 :19:332S. 
67 

Summary and general discussion 
The first part of this thesis deals with clinical and 
pathophysiological aspects of thrombolysis. 
A comparison of intravenous anisoylated plasmino-
gen streptokinase activator complex (APSAC or ani-
streplase) with intracoronary streptokinase for the 
treatment of patients with an acute myocardial infarc-
tion is presented in chapter one. Intravenously admin-
istered anistreplase appeared equally effective as 
streptokinase given intracoronary in lysing the throm-
bus responsible for acute myocardial infarction. The 
advantage of anistreplase would be its rapid and con-
venient mode of administration by single bolus intrave-
nous injection over 5 minutes. The findings of our 
study were confirmed by Anderson et al1 and Relik-
van Wely et al. 2 Earlier studies indicated that adminis-
tration of intracoronary streptokinase is more efficient 
to recanalize the infarct-related coronary artery than 
intravenous streptokinase (60%-75% versus 45-
60%).3·6 So it could be expected that intravenous ani-
streplase might be superior to intravenous streptoki-
nase. In the AIMS study7 a 50% reduction in mortality 
was observed after treatment with anistreplase. com-
pared with placebo. This difference was greater than 
the 25% relative mortality reduction after intravenous 
streptokinase in the GISSI-1 s and ISIS-29 studies. al-
though the confidence intervals overlapped. The abso-
lute reductions in mortality in these studies were: 
AIMS: mortality anistreplase versus placebo: 6 versus 
12%: difference (95% CI) -6% (-9 to -3%): G!SSI-1: 
mortality streptokinase IV versus control: 11 versus 
13%: difference (95% Cl) -2% (-3% to -1 %): !S!S-2: 
mortality streptokinase IV versus placebo: 9 versus 
12%: difference (95% Cl) -3% (-4 to -2%). However 
more recently Anderson et al. directly compared intra-
venous anistreplase with intravenous streptokinase in 
370 patients and observed no differences neither in 
early patency nor in infarct size nor in hospital mortal-
ity.10 Furthermore in the ISIS-3 11 mega-trial no differ-
ences were found in mortality and morbidity between 
anistreplase and streptokinase and r-tPA (duteplase®) 
all administered intravenously. The lack of survival 
difference in spite of superior early patency after r-tPA 
and anistreplase in comparison with streptokinase led 
to considerable discussion and confusion. White 12 in-
dicated that although patency after 90 minutes for r-
tPA is superior. no differences are apparent between 
various thrombolytic agents after 3 hours or 24 hours. 
He questioned the influence of very early patency on 
infarct size and clinical outcome. Others have indicat-
ed that the r-tPA regimen used in G!SSI-2 and ISIS-3 
was not optimaL particularly because no immediate 
anticoagulation with intravenous heparin was achieved 
(ECSG-6)13 
Unfortunately the discussion on the choice of throm-
bolytic drugs has been dominated by financial issues. 
and the use of streptokinase was advocated mainly 
because of considerable difference in price. If this price 
difference would become less important. other factors 
should also be considered. For example. anistreplase 
can be given as a bolus intravenous injection over 5 
minutes. while streptokinase has to be administered via 
an intravenous infusion over a one hour period. There-
fore anistreplase can be used more easily in the ambu-
lance as done in the EMIP study. 14 When a bolus 
injection of anistreplase is administered, or a streptoki-
nase infusion is given. the thrombolytic effect persists 
for 48 hours. On the other hand the action of alteplase 
stops immediately after its infusion is discontinued. 
This might result in a higher reocclusion rate after 
alteplase. unless a high level of anticoagulation is 
maintained. However Anderson et al. 15 in the TEAM-
3 trial found no difference between anistreplase and 
alteplase in mortality and morbidity. Thus it remains 
uncertain whether the prolonged lytic state is indeed 
clinically significant. In contrast with streptokinase 
and anistreplase. alteplase does not produce any aller-
gic reactions or drop in bloodpressure. In wider per-
spective. the difference in price, should not be exagger-
ated because the costs of the thrombolytic drug are only 
a fraction of the total costs of treatment of a myocardial 
infarction. 16 Pharmacological differences and ease of 
use should be considered. Particularly streptokinase 
and anistreplase should be avoided in patients with a 
reinfarction. because of development of anti-streptoki-
nase antibodies when the patient was previously treat-
ed with streptokinase or anistreplase. 
It is possible that in some patients a combination of 
thrombolytic drug may provide a more optimal result. 
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An example of such a regimen is the KAMIT trial. 
where a combination of alteplase and streptokinase 
compaired with streptokinase alone improved coro-
nary patency. without excessive bleeding complica-
tions. 17 This is currently under investigation in the 
GUSTO trial. where the effectiviness of four different 
regimens is compared: streptokinase with aspirin and 
delayed subcutaneous heparin as in ISIS-3. and altepla-
se. streptokinase and the combination of alteplase and 
streptokinase. all with aspirin and intravenous heparin 
are investigated. The dose of intravenous heparin is 
adjusted to APTT measurements. 
It is now appreciated that the study of a single 
thrombolytic drug should be changed to studies of drug 
regimens or strategies. Further drug regimens may 
include newer drugs as hirudine (an antithrombotic 
drug) or antiplatelet drugs (lib-lila receptorblocking 
agents) 18• which might improve further reperfusion 
and prevent reocclusion. 
Chapter two gives insight into the systemic effects 
of anistreplase and intracoronary streptokinase. We 
studied the major components of the coagulation and 
fibrinolytic process and looked for the relation be-
tween the systemic lytic state and clinical events such 
as reperfusion. reocclusion and bleeding complica-
tions. Both intravenous anistreplase and intracoronary 
streptokinase gave rise to a similar degree of activation 
of the fibrinolytic system. which became apparent in 
93% of the patients. In this small patient cohort. there 
were no significant bleeding complications. In the 
Anderson study 1, where a larger group of patients was 
studied. intravenous anistreplase caused less bleeding 
complications than intracoronary streptokinase. This 
probably reflects the increased bleeding risk after vas-
cular access and angiography. 
The third chapter actresses the significance of anti-
bodies to streptokinase in relation to coronary throm-
bolytic therapy both with streptokinase and anistrepla-
se. There is a possibility that patients undergoing 
thrombolytic therapy for acute myocardial infarction 
have had a streptococcus infection in the past. If subse-
quently streptokinase or streptokinase related ani-
streplase is used. their effect may be mitigated by the 
presence of antibodies. Similarly antibodies can be 
induced by previous treatment with anistreplase or 
streptokinase for an acute myocardial infarction. which 
limits the use of these components for the treatment of 
reinfarction. The aim of our study was to investigate 
whether antibodies are responsible for failure to restore 
reperfusion when these drugs are used. In eight patients 
who received streptokinase on two occasions. because 
treatened reinfarction White observed allergic reac-
tions in four patients. 19 In patients where alteplase was 
readministered no allergic reactions were observed. 
Unfortunately antibodies were not measured in this 
study. In our patients without preceding streptokinase 
or anistreplase infusions. we did not find IgE antibo-
dies and did not observe any anergic reactions. 
Furthermore reperfusion rate appeared not to be 
related to lgG antibodies to streptokinase. although the 
70 
systemic state was significantly influenced by such 
anti-streptokinase antibodies. Large series are required 
to determine whether increased IgG antibody levels 
tend to reduce the efficacy of streptokinase and ani-
streplase. Also the increased risk oflate complications 
such as serum sickness and Guillain-Barre syndrome. 
which are occasionally seen after initial treatment20•21 
should be investigated. Therefore streptokinase and 
anistreplase are a good choice for the first infusion in 
patients with myocardial infarction. but for reinfarc-
tion alteplase. saruplase (Pro-urokinase) and uroki-
nase. are probably better alternatives. 
In chapter four we report a study on the influence of 
intravenous anistreplase on blood viscosity and plate-
let function in patients with acute myocardial infarc-
tion. We found a rapid and significant decrease of 
plasma- and blood-viscosity. which paralleled the de-
crease in plasma fibrinogen. Platelet aggregation ra-
pidly decreased and fully recovered within 24 hours. 
which was followed by a state of hyperaggregation 
after 48 hours. This effect disappeared after one week. 
The phase of hyperaggregation might induce reocclu-
sion. particularly if PTCA has been performed. which 
may result in extensive intravascular damage.20 
The results of the study on the rheological effects of 
a nonionic contrast medium in vivo are discussed in 
chapter five. In the management of patients with acute 
myocardial infarction. contrast medium may be inject-
ed for various reasons. This study was performed to 
investigate the influence of nonionic contrast medium 
on rheology and platelet function. We found that non-
ionic contrast has a beneficial effect mainly by causing 
hemodilution. This can be concluded from the observa-
tion that blood viscosity decreases together with a 
marked fall in hematocrit while there was no change in 
plasma viscosity. The fall in hematocrit is caused by 
the added volume of the contrast medium plus a shift of 
water from the extravascular space to the plasma as a 
result of the high osmolarity of the nonionic contrast 
agent. Nonionic contrast had no effect on platelet 
aggregation. 23 
In chapter six we addressed the value of immediate 
PTCA after intravenous streptokinase in acute myocar-
dial infarction. 
In this observational study patients were divided 
into three groups immediately after thrombolysis and 
angiography: patients with total occlusion: patients 
with an open vessel with > 70% residual stenosis and 
patients with an open vessel with < 70% residual 
stenosis in the infarct related vesseL In 28 out of 32 
patients (87%) with total occlusion in spite of thrombo-
lytic therapy. PTCA of the occluded vessel was suc-
cessfuL In those with an open vessel after thromboly-
sis. PTCA was effective in 40 out of 42 patients (95%)! 
During long-term follow-up (mean 23 months) one 
patient out of the group with totally occluded vessels 
after thrombolysis required re-PTCA and two under-
went elective coronary bypass surgery. Furthermore 
one patient had an asymptomatic reocclusion. one had 
a late myocardial infarction and one patient died sud-
denly after l7 months. In the ESCG-5. TAMI-l and 
TAMI-224•25·26• rescue PTCA appeared less satisfacto-
ry: mortality figures were respectively 7%.4% and 3% 
and reocclusion occurred in 17%. 9% and 15%. The 
lower rate of reocclusion in our experience might be 
explained by the fact that we used streptokinase. while 
alteplase or urokinase were used in the ECSG-5 and the 
T AMI studies. It may be postulated that the systemic 
effect after streptokinase protects the patient against 
reocclusion. Furthermore we treated a selected group 
of patients and not all of the patients who arrived with 
a myocardial infarction got thrombolysis. 
The role of PTCA in acute myocardial infarction 
remains controversial22 in spite of several randomized 
trials. 2427·28 More recently it has been proposed to 
perform direct PTCA. without thrombolysis in patients 
with evolving myocardial infarction. This would pre-
vent activation of the coagulation sequence as induced 
by thrombolytic drugs.22 In an ongoing trial Zijlstra et 
aL 29 now compare direct coronary angioplasty versus 
intravenous streptokinase in acute myocardial infarc-
tion. From the preliminary results they concluded. that 
direct PTCA results in a higher patency rate. better 
preserved left ventricular function. and that there is 
less recurrent ischemia. More data are required. how-
ever. before this procedure can be recommended in 
clinical practice. In his thesis on thrombolysis and 
coronary angioplasty for acute myocardial infarction. 
H.Bosker-3° presented recommendations which were 
similar to those reached in the TIM! II-B27 and the 
ECSG-5 studies24 He concluded that some subsets of 
patients may benefit from early PTCA: patients in 
cardiogenic shock. patients with a large anterior wall 
infarction and patients with a large area of myocardium 
at risk. 
The approach we presently follow is summarized in 
the diagram and based on the experience gathered from 
our own studies and literature. 22-31 It should be appre-
ciated. that such a scheme is oversimplified and that 
many other factors may play a role and contribute to the 
decisions in clinical practice. 
Acute myocardial infarction 
:0: 4 hours 
in selected patients: 4- 6 hours 
~ --------.. 
Candidate for 
thrombolysis 
1.500.000 U streptokinase i.v. 
(60 min) 
or 
30 U APSAC i.v. (5 min) 
or 
100 mg rt-PA i.v. (3 hours) 
~~
Contraindication for 
thrombolysis 
Reperfusion No repirfusion7 ___ ._:~-.A 
Positive excercise test 
or 
Recurrent ischemia 
t 
Elective catheterization: 
- PTCA 
-Bypass 
- Conservative 
If patient is stable Unstable or large 
and no large area of area of myocardium 
myocardium at risk at risk 
• • Conservative Emergency 
Stable 
t 
'Watchful waiting' 
catheterization: 
- PTCA 
-Bypass 
- Conservative 
Decision making diagram in patients with acute myocardial infarction. 
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This approach can be explained as follows: 
Timeframe: Most patients with an acute myocar-
dial infarction arrive or are admitted to the hospital 
within 4 hours. In general patients in the Nether lands 
arrive earlier compared with GISSI-2, ISIS-2 and ISIS-
3. For example thrombolytic therapy in our study de-
scribed in chapter one was started at an average of 2.4 
hours after the onset of symptoms and in the study by 
the Interuniversity Cardiology Institute patients were 
entered in the hospital after a median of 90 minutes31 
In contrast in Andersons study 1 conducted in the USA. 
treatment started after an average of 3.3 hours. which is 
approximately one hour later. The more rapid treat-
ment in our study may be related to the short travel 
distances within The Netherlands. Furthermore it is 
possible that educational programmes. can help pa-
tients to recognize the symptoms of a heart attack 
earlier. 
In GISSI-1 18 no benefit of thrombolytic therapy was 
observed after a treatment delay exceeding 9 hours. 
Similarly the EMERAS study. did not show any benefit 
in mortality from thrombolytic therapy after 6 hours. 32 
Therefore we limit thrombolysis to patients admitted 
within 4-6 hours after onset of symptoms. even though 
ISIS-2 suggested some benefit of late therapy in a 
subset of patients. 
Reperfusion: In our practice reperfusion was as-
sessed without coronary angiography on the basis of 
clinical judgement including the general condition of 
the patient. disappearance of chest pain and recovery of 
the ST -segment in the electrocardiogram. It is possible 
that in the future continuous ST -segment monitoring 
will make this decision easier.33.34 
'Unstable': Coronary angiography is considered 
in ·unstable· patients with recurrent pain, new electro-
cardiographic changes. sweating. bloodpressure drop 
or excessive bloodpressure elevation. 
Exercise test: A submaximal exercise test is 
performed in stable patients before they leave the 
hospital. A positive test (ischemic ST -segment chang-
es on the electrocardiogram during excercise with or 
without angina) is an indication for elective coronary 
angiography to assess whether PTCA or CABG should 
be offered. This decision depends on the extent of 
disease27 In our experience only 5%-10% of all pa-
tients treated with a thrombolytic agent need urgent 
CABG or PTCA because of instability. 
The majority of patients can be managed with 
an initially ·conservative' approach. Of these patients 
15%-30% will need PTCA or CABG at a later stage. 
as demonstrated in the TIMI-II study27 and our own 
data. In 1991 27 patients (7%) out of 360 patients with 
an acute myocardial infarction required urgent inter-
ventions and 48 ( 13%) underwent an elective interven-
tion. 
In the second part of the thesis various aspects of 
PTCA are discussed. 
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The initial- and long-term results of the first 100 
patients. who underwent PTCA for left anterior de-
scending artery stenosis in our department are de-
scribed in chapter seven. Although ultimately most 
patients may require bypass surgery. the majority in 
our study did not need surgery over an average follow-
up of I 02 months, despite the fact that 'restenosis · 
(defined as an increase of the luminal diameter stenosis 
of the dilated lesion above 50%) occured in 22% of the 
patients. More than half of the patients remained 
asymptomatic and led a completely normal life after an 
average follow-up of 102 months. It is also noteworthy 
that all these patients undergoing a first PTCA proce-
dure. were discharged from the hospital within 2 days 
and that none needed to be readmitted for anginal 
symptoms. In several large ongoing trials in which 
PTCA is compared with CABG (BART: bypass angi-
oplasty randomized investigation; CABRI: coronary 
angioplasty bypass randomized investigation. and oth-
ers35) the cost/benefit aspect and quality oflife aspects 
of both procedures will be investigated. 
Chapter eight deals with symptomatic coronary ar-
tery disease in a population of75 years or older. This is 
an increasing proportion of patients in our society. If 
the symptoms cannot be sufficiently controlled by 
medical treatment. the question arises what the optimal 
management for those patients should be: PTCA or 
CABG? Data in chapter eight indicate that PTCA gives 
very good results and in most patients may be prefera-
ble to coronary bypass surgery. Indeed our results show 
less major complications (4% in PTCA versus 7% in 
CABG), as well as a lower rate of other complications 
(4% in PTCA versus 30% in CABG) and a shorter 
hospital stay (4.3 days versus 14.2 days). PTCA of the 
culprit lesion alone was performed in 75% of all pa-
tients. At long-term follow-up. there was no difference 
in outcome between the PTCA and CABG patients. A 
point of criticism of this study is the selection of the 
patients. since it was a non-randomized series. and it is 
not recorded why PTCA was done in certain patients 
and CABG in the others (indication bias). An interest-
ing observation was the fact that after a successful 
PTCA or CABG. late mortality in this group mainly 
resulted from non cardiac disease (cancer). 
Factors which increase the risk of complications of 
the PTCA procedure and the results of emergency 
coronary bypass surgery in patients after failed PTCA 
are discussed in chapter nine. Although some groups of 
patients can be identified with increased risk during 
PTCA. it should be appreciated that even in 'low risk' 
patients unexpected complications occur. therefore 
also in these patients the risk is not negligible. The 
number of patients who are candidates for PTCA is 
increasing rapidly. In 1980 in our institution 20 pa-
tients underwent PTCA: in 1991 the number of inter-
ventions has increased to 1199 ! ! ! In order to cope with 
these volumes it has been proposed to conduct low risk 
PTCA without immediate surgical standby. In fact. in 
Germany PTCA is already done on a large scale with 
surgical ·standby' in another remote hospital. Similar 
practice is emerging in the United Kingdom.36 This 
tendency seems to become more accepted by some 
cardiology groups. Apparently. in Germany and in the 
UK the number of centres performing cardiac surgery 
was not sufficient to accommodate the required 
number of PTCA procedures. In order to achieve some 
level of surgical standby a system of rapid transporta-
tion (ambulance. helicopter) to cardiac surgical centres 
was arranged. Recently this situation has somewhat 
improved. because several new centers started with 
cardiac surgery. The safety of remote PTCA has also 
improved through the development of 'bail ouf coro-
nary stenting. which allows to operate patients with 
PTCA complications on an elective basis.37 However 
this approach should be investigated on a large scale, 
before it will be accepted in general practice. 
In spite of new technical developments we believe, 
that remote PTCA should not be accepted in TheN eth-
erlands for several reasons. First of all we have suffi-
cient cardiac surgical centres which are well distribut-
ed over the whole country. Thus, it is always possible 
to send a candidate for PTCA to a centre with surgical 
facilities. Secondly. there is (still) enough capacity for 
performing more PTCA' s in the established centres. 
The waiting-lists do notresultfrom lack of capacity but 
from budgetary restrictions. In several registries, it had 
been shown that large centres performing PTCA have 
higher primary success rates and less complications 
than centres where limited numbers of procedures are 
being done.3839 Finally it should be appreciated there 
are no reliable predictors which allow to identify the 
patient who is at low or high risk of complications 
during the PTCA procedure. In their recent 'Guidelines 
for percutaneous transluminal angioplasty'. the Amer-
ican Heart Association and the American College of 
Cardiology classify the coronary lesions in types A. B 
and C40 This classification is only of limited help in 
predicting complication risk, because even in type A 
lesion. which has a high success rate and low risk of 
acute complications, such complications occur in some 
patients. Thus surgical standby during PTCA is still 
mandatory in all patients. 
The study described in chapter ten was initiated to 
test the idea that the calcium-antagonist diltiazem 
could have a local cardioplegic effect during the PTCA 
procedure. This hypothesis was based on experimental 
evidence that diltiazem is able to delay the occurence of 
pacing induced myocardial ischemia.41 The adminis-
tration of the drug before the intervention would thus 
potentially allow longer balloon inflations which 
might improve the PTCA results42, while the negative 
effects of ischemia would be avoided. However. it 
appeared that intravenous infusion of diltiazem did not 
reduce ST-segment elevation and lactate release43, al-
though cardiac adenosinetriphosphate breakdown dur-
ing angioplasty was reduced. 
Subsequently we studied the effect of the beta-
blocker metoprolol given intravenously during PTCA 
in patients with single-vessel coronary artery stenosis 
(chapter eleven). We found a tendency towards less 
chest pain and a reduction of precordial ST -segment 
elevation which suggests that the degree of ischemia 
was reduced. This was not confirmed by the metabolic 
measurements since there was no effect on cardiac 
lactate. hypoxanthine and urate release immediately 
after deflation of the balloon. Metoprolol did. however. 
reduce the arterial plasma hypoxanthine level through-
out angioplasty by about 30% (p < 0.02 versus place-
bo). A possible explanation for this finding is that the 
beta-blocker metoprolol inhibits extracardiac adeno-
sinetriphosphate catabolism. but not the cardiac adeno-
sinetriphosphate catabolism. Again our results were 
inconclusive. This may be explained by the fact that 
balloon inflation to induce ischemia was limited to 60 
seconds. instead of 90 or 150 seconds as in other 
investigations. 44.45 
It should be appreciated that it has not been estab-
lished which medication should be given during and 
after PTCA. To reduce thrombotic complications ad-
ministration of aspirin or other equivalent anti platelet 
agents is mandatory .46 The value of dextran is still 
unknown.47.48A9 More powerful antiplatelet agents 
such as monoclonal antibodies are under investigation. 
Prolonged postprocedural heparinization may be use-
ful in high risk PTCA patients50 It should be appreci-
ated that patient response to heparin is highly variable. 
The standard '10.000' U heparin bolus injected before 
PTCA leads to activated clotting time (ACT)< 300 sec. 
(what has been associated with thrombus formation) in 
5% of patients with stable angina and in up to 15% of 
patients with unstable angina pectoris. 5 1 Nitrates are 
helpful in the event of occurrence of coronary spasm, 
but are not necessary in most patients.52 The role of 
calcium channel blockers as diltiazem has been advo-
cated to allow longer balloon inflations and prevent 
ischemia. This is probably only a theoretical benefit. 
Serruys et a1.53 showed that nifedipine intracoronary. 
when the left anterior descending artery was occluded 
during PTCA. reduces the contractile and mechanical 
function of the anterior wall of the left ventricle by a 
·regional cardioplegic' effect, but increased the post-
stenotic flow. Nifedipine prevents the metabolism of 
the ischemic cardiac cells from becoming anaerobic 
during transluminal occlusion for periods lasting up to 
90 sec. Halpern et ai.'4 showed a similar but less 
pronounced effect after diltiazem. Piessens et al.43 
reported reduction of ST -segment elevation and lactate 
release after infusion of diltiazem. This was, however. 
not shown in our study described in chapter 10. al-
though we found a reduction of cardiac adenosinetri-
phosphate breakdown. Thus diltiazem may serve as a 
potential cardioprotective agent. Serruys55 showed a 
similar effect for nifedipine. It should be appreciated 
that in spite of some beneficial effect of calcium chan-
nel blockers demonstrated in these studies it still needs 
to be proven whether it is indeed beneficial to locally 
treat the myocardium with a calciumantagonist imme-
diately before PTCA. The role of calcium channel 
blockers during coronary spasm. occassionally seen 
during PTCA is well established.5657 Nevertheless in 
our study where half of the patients did not get calcium 
73 
channel blockers, no spasm was observed. It is possible 
that the new soft PTCA balloon material gives less 
stimuli to provoke spasm. in contrast with the old rigid 
catheters. The use of beta-blockers to prevent ischemia 
during PTCA is discussed extensively by Zalewski et 
al.45 and Feldman et al.44 They found a reduction in the 
degree of myocardial injury. judged by the extent of 
ST-segment elevation during occlusion of the left ante-
rior descending artery and less pain during balloon 
inflation. We, however. could not confirm these find-
ings in our study with metoprolol (chapter ll). So the 
benefit of using this drug during PTCA needs further 
investigation. 
In this thesis some aspects of thrombolysis and inter-
ventional cardiology are discussed. Our aim was to 
optimize these new treatment modalities after their 
implementation in a nonacademic institution. We be-
lieve. that it remains mandatory to assess the results of 
such interventions in clinical practise. especially when 
these are still in an evolutionary phase. Continuous 
critical assessment of our medical practice is most 
essential in improving our therapeutic decisions to the 
benefit of our patients. 
As Willem Einthoven said: 
.. The truth is all that matters. and what you and I think 
is inconsequential.'' 
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Samenvatting 
Dit proefschrift behandelt twee onderwerpen die in de 
afgelopenjaren het karakter van de klinische cardiolo-
gie en meer bepaald de behandeling van patienten met 
coronarialijden sterk hebben beYnvloed. 
Dee! een behandelt de trombolyse van het acute hartin-
farct en deel twee behandelt de interventie cardiologie. 
Seder! de herintroductie van trombolyse als behande-
ling bij het acute hartinfarct in 1979 door P. Rentrop is 
door vele grate studies bewezen dat het geven van een 
trombolyticum een verbeterde overlevingskans geeft. 
Aanvankelijk werd streptokinase intracoronair toege-
past. hetgeen omslachtig is en 24 uur per dag standby 
van de catheterisatiekamer vereist. 
In ooze kliniek vergeleken wij daarom het trombolyti-
cum APSAC (anisoylated plasminogen streptokinase 
activator complex. anistreplase) een middel dat intra-
veneus in 5 minuten als een bolus gegeven kan worden 
met intracoronair toegediende streptokinase. 
De resultaten. beschreven in hoofdstuk 1. Iaten zien dat 
intraveneus toegediende anistreplase even effectief is 
als intracoronair toegediende streptokinase, anis-
treplase heeft echter voordelen: de snelle toedienings-
vorm. de lage reocclusie en de goede verdraagzaam-
heid door de patient. 
Hoofdstuk 2 bebandelt de effecten van intracoronair 
toegediende streptokinase en intraveneus toegediende 
anistreplase op bet stollingsmecbanisme. Er bleek vrij-
wel geen verschil te zijn. Slechts de totale fibrino-
lytische activiteit gemeten door de euglobuline-clot-
lysistijd bleek Ianger te duren. Dit is mogelijk de 
verklaring voor de lagere reocclusie in de anistreplase 
groep, vergeleken met reocclusie in de streptokinase 
groep. 
In hoofdstuk 3 wordt nagegaan of circulerende antili-
chamen tegen streptokinase in bet bloed bij trombo-
lytische therapie met streptokinase en anistreplase ver-
antwoordelijk zijn voor het feit. dat niet bij 100% van 
de patienten reperfusie wordt bereikt. In deze studie 
konden we niet aantonen. dat reperfusie beYnvloed 
wordt door IgG antilichamen. wanneer streptokinase 
en anistreplase in een tberapeutische dosering worden 
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toegepast. We! werd de systemische lyse duidelijk 
be"inv loed door de antilichamen zonder echter de reper-
fusie te be"invloeden. 
In boofdstuk 4 wordt ingegaan op bet effect van ani-
streplase op de viscositeit van het bloed en bloed-
plaatjesfunctie. Verondersteld wordt dat een reductie 
van viscositeit gunstig kan zijn omdat bet bloed beter 
zou kunnen doorstromen. We von den dat inderdaad de 
viscositeit zowel in plasma als bloed significant afnam 
samen met een daling van bet fibrinogeengehalte. Bo-
vendien vonden we dat er na de fase van inhibitie van 
plaatjesaggregatie een tot twee dagen later een fase van 
hyperaggregatie ontstaat. Dit is mogelijk een verkla-
ring voor de minder goede resultaten van PTCA enkele 
dagen na trombolyse. Nader onderzoek is noodzakelijk 
om deze hypothese te toetsen. 
In hoofdstuk 5 worden de rheologische effecten in bet 
bloed bebandeld van een ··non-ionisch" contrastmiddel 
dat wordt gebruikt tijdens catheterisatie. We vonden 
een duidelijke verlaging van de bloedviscositeit door 
een daling van de haematocriet. De plasmaviscositeit 
bleef gelijk ondanks de boge viscositeit van bet con-
trast. De haematocrietdaling wordt deels veroorzaakt 
door bet volume van bet contrast en door een verschui-
ving van water van de extravasculaire ruimte naar bet 
plasma. als gevolg van de hoge osmolariteit van bet 
contrastmiddel. Dus. uit rheologisch oogpunt. is een 
""non-ioniscb"" contrastmiddel uiterst geschikt omdat 
bet hemodilutie geeft en dus de circulatie bevordert. 
In boofdstuk 6 komt een controversieel onderwerp aan 
de orde: bet nut van percutane transluminale coronair 
angioplastiek (PTCA) van de verantwoordelijke steno-
se voor bet hartinfarct na trombolyse. De studie is niet 
gerandomizeerd en de getallen zijn relatief klein. Het 
blijkt dat de patienten in onze kliniek die een PTCA 
ondergingen het goed deden. De patienten die een 
afgesloten vat hadden v66r de PTCA deden het zelfs 
beter dan degenen die een open vat hadden en dus geen 
PTCA nodig had den omdat de vernauwing in het vat na 
trombolyse minder dan 70% was. Het is niet mogelijk 
uit dit niet gerandomizeerd onderzoek conclusies te 
trekken. Men kan zich echter wel afvragen of de 
afwezigheid van een ernstige stenose na behandeling 
bij deze patienten niet een rol speelt. 
In deel 2 van dit proefschrift wordt ingegaan op ver-
schillende aspecten van de interventie cardiologie. 
In hoofdstuk 7 worden de lange termijnresultaten be-
sproken van de eerste I 00 patienten die in ons zieken-
huis een PTCA van de ramus descendes anterior onder-
gingen. Het blijkt dat na de eerste behandeling meer 
dan de helft na 85 jaar geen angina pectoris heeft en 
geen dokter meer heeft geraadpleegd voor hart-
klachten. Dus PTCA is een uitstekende behandelings-
methode. 
Hoofdstuk 8 behandelt de korte- en lange termijnre-
sultaten van patienten die vijfenzeventig jaar of ouder 
waren en die of een PTCA of een bypassoperatie on-
dergingen vanwege medicamenteus niet te behandelen 
angineuze klachten. Ofschoon dit geen gerandomi-
zeerd onderzoek is. kunnen toch enkele belangrijke 
concl usies worden getrokken. PTCA blijkt bij oudere 
patienten een veilige procedure te zijn. Ongeacht de 
uitgebreidheid van het coronarialijden blijkt dilatatie 
van de laesie. verantwoordelijk voor de klachten. 
voldoende. De peri-procedurale complicaties zijn 
minder vergeleken met patienten die een kransvatom-
leidingsoperatie ondergingen. In onze optiek verdient 
PTCA daarom de voorkeur boven bypasschirurgie 
bij deze categorie patienten. wanneer de laesie. ver-
antwoordelijk voor de klachten. kan worden vast-
gesteld. 
Hoofdstuk 9 behandelt de uitkomst van patienten die 
vanwege een PTCA met een complicatie een spoed 
bypassoperatie dienden te ondergaan. Uit deze studie 
blijkt eens te meer dat adequate chirurgische standby 
van groat belang is. De mortaliteit van alle patienten 
die een spoedoperatie ondergingen vanwege een mis-
lukte PTCA bedroeg 2.6%. ondanks het feit dat 24 
patienten in cardiogene shock waren toen ze werden 
geopereerd. Snelheid van handelen na een PTCA met 
complicaties is van levensbelang! 
Hoofdstukken I 0 en II behandelen het effect van 
intraveneus diltiazem en metoprolol (een beta-receptor 
blokker) op myocardischemie veroorzaakt door het 
opblazen van de ballon tijdens PTCA. In samenwer-
king met het Cardiochemisch laboratorium van het 
Thoraxcentrum van de Erasmus Universiteit in Rotter-
dam werden diverse metabolieten gemeten zoals 
lactaat. hypoxanthine en uraat. Verder werd het ECG 
continu geregistreerd. We vonden dat diltiazem de 
cardiale adenosinetrifosfaatafbraak reduceert tijdens 
PTCA. wat blijkt uit een verminderde produktie van 
uraat en hypoxanthine. diltiazem had echter geen in-
vloed op de lactaat-produktie en ST-segment afwij-
kingen. 
Voor metopro!ol gold dat het mogelijk de pijn op de 
borst tijdens PTCA verminderde en dater minder ST-
segment elevatie optrad. maar dat het geen invloed had 
op de lactaat en oxypurine uitstorting. Het had wei 
invloed op de arterie!e hypoxantbineproduktie. water 
mogelijk op duidt dat metoprolol het extracardiale 
adenosinetrifosfaat catabolisme bei"nvloedt. 
Dit proefschrift geeft antwoord op een aantal vragen 
betreffende nieuwe behandelingsmethoden uit de kli-
nische praktijk en draagt bij aan de discussie over een 
aantal controversiele onderwerpen. Duidelijk is dat 
zowel in de trombolyse als in de interventie cardiologie 
nog vele vragen onbeantwoord blijven. 
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